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Abstract
Negative regulatory factors inhibit the proliferation of haematopoietic stem 
cells thus protecting them from differentiation pressures. One of the negative 
regulators of stem cell proliferation is the tetrapeptide Acetyl-Seryl-Aspartyl-Lysyl- 
Proline (AcSDKP). This peptide is endogenously produced in vivo and long term 
bone marrow cultures and is degraded by angiotensin 1-converting enzyme (ACE) 
both in vivo and in vitro. The aim of these investigations was to study the role of ACE 
on haematopoietic stem and progenitor cell proliferation. Since the N-domain ACE 
active has been implicated in AcSDKP degradation, an analysis of two ACE 
inhibitors (captopril and lisinopril) shown to have differential effects on the N-domam
ACE active site was conducted.
Both captopril and lisinopril equally reduced ACE activity in plasma in vitro. 
However, captopril had a lesser effect on reducing serum ACE activity in vitro than 
lisinopril. Captopril and AcSDKP together reduced the proportion of GM-CFC in S- 
phase after 7 hours of in vitro incubation. In addition, ACE resistant AcSDKP
analogue (AcSDxgKP) when incubated with bone marrow cells in the absence of 
captopril also reduced the proportion of GM-CFC in S-phase. This finding suggest 
that the effect of captopril and AcSDKP on GM-CFC proliferation was due to
AcSDKP alone.
Haematopoietic stem cells were induced into cell cycle by in vivo 
administration of either 2 Gy-y-irradiation or the two cytotoxic drugs, cytosine 
arabinoside (Ara-C) (100 mg/kg i.p.) or 5 flourouracil (5 FU) (150 mg/kg i.v). Bone 
marrow cells were sampled and incubated in vitro for up to 24 hours. Captopril 
together with AcSDKP reduced the proportion of high proliferative colony forming 
cells-1 (HPP-CFC-1) in S-phase following 2 Gy-y-irradiation. Lisinopril together with
IX
AcSDKP had no such effect. In addition, captopril alone in vitro reduced the 
proportion of HPP-CFC-1 in S-phase induced into cell cycle by cytotoxic drugs. 
Lisinopril had no such effect. Incubation alone reduced the proportion of HPP-CFC-1 
in S-phase in cytotoxic drug treated bone marrow cells. When cultures, which were 
incubated with captopril, were assayed for AcSDKP levels, captopril induced an
increase in AcSDKP levels in both control normal bone marrow cells and cells
derived from Ara-C treated mice. However, it did not affect AcSDKP levels in 
cultures derived from 5 FU and 2 Gy treated mice, AcSDKP together with captopril 
were shown to inhibit S-phase cell entry of HPP-CFC-1 when they were incubated 
with bone manow cells derived from mice treated with either 2 Gy-y-irfadiation or 
cytotoxic drug insults. Interestingly, captopril was unable to reduce the proportion of 
SA2 leukaemic cells in S-phase
Captopril on its own at therapeutic doses reduced the proportion of HPP-CFC- 
1 in S-phase in vivo regardless of the insult used to induce HPP-CFC-1 into cell cycle. 
Lisinopril slightly reduced the proportion of HPP-CFC-1 in S-phase following Ara-C 
treatment only. Captopril induced an in vivo increase in AcSDKP levels in all the 
models tested. Captopril also reduced the proportion of HPP-CFC-1 and GM-CFC in 
S-phase following fractionated doses of Ara-C. Captopril’s inhibitory effect on GM- 
CFC proliferation following fractionated dose of Ara-C was diminished after 7 days 
while it was sustained with HPP-CFC-1.
Long-term bone marrow cultures revealed that captopril and AcSDj/KP had 
the same effect on cellularities of both layers and on the proliferation of HPP-CFC 
and GM-CFC in both layers. From the present investigations, it can be concluded that 
captopril is a potent inhibitor of HPP-CFC-1 proliferation. This effect may in part be 
mediated by AcSDKP mechanism.
J
Chapter 1 - Introduction 1
CHAPTER 1
1,0 HA lEMA/TOP O KS1S
1.0.1 General haematopoiesis
Blood cells are constantly produced and destroyed during an animal’s life 
span. Despite a wide variation in the type of mature cells that make up the 
haematopoietic system, all haematopoietic cells originate from pluripotent stem cells. 
Stem cells have been defined as cells capable of self-renewal without diminishing in 
function and numbers and they furnish daughters to provide new functional cells of 
the haematopoietic tissue (Schofield, 1983). Others have suggested that a fixed 
number of stem cells is laid down during embryogenesis to supply the body’s needs 
throughout its life time and these cells are randomly recruited into proliferation, 
differentiation, and development as required (Ogawa, 1993; Dexter, 1987). 
Haematopoietic stem cells originate in the foetus from the intra-embryonic 
mesodermal area close to the aorta, gonads, mesonephros and also from the yolk sac 
(Medvinsky et al., 1993). They then migrate to the foetal liver and finally settle in the 
bone mainow (Moore & Metcalf, 1970). It is possible to isolate cells with stem cell 
potential in all these organs. In humans, cord blood is also a source of cells with stem 
cell potential (Caux et al., 1989). Stem cells give rise to progenitor cells. Progenitor 
cells are lineage restricted and they form colonies when appropriate growth factors are 
added to in vitro cultures (Metcalf et al., 1993; Moser, 1991) and are usually 
committed to one or more lineages. The types of colonies formed by progenitor cells 
in agar cultures define them. In contrast to stem cells, a large proportion of progenitor 
cells is in S-phase of the cell cycle at any one time (Millard & Okell, 1975).
Chapter 1 - Introduction 2
Progenitor cells divide to give rise to mature cells that carry out the function 
of the haematopoietic system. This can be achieved over a very short period of time 
according to the physiological need (Moser, 1991). Therefore under normal 
circumstances the number of functional haematopoietic cells remains constant.
This thesis will first introduce a general review of different stem cell assays 
and stem cell proliferation regulation mechanisms. Then factors involved in 
haematopoietic stem cell proliferation will be analysed with particular emphasis on 
negative regulators of stem cell proliferation. The major aim of this project is to 
define ways of preserving stem cell integrity during tumour therapy. The emphasis is 
on stem cell proliferation inhibitors.
1.0.2 An overview of haematopoietic stem cell assays
Several in vivo and in vitro assays have been devised for assaying cells with 
stem cell characteristics in both mice and man. The in vivo assays include 
transplantation of mouse bone marrow cells into lethally irradiated mice or human 
haematopoietic cells into immunocompromised (SCID) mice and preimmune foetal 
sheep (Bock, 1997). The in vitro stem cell assays include direct clonogenic assays and 
secondary clonogenic assays. Direct clonogenic assays are the most direct quantitative 
means of measuring haematopoietic stem cells by colony formation in vitro. On the 
other hand the secondary clonogenic assays are qualitative assays. These secondary 
clonogenic assays assay for cells that do not themselves form colonies in semisolid 
media but can produce clonogenic progeny if cultured for a certain period of time. In 
general test cells are cultured for several days/weeks and an analysis of the number of 
clonogenic cells is performed at set times during the culture period.
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1,0.3 Colony Forming Unit-Spleen (CFU-S) stem cell assay
A subset of cells from normal bone marrow with the ability to protect lethally 
irradiated mice from haematotoxicity in the short term by forming colonies in the 
spleens after 10 days post transplantation was observed in 1961 by Till & McCulloch. 
They observed that the number of colonies in the spleens of rescued mice was directly 
proportional to the number of normal bone marrow cells transplanted. Moreover each 
colony originated from a single cell. The colony contained undifferentiated cells at 
day 10. Erythroblasts were observed in the centre of the colony and myeloid cells 
were observed at the peripheral of the colony. However at day 11-post transplantation, 
the process of differentiation was more marked with erythropoiesis, granulopoiesis 
and up to 5 megakaryocytes observed in the colony. Therefore cells responsible for 
the formation of colonies were deemed to have stem cell properties. Since a lot of 
bone marrow cells were needed to produce a few colonies, spleen colony forming 
cells responsible for individual colonies were called a unit. This procedure has 
become the in vivo haematopoietic stem cell assay called the “Colony Forming Unit- 
Spleen” (CFU-S) assay.
The potential of transplanted normal bone marrow cells to form spleen 
colonies can be assayed at different times from day 7 onwards. Cells obtained from 
spleen colonies that develop early are incapable of forming spleen colonies when 
reinjected in lethally irradiated mice and thus contain no CFU-S (Siminovitch et al., 
1963). Moreover early CFU-S (Day 7) colonies are known to disappear from the 
spleen within 72 hours and they are mainly composed of erythroid cells (Magli et al., 
1982). On the other hand spleen colonies sampled after 12 days contain cells capable 
of forming multilineage colonies (Ploemacher & Brons, 1988a). Therefore it can be
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argued that early (CFU-S day 7) and the late (CFU-S day 14) spleen colonies 
originate from different colony forming cell populations.
The individual colony-forming cells, have a heterogeneous population of cells 
with regards to proliferation and differentiation potential (Lewis et al., 1968; Fowler 
et al., 1967; Mulder et al., 1987; Magli et al., 1982; Becker et al., 1963). Cells from an 
individual spleen colony can differentiate along the erythrocytic, 
granulocytic/monocytic and megakaryocytic series (Lewis et al., 1968). Day 7 and 
day 14 colony forming cells have different sensitivities to S-phase specific drugs as 
shown by the increased sensitivity of day 7 colony forming cells to 5 fluorouracil (5 
FU) compared to day 14 colony forming cells (Hodgson & Bradley, 1979). In 
addition, day 7 colony fonning cells have a short life span and they produce mainly 
cells of the erythroid series (Magli et al., 1982). Day 7 and day 12 colony fotming 
cells express different cell smface antigens (Moore et al., 1980; Caux et al., 1989; 
Ploemacher & Brons, 1988a). Late CFU-S show heterogeneous Rho staining while 
early CFU-S are selectively labelled with Rho (Mulder et al., 1987). In addition day 7 
colony forming cells have DNA that stains more strongly with Hoechst-33342 than 
day 14 CFU-S (Wolf et al., 1993). Therefore it can be concluded that cells responsible 
for CFU-S formation are heterogenous with varying stem cell potentiah It seems that 
cells with a greater stem cell potential form colonies after a long time in vivo while 
cells with less stem cell potential form spleen colonies after a short time following 
transplantation. However in order to rescue mice from the cytotoxic effects on the 
stem cell population following irradiation for example, colony fonning cells with 
short and long stem cell potential are needed to be transplanted together (Jones et al., 
1990).
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1.0.4 An overview of in vitro stem cell assays
There are four main in vitro stem cell assays. Two of these assays are direct 
stem cell clonogenic assays and they depend on the ability of different combinations 
of growth factors either in conditioned media or in a pure form to induce colony 
formation in agar cultures from haematopoietic bone marrow cells. These are the blast 
colony forming cell (Bl-CFC) assay and the high proliferative potential colony 
forming cell (HPP-CFC) assay. The secondary clonogenic assays assay cells with 
stem cell potential by their ability to give rise to clonogenic progenitor cells that can 
be assayed. These assays include the long-term bone marrow culture (LTBMC) and 
the long-term culture-initiating cells (LTCIC). These assays consist of two major 
components. These components are the haematopoietic cells and the stromal cells of 
the haematopoietic microenvironment. The other secondary clonogenic assay 
comprises a group of assays called the delta (A)-assays. In delta assays, bone marrow 
cells are sorted such that they are depleted of committed progenitors and enriched for 
primitive haematopoietic cells and are cultured in a seven-day suspension culture in 
the presence of a combination of various cytokines (Bock, 1997; Gordon, 1993; 
Bodine et al,, 1991; Verfaillie & Miller, 1995). The effects of cytokines on these cells 
are measured in clonogenic assays for committed progenitor cells. There are several 
variants of delta assays utilising the property of early haematopoietic cells to adhere to 
stroma or plastic (Gordon, 1993).
1.0.5 Blast-colony forming cell stem cell assay
In mice, Bl-CFC assay is generated in the presence of medium conditioned by 
pokeweed mitogen-stimulated mouse spleen cells with or without erythropoietin 
(Suda et al., 1983; Nakahata & Ogawa, 1982, Humphries et al., 1981). Media
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conditioned by leukocytes in the presence of phytohemagglutinin and erythropoietin 
on days 4 or 5 promotes the same cell population from human bone marrow cells 
(Frauser & Messner, 1978). Using mouse cells the Bl-CFC assay generates mainly 
macroscopic erythroid colonies on day 9. The multipotential characteristics of the Bl- 
CFC assay are characterised by individual colonies that contain granulocytes, 
macrophages, megakaryocytes and erythroid cells. These colonies are called CFU- 
GEMM colonies (CFU- Mixed).
A variation of Bl-CFC developed by Gordon et al., (1985) is assayed by 
adding bone marrow cells to preformed stromal layers. Stem cells bind to stromal 
cells within 2 hours of coincubation of bone cells to the preformed stroma. Bound 
stem cells produce colonies of undifferentiated blast cells. These blast colony-forming 
cells can self-renew as well as give rise to multipotential and lineage-committed 
colony-forming progenitor cells (Gordon et al., 1987).
Bl-CFC while originating from a single cell also contains a heterogeneous 
population of cells at different days of incubation period. Each Bl-CFC contains cells 
of different lineages (Suda et al., 1983). Most of Bl-CFC colonies show terminal 
differentiation at day 10 of culture towards the erythroid series. However if colonies 
are cultured over a long period of time, three types of colonies are observed on day 
16. These three types of colonies are: the mast cell colonies, granulocyte- 
macrophage/megakaryocyte (GMM), and cells with greater self renewal potential, 
termed stem cells (Nakahata & Ogawa, 1982). Some macroscopic erythroid blasts 
contain cells capable of generating CFU-S and express multiple haematopoietic 
differentiation (Johnson, 1980). Humphries et al., (1979), assayed 25 macroscopic 
blasts and found that only 11 produced spleen colonies. There is also a heterogenous 
distribution of cells capable of forming CFU-S among Bl-CFC with some producing
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up to four times the average number of CFU-S (Humpries et al,, 1981). The number 
of daughter stem cells detectable in individual primary Bl-CFC clones varies 
markedly from one clone to the other (Humpries et al., 1981), These observations 
show that the cells responsible for Bl-CFC colony fonnation are as heterogeneous as 
the ones responsible for CFU-S colony formation. They also show that both these 
assays are multipotential.
1.0.6 High proliferative potential-colony forming cell stem cell assay
As reviewed by Bertoncello (1992), HPP-CFCs require multiple 
haematopoietic growth factors acting in synergy in order to divide in agar cultures and 
form colonies greater than 0.5 mm in diameter containing at least 50,000 cells. Cells 
which form high proliferative potential colonies in vitro are relatively resistant to the 
cytotoxic effects of 5 FU in vivo. Different populations of cells with high proliferation 
potential can be recruited with different combinations of growth factors. One such 
cell population is called the colony forming unit type A (CFU-A). In this assay
conditioned media from L929 fibroblasts cell line and AF1-19T a rat fibroblast cell
line transformed with the malignant hystiocytosis sarcorma virus, are combined and 
colonies of diameter > 2 mm are scored at day 11 (Pragnell et al., 1988). McNiece et 
al, 1986, 1987, 1988a, 1988b, 1989, 1991; Falk et al., 1988, have identified a number 
of HPP-CFC from human and mouse bone marrow cells by culturing cells with 
different combinations of growth factors.
The heterogenity of HPP-CFC is recognised by the different composition of 
cells in colonies recruited by different combinations of growth factors. For example 
HPP-CFC surviving 5 FU treatment can only be detected in clonal agar cultures in the
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presence of interleukin la (IL-la) plus interleukin 3 (IL-3) plus macrophage colony 
stimulating factor (M-CSF, CSF-1) (Bartelmez et al., 1989). While HPP-CFC that 
require less than 3 growth factors are ablated by 5 FU, they re-emerge sequentially in 
the bone marrow during haematopoietic regeneration following treatment. McNiece et 
al., (1988b) demonstrated that granulocyte macrophage-colony-stimulating factor 
(GM-CSF) alone or in combination with M-CSF stimulated HPP-CFC colonies that 
were depleted in vivo but regenerated more rapidly than the ones stimulated by M-
CSF alone. This was observed in cultures of bone marrow cells from mice treated
with 5 FU 2, 4,and 8 days before sampling. If human stem cell factor (hSCF) is 
combined with GM-CSF, granulocyte-colony-stimulating factor (G-CSF), IL-3, or 
erythropoietin (hEpo) an increase in colony number and size is observed. When 
stained, cells have the morphology similar to the one recruited by single growth 
factors without hSCF (McNiece et al., 1991). Therefore hSCF responsive HPP-CFC 
are a heterogenous population of cells. Macrophage progenitor cells which respond to 
M-CSF alone form colonies with a diameter of <0.5 mm after 14 day of culture. 
These colonies have been called the low proliferative potential colony forming cells 
(LPP-CFC) (Bradley & Hodgson, 1979). From these observations Kriegler et al., 
1994, observed a hierarchy of HPP-CFC according to stem cell potential and 
progenitor cell maturity by using regenerating bone marrow after 5 FU and cell 
sorting using Rho. (Fig. 1.1 shows the proposed hierarchy and heterogeneous nature of 
the HPP-CFC compartment.)
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Fig. 1.1, HPP-CFC Relationships. Adapted from Kriegler et al., 1994
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1,0.7 Secondary cionogenic (qualitative) stem cell assays
Bone marrow light density cells isolated from mice treated with 5 FU in vivo 
and cultured in the presence of SF+IL-3 have no cionogenic potential in soft agar 
assays but have myeloid-lymphoid potential as long-term culture-initiating cells 
(Bertolini et al., 1997). In LTBMCs, haematopoietic cells are placed into flasks and 
the stromal progenitor cells adhere to culture flasks and form a confluent layer 
consisting of fibroblasts, fat cells, macrophages and some endothelial cells (blanket 
cells) (Gordon, 1993; Gartner & Kaplan, 1980; Dexter et al., 1976, Hasthorpe et al., 
1992). This enables a continuous production of haematopoietic cells. Some 
haematopoietic cells adhere to the stroma while others are released in the culture 
medium. Therefore progenitor cells developed from these cultures can be assayed in 
the adherent as- well as the non-adherent layers. In human bone marrow cells, LTCICs 
assay haematopoietic cells with the ability to seed a preformed stroma that is normally 
irradiated. Bone marrow cells are put on an irradiated stroma and they produce 
precursor cells that are assayed from 5 week of culture (Sutherland et al., 1990). For a 
continual survival of cultures, they need to be fed at weekly intervals by fresh media 
replacement. Ploemacher et al. (1989) devised an in vitro limiting-dilution assay of 
long-term repopulating haematopoietic stem cells in mice by overlying bone marrow 
cells on irradiated stromal layers. Haematopoietic stem cells give rise to time- 
dependent clonal amplification under the stromal layers.
Non adherent cells from LTBMC which support mononuclear differentiation 
lose the ability to form CFU-S faster than cells from cultures which support 
granulocyte differentiation (Dexter & Lajtha, 1974). Once long-term bone marrow 
cultures have been established, proliferation of cells capable of forming CFU-S,
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production of megakaryocyte precursor cells (CFU-M), and granulocyte precursor 
cells (CFU-G) and extensive granulopoiesis can be maintained for many months. 
However only immature erythroid progenitors (early BFU-E) are maintained in long 
term culture (Eliason et al., 1979; Dexter et al., 1976). In the presence of anaemic 
mouse serum or normal mouse serum plus erythropoietin (Epo), the most primitive 
erythroid progenitors (BFU-E) mature into colony-forming units-erythroid (CFU-E) 
with suppression of granulopoiesis (Dexter et al., 1981). CFU-E can also be produced 
in the presence of Epo incubated on a mechanical shaker (Eliason et al., 1979). 
Therefore, LTBMCs are capable of producing a heterogeneous population of 
haematopoietic progenitor cells. Additional evidence of mutipotentiality and 
heterogeneity of LTBMC is shown by the fact that CFU-C, BFU-E and CFU-G /E are 
consistently detectable in the adherent layer for at least 8 weeks. 70%-75% of BFU-E 
and CFU-G / E are located in the adherent layer at week 2-3 and more than 90% by 
week 7-8 (Coulombel et al., 1983).
From the above observations, all stem cell assays used to study 
haematopoiesis contain cells at different stages of maturation with regard to stem cell 
potential. Specific haematopoietic cell progeny can be derived from these stem cell 
assays. All in vitro assays can yield CFU-S if retransplanted into lethally irradiated 
mice (Nakahata & Ogawa, 1982; Dexter, 1979; Eckmann et al., 1988). In general 
these assays favour myeloid differentiation with limited or no lymphoid 
differentiation. However, it is possible to recruit cells of the lymphoid series from 
bone marrow cells following cell sorting for cells with stem cell potential (Sprangrude 
et al., 1988; Bertolini et al., 1997). The lymphoid cells (T lymphocytes) can be 
recruited from human Bl-CFC by addition of T-cell growth-promoting medium 
(Messner et al., 1981). Removal of corticosteroids and increasing incubation
Chapter 1 - Introduction 12
temperature from 33°C to 37°C after establishment of LTBMC results in the 
development of B-lymphocytes (Denis & Witte, 1986; Dorskind, 1986).
1,0.8 Stem celt self renewal
The most important characteristic of stem cells is that they should be able to 
self renew. All available stem cell assays, whether qualitative or quantitative, show 
this to be the case (Williams et al., 1977; Schofield et al., 1980; McNiece et al., 1987; 
Mauch et al., 1980). Self-renewal is influenced by the primitiveness of cells and the 
amoimt of cell divisions they have gone through (Rosendaal et al., 1979). As shown in 
the long-term bone marrow cultures, CFU-S within the adherent stromal cell layers 
have a significantly greater self renewal capacity than CFU-S from the non adherent 
layer (Mauch et al., 1980). The self renewal capacity of the adherent layer CFU-S 
decreases as the total number of cells capable of forming CFU-S per flask increases 
(Mauch et al., 1980).
Murine Bl-CFC have been shown to self renew and it has been argued that 
the determination of self-renewal is intrinsic to stem cells themselves with growth 
factors playing a permissive rather than directive role (Humphries et al., 1981). The 
observation that CFU-GEMM colonies can be derived from CFU-GEMM suggests 
that early stem cells have a self-renewal capacity (Nakahata & Ogawa, 1982).
Stem cells have a finite probability of differentiating into committed lineage 
restricted progenitor cells. If stem cells are induced into cell division, they are likely 
to get committed to specific lineages and differentiate. For example stem cell self­
renewal is decreased after recovery from the alkylating agents. Indeed there is a 
permanent defect in self-renewal capacity of the bone marrow stem cells after 
busulfan (Heilman et al., 1978). Stem cells are also at risk of being depleted with
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prolonged chemotherapy (Blackett & Adams, 1972), A permanent loss in stem ceil 
self renewal capacity has also been observed following weekly irradiation of mice for 
a total dose of 3,400 to 4,000 cGy (Mauch et al., 1988).
1.1 IDENTIFICATION AND CHARACTERIZATION OF
HAEMATOPOIETIC STEM CELLS
It is difficult to isolate cells with all the characteristics of stem cells in normal
bone marrow. However there are combinations of physical and immimological 
methods that are used to isolate a population of haematopoietic cells that have many if 
not all characteristics of stem cells. For example, the pretreatment of bone marrow 
cells with 5 FU spares cells with stem cell characteristics and diminishes progenitor 
cells with less stem ceil potential (Hodgson & Bradley, 1979; Brandt et al., 1988; 
Bertolini et al., 1997; Harrison & Lemer, 1991).
The use of dyes like rhodamine 123 (Rho) and Hoechst 33342 that are 
selectively taken up by a subset of haematopoietic cells has also been crucial for 
isolating cells with stem cell characteristics. Rho is a supravital dye that is a substrate 
for transport mediated by the P-glycoprotein (P-gp), an efflux, pump responsible for 
multidrug resistance in tumour cells. The highest P-gp levels are found in 
haematopoietic cells that show stem cell characteristics (Chaudhary & Roninson, 
1991). For most stem cell assays in general, rhodamine dull cells show characteristics 
which places them closer to stem cells titan rhodamine bright cells (Ploemacher & 
Brons, 1988b; Srour et al., 1993). Moreover rhodamine dull cells can be divided 
further into subsets using calcium channel blocker, verapamil. Most dull cells 
become positive for Rho when incubated in the presence of verapamil while a small 
proportion of cells remains negative. The Rho'WP' have along term repopulating
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ability while the Rho/VP+ have a short term repopulating ability (Zijlmans et al., 
1995) when ttruTplanted into lethally ir^rr^c^i^ttjd mice. Hoechss 33342 is a DNA 
binding dye. Cells with low levels of binding with Hoechst 33342 have properties 
which places them closer to ceils with stem cell potential (Wolf et ah, 1993).
In addition to chemical methods, physical methods are also available. These 
are coimterflow centrifugal elutriation (CCE), light scatter and free flow 
electrophoresis methods. In the CFU-S and HPP-CFC assays, cells elutriated at lower 
flow rates resemble lymphocytes in appearance and have long-term marrow 
repopulating ability requiring more growth factors to clone than cells elutriated at 
high flow rates (Jones et at, 1990; Yoder et al., 1991). Light scattering properties of 
haematopoitic cells differ. Using light intensity measured in a forward (FLS) and 
perpendicular direction to the incident light (FLS), cell size and shape can be 
determined. During maturation, different spleen colony forming cells show an 
increase in PLS intensity (van den Engh & Visser, 1979). Free-flow electrophoresis 
sorts cells on the basis of electric charge. Cells are first treated with neuraminidase to 
remove sialic acid and are then labelled with a lectin called wheat germ agglutinin 
(WGA) (Visser & van Bekkum, 1990). This allows free-flow electrophoresis to be 
employed in isolating cells with stem cell potenltaL
The last commonly used method to identify and separate cells with stem cell 
potential from other cells is to utilise the ability of cells to lose and acquire specific 
cell surface antigens as haematopoietic cells progress in the hierarchy from stem cells 
to mature end cells. These antigens may be part of cytoadhesion molecules. The 
cytoadhesion molecules may represent integrins, selectins or immunoglobulins 
(Simmons et al., 1997). These cytoadhesion molecuMs allow stem cells and stromal 
cells of the microenvironment to interact. As cells progress from the stem cell
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compartment to mature end cells, they progressively lose some of these antigens as 
they prepare to be released into the circulation.
In human progenitor cells, the CD34 (cluster of designation 34) antigen is 
crucial to the identity of progenitor cells with stem cell potential (Andrews et al.,
1990) . I antigens (la) in mice and DR antigens in humans, also known as class II 
major histocompatibility complex antigens (MHC-II), are absent on CD34 positive 
progenitor cells but get acquired as cells mature (Moore et al., 1980). The loss of 
CD34 expression precedes the expression of MHC-II (Caux et al,, 1989). A subclass 
of human CD34+CD38* progenitor cells has most characteristics of stem cells and is 
commonly assayed in human haematopoietic stem cell assays (Terstappen et al.,
1991) . Indeed haematopoietic cells expressing CD34+HLA’DRaCD3S~ antigens can 
differentiate into haematopoietic precursors. Interestingly, haematopoietic cells 
expressing CD34+HLA'DR'CD38' antigens can also give rise to stromal cells capable 
of supporting the differentiation of precursor cells (Huang & Terstappen, 1992) in 
addition to producing haematopoietic precursor cells.
In mice HPP-CFC which express Qa-m7 (la) antigenic detenninant have 
marked stem cell potential (Bertoncello et al., 1986). Moreover, the absence of the 
maturation antigens, B220 and 7/4 on cells with stem cell characteristics makes it 
possible to isolate a purified population of HPP-CFC (Bertoncello et aJ., 1989). The 
other antigen commonly used in isolating cells with stem cell potential is the Thy-1 
agent. Thy-1 antigen was produced and identified from pre-T hybridomas (Aihara et 
ah, 1986). While Thy-1 aitigen is mainly used to isolate murine bone marrow cells 
with stem cell properties, it can sometimes be used in combination with the CD34 
antigen (Andrews et ah, 1990) to isolate human bone marrow cells with stem cell 
properties. The Thy-1 antigen is present on murine bone marrow cells which form
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HPP-CFC colonies and those that have long term marrow repopulating ability 
(Boswell et al., 1984; Sprangrude et al., 1988).
Using a combination of the above methods, a large mmiber of almost pure 
CFU-S day 12 (which have a strong affinity to bind to WGA) can be separated from 
lipopolysaccharide-(LPS)-stimulated mouse spleen using centrifugal elutriation, 
fluorescence-activated cell sorting (FACS) (light scatter) and WGA-fluorescein 
isothiocyanate (FITC) (Ploemacher & Brons, 1988d). When interleukin-3 (IL-3) 
receptor-associated antigen (IL-3 RAA) and WGA are combined, some day 12 CFU-S 
are IL-3RAA7WGA+. This day 12 CFU-S cell population was also found to have 
long-term marrow repopulating ability (Ogata, 1992). Using a combination of CCE, 
WGA, FITC, FLS and PLS, Ploemacher & Brons (1988c; 1989) identified a cell 
population that was able to generate day-12 CFU-S and also had radioprotective 
ability (30-day survival) with the ability to repopulate the bone marrow or spleen over 
a 13-day period. They termed this cell a pre-CFU-S.
A sub-population of very primitive haematopoietic cells with long-term 
haematopoietic repopulating ability, HPP-CFC formation and the ability to 
completely repopulate the myeloid and the lymphoid B and T cell compartment after 
transplanting into lethally irradiated mice has also been isolated. This was achieved by 
using a combination of fluorescence-activated cell sorter (FACS), Rho and Hoechst 
33342. Cells with low binding of both dyes are enriched with cells showing stem cell 
characteristics (Wolf et al., 1993). In addition haematopoietic cells with competitive 
long term marrow repopulating ability have also been purified from 5 FU treated bone 
marrow using Thy-1 and H-2K antigen expression and flow cytometry with sorting 
based on light scatter (Szilvassy et al., 1989). The combination of Thy-1 antigen and 
absence of lineage expression on haematopoietic cells have also enabled the isolation
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Lymphoid stem cell
Fig. 1.2. Relationship of different haematopoietic cell population as determined 
by cell sorting.
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of cells with stem cell properties. Cells with Thy’lloLmeage*Stem cell antigen- 
l+(Thy-lioLm*Sca-l+) antigenic expression have stem cell properties Indeed these 
cells are virtually a pure population of primitive myeloerythroid stem cells 
(Sprangr^ide et al., 1988). This cell population gives a rapid and sustained 
haematopoietic recovery in lethally irradiated mice after transplantation (Uchida et al., 
1994). (Fig, 1.2 summarises different relationships of haematopoietic cells as 
identified by cell sorting).
1,2 STEM CELL KINETICS
1.2.1 Cell cycle regulation
DNA content and the expression of Ki-67 antigen can be used to determine
the phases of cell cycle. Ki-67 antigen is not expressed in quiescent ceils, but is 
quickly up regulated as cells are induced into cycle (Jordan et ai., 1996). As 
summarised by veer Reddy, (1994), there are four distinct phases of cell cycle called 
the Go/i, S, G2 and M phases. Cycle-dependent protein kinases (CDK) are crucial 
regulators of the timing and coordination of eukaryotic cell-cycle events. Two of these 
CDKl (CDC2) and CDK2 are 34-KDa proteins containing a conserved kinase 
catalytic core. Tliey are inactive as monomer and their activation requires binding to 
cyclins as well as phosphorylation by a CDK-activating kinase on threomne-161 or 
160 respectively. There are five types of cyclins called A,B,C,D,E. Cyclin-A is first 
detected near Gj/S transition while cyclin-B is first synthesised during S-phase. 
Cyclins C, Dl, and E are synthesised during Gi phase, Cyclin E peaks at the Gj/S 
transition. Cyclin-D types are expressed when cells are activated by growth factors 
and their levels rise earlier than type E-Cyclins. CDKl when completed with B-type
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cyclins is the major protein kinase acting at -the S/Ga and Ga/M transitions. CDK2 
when complexed with cyclin-A act at tlie beginning of S-phase (Li et al., 1993). The 
rest of the cyclins regulate various CDKs and control various Gi, Gi/S, and Ga/M 
transition points.
Transition from Go to Gi and S-phase is dependent on growth factors and the 
synthesis of enzymes of DNA replication and other signal molecules during G|. In the 
absence of Ca2+, cells at Gi/S boundary enter quiescence and there is a direct 
correlation between intracellular calmodulin levels and the ablitty of cells to replicate 
DNA (veer Reddy, 1994). Indeed it has been demonstrated that growth factor induced 
proliferation involves a 68 KDa calmodulin binding protein (veer Reddy et al., 1992). 
Crucial to Gj/S transition is the retinoblastoma gene protein (pRb). The product of the 
Rb gene is pl05 with related proteins identified by their interaction with adenovirus 
ElA oncoproteins, pi07 and pRb2/pl30 (Baldi et al., 1995; Claudio et al., 1996). 
These gene products act at the restriction point (R) in late Gj phase.
DNA replication-dependent bistone H4 genes are regulated by a mechanism 
involving interaction of histone nuclear factor-D (HiNF-D) homeodomain protein 
CDF/cut with Rb-related proteins (van Wijnen et al., 1996), As reviewed by 
Weinberg, (1995), pRb is normally underphosphorylated but gets 
hyperphosphorylated at the R point enabling S-phase transition from Gi phase of 
proliferating cells. pRb remains hyperphosphorylated through out the rest of the cell 
cycle. The underphosphorylated pRb binds the DRTF1/E2F transcription factor (Lam 
& La Thangue, 1994). In addition the hypophospharylated pp60 fraction of the pRB 
has been shown to translocate to the nucleolus (Rogalsky et al., 1993).
As reviewed by Lam & La Thangue, (1994), DRTF1/E2F is a group of 
DNA-binding heterodimers in which an E2F family interacts with a DP family
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protein. E2F (Adenovirus E2 gene) is a family of transcription factors which 
comprises of five distinctly related factors all targeted to variants of the consensus 
nucleotide sequence TITCGCGC. This sequence is present in genes whose products 
are involved in cell growth notably c-myc, B-myb, cdc2, dihydrofolate reductase, 
thymidine kinase and E2F-1 gene itself, E2F-1, E2F-2, and E2F-3 are under the 
direct control of pRb while E2F-4 and E2F-5 are under the control of pl07 and pi 30. 
Cyclin D with CDK4/CDK6 and cyclin E with CDK2 kinases phosphorylate the Rb. 
This releases the E2F factors that initiate crucial steps towards S-phase progression. 
At S/G2 transition, DP-1/E2F-1 binds to cyclin A-kmase thus stopping DNA 
replication (Krek et al., 1994, Lam & La Thangue, 1994). Cyclin dependent kinase 
inhibitors can affect the phosphorylation of the pRb. Since p27 kip interacts with 
CDK2, CDK4 and CDK6 while pi 5 competes with Cyclin D for binding to 
CDK4/CDK6, liigh levels of these inhibitors will prevent pRb phosphorylation 
(Weinberg, 1995). Moreover, p27kip has been shown to be an essential component of 
the pathway that connects mitogenic signals to the cell cycle at the restriction point 
(Coats et al., 1996).
p53 has been shown to have an important role as a feedback control that 
keeps cells from entering S-phase when they contain -damaged DNA by activating the 
expression of p21 which blocks the activities of both CDK2 and CDK4/CDK6
(Weinberg, 1995). Bcl-2 prevents aptoptosis without any effect on cell proliferation 
(Otani et al., 1993). Therefore the complexity of events that occur at Gi/S transitions
ensures that only cells with intact DNA are able to replicate.
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1.2.2 Haematopoietic stem cellproliferation characteristics
Using thymidine as an S-phase specific cytotoxic agent, it was found that the 
proportion of CFU-S in S-phase of cell cycle in normal murine bone marrow cells is 
less than 10% (Blackett et al. 1974; Lahm & van Putten, 1972). Using cytosine 
arabinoside (l-p-D-anabmofuranosylcytosine) (Ara-C) another S-phase specific agent, 
it was shown that the same proportion of both haematopoietic progenitor and stem 
cells are in S-phase (Millard & Okell, 1975). Ara-C enters cells through a nucleoside 
transporter by a process of facilitative diffusion (Cole & Gibson, 1997; Crisp et al.,
1996) , It is then phosphoiylated by deoxycytidine kinase to Ara-CMP. Ara-CMP is 
further phosphoiylated by deoxytidine monophosphate kinase to Ara-CDP. Finally, 
Ara-CDP is phosphorylated to the active cytotoxic metabolite Ara-CTP by nucleoside 
diphosphate kinase (Cole & Gibson, 1997; Crisp et al., 1996). Unlike cytosine, Ara- 
CTP incorporation into DNA hinders chain elongation and induces strand breakage 
resulting in cell death. In vivo Ara-CTP is converted into an inactive metabolite, 
uracil arabinoside (Ara-U) which is excreted, by cytosine deamase (Cole & Gibson,
1997) .
It has however' been shown recently that (30 ± 7)%o of Rho/Ho dull primitive 
haematopoietic cells are actively cycling using continuous administration of 
bromodeoxyuridine over one week. Tlie proportion of these cells in S-phase increased 
to (60 ± 14)% and (89 ± 3)% at 4 and 12 weeks respectively (Bradford et al., 1997). In 
general quiescent stem cells are much more refractory to recnntment into cell cycle 
and they require a combination of growth factors in vitro and at least 72 hours to be 
recruited (Jordan et at, 1996). 97% of Thy-1.1k'w LiS'Sea-i+ which exhibit a low level 
of staining with Rho are in G<G| and 70% Rho bright cells of the same cell
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population are proliferating (Fleming et al., 1993). Interestingly, small erythroid 
colonies present in the nonadherent layer and granuloc>le / macrophage colonies in
Fig 1.3 Progression of cells from the stem cell compartment to the mature cell
compartment (adapted from Uchida et al 1993)
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both adherent and nonadherent layers are actively dividing while big colonies of the 
same cell population are mainly quiescent in the adherent layer but are recruited into 
cycle following media change (Cashman et al., 1985). Uchida et al.(1997) showed 
that human bone marrow CD34+Thy-1+Lin" from individuals treated with 
cyclophosphamide and GM-CSF or G-CSF alone are proliferating, while the 
peripheral blood CD34+ Thy-l+Lm' from the same individuals were in Gq/Gi pha&w
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About 30% of CFU-S are in S-phase 10 minutes after 150 rads irradiation in mice 
(Lahiri & van Putten., 1972). (Fig. 1.3 gives a general view of the progression of cells 
from the stern cell compartment to the mature cell compartment)
The Go phase of the cell cycle is crucial to the integrity of stem cells to 
maintain their stem cell potential. For example, prolongation of cells in Gi phase of 
the cell cycle induces cellular differentiation (Carroll et al,, 1995), There is evidence 
that suppression of apoptosis allows differentiation and development of multipotent 
haematopoietic cells in the absence of added growth factors (Fairbain et al., 1993). 
Therefore if stem cells are recruited from Go to Gi, they may differentiate if they are 
not allowed to self-renew and to return to Go.
1.3 BONE MAWROW MICROENVIRONM'ENT
1.3.1 The role of the stromal cells
In vitro, the microenvironment is characterised by the adherent stromal layer 
formed by LTBMCs. This layer consists of ‘endothelial like cells’, fat cells, 
macrophages and fibroblasts (Dexter et al., 1976). The microenvironment is 
transplantable as shown by the fact that people who receive a bone marrow transplant 
develop stromal cells which are derived from the donor in LTBMC (Keating et al., 
1982). Stromal cells are strongly positive for alkaline phosphatases and smooth 
muscle actin (Liesveld et al., 1989). Haematopoietic cells and stromal cells following 
in vitro cultures may originate from the same cell population (Huang & Terstappen, 
1992). One of the functions of the stromal cells is to support stem cell renewal 
(Zipori, 1989; Zuckerman et al., 1986).
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1,3.2 Stromal cells ami extra cctttUar matrix
Stromal cells are associated with the extra cellular matrix. Extra cellular 
matrix consists of ground substances in the form of glycoproteins or proteoglycans 
(glycosaminoglycans). These molecules may be utilised by haematopoietic cells in 
their maturation. For example, haemonectin a 60 KDa glycoprotein in bone marrow is 
a lineage and organ-specific attachment molecule for cells of the granulocytic lineage 
(Campbell et al., 1987). Moreover binding of CFU-S to marrow stromal cells is 
mediated by recognition of ground substances with galactosyl or mannosyl moieties 
(Aizawa & Tavassoli, 1987). The attachment of erythroid cells to fibronectin, a 
glycoprotein, increases with their degree of differentiation (Coulombel, et al., 1988). 
A 115-kD molecule on the erythroid cells is involved in the cellular interaction with 
fibronectin. As cells mature they lose this protein and the net result is cell detachment 
from stroma (Patel et al., 1986). There are other ground substances found in the 
extracellular matrix. For example, chondroitin 6- sulfate, a proteoglycan, is 
considered as one of the extra cellular matrix component which is involved in the 
construction of the haematopoietic microenvironment (Oguri et al., 1987, Okayama et 
al., 1988).
Ground substances may also be useful in the presentation of growth factors 
to haematopoietic cells. Heparan sulphate glycosaminoglycans have been shown to 
bind and protect basic Fibroblast Growth Factor (bFGF) from degradation by plasmin 
(Saksela et al., 1988). GM-CSF can be eluted from cultured stromal layers showing
that this colony stimulating factor binds to stromal cells (Gordon et al., 1987a).
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1.4 GROWTH FACTORS,
1.4.1 Role of Growth Factors (n haematopoiesis
Most growth factors (cytokines) are single subunit glycoproteins containing 
disulfide bonds with a molecular weight of 14,000-28,000 daltons. However some of 
them are heterodimers with alpha and beta chains. M-CSF is unique in that it is a 
dimer of identical subunits (Nicola, 1987, Chiarugi et al., 1993). Individual growth 
factors display multiple activities (pleiotypic), they can interact with different cell 
types eliciting different functions (pleiotropy). They also have overlapping activities 
(redundancyXChiarugi et al., 1993; Metcalf, 1993). Growth factors exert their 
mitogenic effect by interacting with specific receptors on responsive cells. As 
reviewed by Chiarugi et al., 1993, there are five classes of haematopoietic and 
immune receptors characterised on the basis of molecular and type of signalling. Class
1- superpolymeric receptors activating both tyrosine kinases and phosphatases. Class
2- reseptorral tyrosine kinases that dimerize and phosphorylate several substrates. 
Class 3-heterodimeric cytokine receptors consisting of alpha and beta chains that lack 
intrinsic tyrosine kinase activity but associates with src-like tyrosine kinases. Class 4- 
seven membrane-spanning domain receptors, which increase intracellular Ca^a+. Class 
5-an IL-1 receptor induces formation of drasylglycerol.
In the haematopoietic system, growth factors can be categorised into 3 
groups. There are late, intermediate, and early acting growth factors. This 
categorisation is based on the activity of growth factors on haematopoietic cells as 
they progress from the stem cell compartment to the mature precursor cell 
compartment (Ogawa, 1993). Growth factors in each category activate 
phosphoildylinostinol 3-kinase in haematopoietic cells (Gold et al., 1994). With SCF,
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tm early acting growth factor, having the greatest potency followed by IL-3, an 
intermediate acting growth factor. IL-5, a late acting growth factor having the least 
potency (Gold et al., 1994, Ogawa, 1993). In addition, haematopoietic stem cells 
contain high levels of receptors for early acting growth factors c-kit and IL-6R, IL-IR, 
G-CSF receptor with some receptors for intermediate acting growth factors like IL-3 
receptors (Orlic et al., 1995, McKinstry et al., 1997) Pluripotent haematopoietic stem 
cells also contain high levels of the transcription factor GATA-2, p45, NF-E2 and c- 
myb. They do not express c-fns and do not have receptors for G-CSF and IL-5 or IL- 
7, all late acting growth factors (Orlic et al., 1995, Ogawa, 1993).
Synergistic effects of early factors are to shorten the Go phase of primitive 
haematopoietic cells. There is also similarity in function of some of the early acting 
growth factors as shown by biochemical mechanisms of their signal transduction (de 
Jong et al., 1997). As reviewed by Ogawa, (1993), intermediate acting growth factors 
influence multipotent progenitor cells after they exit from Go. Cells lose 
responsiveness to some of as they terminally differentiate. Because these factors are 
intermediate, they can interact with both late and early growth factors to influence cell 
maturity and recruitment into cell cycle. Late growth factors allow lineage expression 
of progenitor cells (Ogawa, 1993).
1.4.2 Growth Facto or and haamatopoiettc meroenvironment
The type of growth factor produced by stromal cells is influenced by the 
microenvironment formed. For example stromal ©ells cultured and maintained for 
myelopoiesis produce growth factors responsible for myelopoiesis while the ones 
maintained for lymphopoiesis do not produce these growth factors. However if there 
is an alteration of conditions such that myelopoiesis cultures are switched to
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lymphopoiesis, they lose their ability to produce growth factors responsible for 
myelopoiesis. The same is true for lymphopoiesis cultures switched to myelopoiesis 
(Johnson & Dorshkind, 1986). Gutierrez-Ramos et al.(1992), showed high mRNA
levels of IL-1 to IL-7 with no IL-5 mRNA in three bone marrow and foetal liver
stromal clones. A stromal cell line called, MC3T3-G2/PA6 (PA6) expressed SCF, M- 
CSF and high levels of Sca-1 in culture after 45 weeks (Satoh et al., 1997).
There may be a feedback loop in the production of growth factors by stromal 
cells. Indeed, exogenous as well endogenous IL-1 (p) induces human bone marrow 
stromal cells to produce IL-ip, IL-6, GM-CSF, G-CSF and M-CSF in LTBMC (Fibbe 
et al., 1988; Eaves et al., 1991). Moreover, there is also evidence that mononuclear 
phagocytes recruit stromal cells to produce multilineage growth factors in vitro 
(Broudy et al., 1986). Exposure of stromal cells to irradiation increases their 
production of GM-CSF (Alberico et al., 1986). Transforming Growth Factor-p (TFG- 
p) mRNA is constantly found at all times in LTBMC and is not influenced by media 
manipulation. However, addition of antibody against TGF-p to LTBMCs induces 
quiescent cells into the cell cycle (Eaves et al., 1991).
1.5 REGULATION OF STEM CELL PROLIFERATION
1.5.1 Stimulators of stem cell proliferation
Stimulatory factors of stem cell proliferation induce stem ceils into cell cycle 
(Lord et al., 1977). Bone marrow cell suspensions taken from mice following 
cytotoxic insults are enriched with stimulatory factors for haematopoietic stem cell 
proliferation (Ali et al., 1989; Frindel et al., 1976; Lord et al., 1977; Lord, 1986; 
Wright & Lord, 1978). These factors are produced when mice are irradiated or given
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cytotoxic drugs (Aii et at, 1989; Frindel et al., 1976). Ceils that survive the insult and 
are not proliferating are responsible for the production of these factors. The 
concentration of stimulatory factors is seen to increase very rapidly after an insult to 
the haematopoietic system (Ali et al., 1989). These factors are not species spesifrs 
(Cork et al., 1986) and they are produced by monocyte / macrophage lineage cells 
expressing the I a antigen (Wright et ah, 1982; Ali et al., 1989), The nature of the feed 
back mechanism for the production of stimulatory factors is controlled both locally 
and by humoral factors (Ali et al., 1989; Frindel et al., 1976). Moreover, these factors 
can be separated following Amicon Diaflo membrane ultrafiltration in a molecular 
weight fraction of 30-50 KDa (Lord et al., 1977). The rate of stimulator production 
depends on the dose of the insult The greater the insult the longer it takes for 
stimulators to be produced. For examples, 0.5Gy irradiation allows the production of 
stimulators within 30 minutes while it takes 6 hours for stimulatory factors to be 
produced following higher doses (Ali et at, 1989). Following hydroxyurea treatment 
to mice, there is no observable effect on haematopoietic stem cell cycling within 2 
hours. Stem cells are recruited into cell cycle only after 4 hours (Hodgson & Blackett, 
1977). Some tumour cells also produce stimulatory factors (Frindel et aL, 1978). 
Stimulatory factors are produced very rapidly and the production of these factors is 
switched off as soon as they exert their influence on stem cell kinetics. It is suggested 
that an unknown mechanism triggers stimulator producing cells to secrete stimulators 
which are transported to responder cells which then rnriiaie DNA synthesis (Frindel et 
al., 1979).
It is possible that cytokines may be the mediators of stimulatory effect on stem 
cell proliferation. This is confirmed by the fact that GM-CSF or G-CSF has been used 
as a stimulator to rescue murine haematopoietic system after cyclophosphamide
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(Homung & Longo, 1992). However the use of growth factors as exogenous 
haematopoietic stem cell stimulatory factors may result in some loss of stem cell 
ability to repopulate the bone marrow. This is because such treatments recruit more 
than necessary stem cells into a proliferative state hence induce them to differentiate. 
The net result is a permanent loss of some stem cells leading to bone marrow aplasia 
(Moser & Paukovits, 1991; Moore, 1992 Review paper).
Stem cells show different responses to the effect of stimulatory factors. Day 7 
colony forming cells are more easily influenced by stimulatory factors than day 12 
colony forming cells (Wright et al., 1985). In addition, cells that form CFU-S isolated 
from the axial parts of the femurs are less sensitive to stimulatory factors compared to 
cells that form CFU-S isolated from the marginal parts of the femurs (Lord, 1986). It
has been observed before that mature cells with some stem cell characteristics have a
higher probability of being influenced by stimulatory factors than primitive stem cells 
(Tejero et al., 1984).
1.5.2 Inhibitors (Negative factors) of stem celt proliferation
Negative regulatory factors lack cell specificity within the haematopoietic 
system, acting at different levels of differentiation and on several lineages. The 
mechanism involved in the control of murine and human stem cell proliferation is 
thought to be identical and inhibitors of stem proliferation are also not species 
specific (Wright et al., 1980a). In contrast to stimulators, inhibitors of stem cell 
proliferation have a great influence over the older CFU-S that form colonies on 
day 12 (Wright et al., 1985).
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Fig, 1.4 The influence of stimulators and inhibitors on haematopoietic ceils, 
(Adapted from Tejero et al., 1984)
If inhibitors of stem cell proliferation can be maintained at a high enough 
concentration while phase specific cytotoxic therapy is given in the treatment of 
neoplastic diseases, haematopoietic stem cell proliferation can be suppressed. This 
can protect stem cells from the cytotoxic effects of these drugs (Tubiana et al., 
1993 Review paper, Guigon & Bonnet, 1995 Review paper). Therefore patients 
might perhaps be spared from bone marrow failure which follows both 
radiotherapy and chemotherapy (Mauch & Heilman, 1989; Morley et al., 1975). 
(Fig. 1.4 summarises the feed back loop imposed by stimulators and inhibitors of 
stem cell proliferation.)
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1.6 SOME IMPORTANT INHIBITORS OF STEM CELL
PROLIFERATION.
Inhibitors of stem cell proliferation include transforming growth factor-p 
(TGF-p), leukaemia associated inhibitor (LAI), haemoregulatory peptide 5b 
(pEEDCK), inhibin, normal bone marrow extract-IV (NBME-IV) which has been 
identified as macrophage inflammatory protein la (MIP la), tumour necrosis
factor-a (TNF-a), and AcSDKP. These factors have been isolated separately from 
platelets, placenta, kidney, myeloid leukaemia cells, granulocytes, sertoli cells, 
adult and foetal bone marrow cells, and conditioned medium of normal blood and 
bone marrow cells (Axelrad, 1990 Review paper).
Glutathione inhibits GM-CFC with no effects in vitro on CFU-E. Oxidised
glutathione has a stimulatory effect on colony growth of granulocyte (Fetsch & 
Maurer, 1990). Both prostaglandins and iactoferrin have an inhibitory effect on 
the proliferation of GM-CFC in vitro, prostaglandins being more inhibitory on 
macrophages while neutrophils are inhibited more by Iactoferrin (Pelus et al., 
1979). Interferons selectively inhibit CFU-E proliferation in mice and BFU-E 
proliferation in humans. This inhibitory effect is dose dependent but independent 
of erythropoietin (Ortega et al., 1979). Human gamma interferon (r-y -IFN) 
suppresses colony formation by GM-CFC, BFU-E and multipotent cells (GEMM- 
CFC) in long-term bone marrow cultures with toxic effects on the stromal cells
(Coutinho et al., 1986). Interferon-y also selectively inhibits very primitive 
CD34+CD38" but not CD34+CD38+ human haematopoietic progenitor cells 
(Snoek et al., 1994).
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1.6.1 Haemoregulatory pentapeptide pGlu-Glu-Asp-Cys-Lys (HP5b, 
orpEEDCK)
This pentapeptide was isolated and purified from extracts of granulocytes 
(Paukovits et al., 1982). In vitro, pEEDCK inhibits CFU-C at a concentration of 
10‘7 M while in vivo it produces a non-significant reduction of CFU-S numbers 
per femur. The inhibitory effect of pEEDCK on CFU-S numbers is reversible 
(Laerum & Paukovits, 1984). Pre-CFU-S are protected by pEECDK from 
depletion following cytotoxic drug treatment (Paukovits et al., 1993). Purified 
pEEDCK from skin extracts inhibits proliferation and enhances terminal 
differentiation in cultured mouse epidermal cells (Reichelt et al., 1987; Elgjo et 
al., 1986). Surprisingly, the oxidised pEEDCK forms a dimer that has a 
stimulatory effect on colony formation (Laerum et al., 1988).
A single injection of 30pg/kg pEEDCK monomer given to mice 2 hours 
before a second Ara-C injection delays the onset of neutropenia by 2 to 3 days.
Post chemotherapy infusion of the peptide in, the form of a dimer at 1.4 gg/kg 
produces a four fold increase in progenitor cells 2 days post therapy. Animals 
given the two forms of the peptide together are protected from leukocyte 
depression by Ara-C (Paukovits et al., 1991). The dimer’s stimulatory function is 
thought to be mediated through its effect on influencing stromal cells to produce 
colony stimulating activity (King et al., 1992, Veiby et al., 1992). A stable 
pentapeptide made by substituting the -SH with an isosteric methylene group has 
an inhibitory effect on cycling GM-CFC without any effect on colony numbers. It 
directly inhibits Lin'Scal+ HPP-CFC stimulated by SCF+IL-3+IL-1 but not those 
stimulated with M-CSF+IL-3+IL-1 (Veiby et al., 1996). The pentapeptide
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synergises with TNF-a and /or IFN-y in its inhibitory effect at low concentrations
(Lu et ai,, 1989).
pEEDCK protects mice from the cytotoxic effects of cytosine arabinoside 
(Ara-C) without changing Ara-C's cytotoxic effects on transfonned leukaemic 
cell line (Paukovits et ah, 1990). Surprisingly, the myeloid cell line (HL-60) 
which was directly inhibited by pEEDCK was killed by Ara-C in the presence of 
the pentapeptide (Paukovits et al., 1990). The fact that the pentapeptide has a 
direct inhibitory action on HL-60 leukaemic cells might result in residual disease 
after chemotherapy if pEEDCK has to be used as an adjuvant to chemotherapy.
1.6.2 Transforming growth factor—
TGF-P inhibits Thy-1 expression on bone marrow cells induced by IL-3 
(Keller et ah, 1990). In addition TGF-p inhibits all subpopulations of HPP-CFC, 
multipotent and mixed colony cells with no effect on single granulocyte or 
macrophage colonies (Keller et ah, 1990). TGF-p has a strong inhibitory effect on 
the proliferation of CD34++CD38' and CFC generation of CD34'H'CD38' 
progenitor cells with little effect on the proliferation of CD34+CD38+ cells (van 
Ranst et ah, 1996). Moreover, TGF-p inhibits normal bone marrow myeloid 
precursor cells induced to proliferate by IL-6, IL-1 or lipopolysaccharide, but has 
little effect on the inhibition of precursor cells stimulated by IL-3, M-CSF or GM- 
CSF (Lotem & Sachs., 1990). TGF-p added at the time of media change, in long­
term bone marrow cultures, inhibits primitive haematopoietic progenitor cells 
from entering S-phase (Cashman et ah, 1990a). This inhibitory effect may involve 
apoptosis of haematopoietic progenitor cells (Hong et ah, 1997). TGF-p has a
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similar inhibitory effect on the proliferation of very primitive normal and chronic 
myeloid leukaemia progenitor cells (Cashman et a!., 1990b). While this leukaemia 
inhibitory effect may be advantageous, these leukaemia cells may be protected 
from cytotoxic agents during therapy resulting in the recurrence of tlie disease.
1.6.3 Tumour necrosis factor a
TNFa pretreatment results in enhanced regeneration of circulating 
neutrophils in animals given cell cycle specific chemotherapeutic agents (Slordal 
et al., 1990). The effect of TNFa on cultures of L-celi line is cell cytostasis in the 
G2 phase of cell cycle (Darzynkiewicz et al., 1984). In human long-term bone 
marrow cultures, TNFa strongly potentiates IL-3 induced short term proliferation 
of human CD34+ haematopoietic progenitor cells which ceases after 10-12 days 
(Caux et al., 1991). After 10-12 days, TNFa inhibits granulocytes by arresting 
cells in Go/Gj phase (Caux et al., 1991) and stimulates monocyte proliferation.
TNFa reversibly blocks differentiation of monocytes at the level of CD 13' and 
CD 15* (Caux et al., 1991). It has a rapid and transient inhibition on the non­
adherent layer cell proliferation with a late effect on the inhibition of the adherent
layer cells (Khoury et al., 1992). TNFa also induces production of IL-6 and tlie 
disappearance of adipocytes (Khoury et al., 1992) in the adherent layers of 
LTBMCs. This cytokine inhibits the proliferation of the CFU-S population and 
induces significant plasma CSF activity and confers radioprotection of CFU-S 
when administered to mice before imadiation (Warren et al., 1990). TNFa like
TGF-p inhibits the proliferation of CD34CD38' and CFC generation of 
CD38^CD38* progenitor cells with little effect on the proliferation of
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CD34+CD38+ cells (van Ranst et al., 1996). However TNF inhibition of cell cycle 
may also involve programmed cell death of haematopoietic progenitor cells (Hong 
etal., 1997).
1.6.4 Macrophage inflammatory protein la
Macrophage inflammatory protein belongs to a group of cytokines called 
chemokines (Broxmeyer et al., 1993). As the name suggests macrophage 
inflammatory proteins are produced by macrophages and they are heparin binding 
proteins which cause localised inflammatory reactions after injection into foot 
pads of C3H/HeJ mice (Wolpe et al., 1988). Using the CFU-A assay for primitive 
stem cell proliferation, the stem cell inhibitor isolated by Amicon Diaflo 
membrane ultrafiltration in the molecular weight fraction 50-100KDa from bone
marrow extracts was identified as MIP la (Graham et al., 1990). MIP la prevents 
recruitment of quiescent stem cells into cell cycle when added to regenerating 
bone marrow cells (Dunlop et al., 1992; Lord et al., 1992) and protects 
multipotent haematopoietic cells from the cytotoxic effects of hydroxyurea in vivo 
(Lord et al., 1992). MIP la has a weak inhibitory action on the proliferation of 
CD34^CD38' cells and enhances primary proliferation of CD34+CD38+cells and 
generation of secondary CFC (van Ranst et al., 1996). MIP la suppresses the 
proliferation of cells that are responsible for day 12 CFU-S in a dose dependent 
manner with little effect on cells responsible for day 8 CFU-S (Dunlop et al., 
1992).
MIP la, IL-3 and diffusible marrow-derived stromal factors maintain
human haematopoietic stem cells for at least eight weeks in vitro by an unknown
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mechanism (Verfailiie et al., 1994). In addition to inhibiting haematopoietic cell 
proliferation, MIP la enhances the stimulatory activity of GM-CSF or M-CSF on 
the mature bone marrow CFU-GM (Broxmeyer et al., 1990). The activity of this 
chemokine on haematopoietic cell proliferation can be antagonised by other 
members of the chemokine family. For example, MIP Ip abrogates the capacity of 
MIP la to suppress myeloid progenitor cell growth (Broxmeyer et al., 1991). 
Moreover, a large quantity of MIP la monomer is needed to exert inhibitory
influence because MIP la aggregates to form inactive dimers that have no 
inhibitory effect on haematopoietic cell proliferation (Mantel et al., 1993). 
Interestingly, TGF-p inhibits MIP la gene expression in the bone marrow derived 
macrophages (Maltman et al., 1993).
The problem with most of the above inhibitors is that some of them have 
stimulatory effects on cell proliferation, others are not specific in their action 
while others are toxic. There is a growing interest in a tetrapeptide, Acetyl-Ser- 
Asp-Lys-Pro (AcSDKP), which has most of the desired properties as a selective 
inhibitor of normal cell proliferation without affecting tumour cell proliferation. 
The rest of the review will concentrate on the physiological properties of
AcSDKP.
1.7 THE TETIR^PEPTII>E (AcSDKP)
1.7.1 Sources ofAcSDKP
The first identification of a peptide with low molecular weight, which 
could inhibit murine haematopoietic stem cell recruitment into cell cycle after 
irradiation was in the extracts of foetal calf bone marrow (Frindel & Guigon,
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1977). Furthermore foetal calf liver extracts were also identified as a source of a 
non species specific low molecular weight substance which prevents CFU-S 
entering S-phase after cytosine arabinoside (Ara-C) treatment (Guigon et al., 
1984). Using the foetal calf bone marrow the stmcture of the inhibitory peptide 
was identified as a low molecular weight (Mw 487) tetrapeptide Acetyl-Ser-Asp- 
Lys-Pro (AcSDKP) (Lenfant et al., 1989b). The same molecular structure showing 
the same inhibitory phenomenon was also identified in human placental extracts 
(Lopez et al., 1991). It has been shown subsequently that AcSDKP is synthesised 
in mice under steady state condition and is secreted by long-term bone marrow 
cultures (Wdzieczak-Bakala et al., 1990).
Thymosin (34 has the SDKP sequence of amino acids at the beginning of
its N-terminal sequence (Lenfant et al., 1989b; Voelter et al., 1995). Thymosin p4 
is a ubiquitous polypeptide that is active in the regulation and differentiation of 
thymus dependent lymphocytes. High concentrations of thymosin (34 are found in 
peritoneal macrophages in mice (Hannappel et al., 1982). Interestingly AcSDKP 
is produced by macrophages in long-term bone marrow cultures (Li et al., 1997), 
showing a common source of these two peptides. Indeed studies have shown that
AcSDKP can be generated from thymosin (34 both in vivo and in vitro (Grillon et 
al., 1990). AcSDKP like substance is present in all mouse tissues with a high 
concentration in the spleen with a poor correlation to thymosin (34 distribution 
(Pradelles et al., 1991). Therefore, further studies are needed to confirm that
AcSDKP is cleaved from thymosin (3*4 under normal steady state in vivo in both
mice and man.
While a possibility exists that thymosin (34 may be the precursor molecule
for AcSDKP production in vivo, thymosin p4 may not be the only source of
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AcSDKP as SDKP peptide sequence is also found in TNFa and rat liver
phenylalanine hydroxylase (Lenfant et al., 1989b). Thymosin (34 inhibits actin 
assembly which disrupts cell division. However, the antiproliferative activity of 
AcSDKP in not mediated by a thymosin (34 like effect on actin assembly 
(Cheviron et al., 1996). In addition to this, thymosin (34 is a human 
haematopoietic stem cell (CD34+) proliferation inhibitor in its own right (Bonnet 
et al., 1996). Studies have been carried out to compare the mode of action of
AcSDKP and TNF a on haematopoietic stem cell proliferation (Bonnet et al., 
1995). These two molecules also do not display the same mode of action.
1.7.2 Mechanism ofAcSDKP action
Mice treated with Ara-C have reduced levels of AcSDKP. As a result the
pluripotent haematopoietic stem cells (CFU-S) enter into cell cycle. However after
some time a feed back mechanism causes an increase in AcSDKP levels and stem
cells are switched to a quiescent state (Frindel et al., 1992b). Using HPP-CFC and 
CFU-S cell populations, it has been shown that AcSDKP does not have a direct 
inhibitory effect on cell proliferation after a short in vitro incubation. AcSDKP 
however, blocks the action of stimulators of stem cell proliferation that are found 
in regenerating haematopoietic tissues (Robinson et al., 1992; Monpezat & 
Frindel, 1989). AcSDKP shows a direct and reversible inhibitory effect on the 
growth of human CD34+ subpopulations in response to growth factor stimulation 
(Bonnet et al., 1993). In the studies of Bonnet et al., (1993) AcSDKP was shown 
to reduce the numbers of both CD34+HLA-DRhlgh and HLA-DRlow populations.
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AcSDKP also demonstrated a greater inhibitory effect on the most primitive cells 
contained in the CD34++HLA-DRlow subpopulation.
While AcSDKP does not affect cycling murine haematopoietic progenitor 
cells after a short incubation period in mice (Robinson et al., 1992; Monpezat & 
Frindel, 1989), the peptide has an inhibitory effect on human progenitor cells 
(Guigon et al., 1990). This inhibition shows a bell shape response curve with no 
observable inhibitory effect at higher or lower AcSDKP concentration. Recent 
observations suggest that cycling murine progenitor cells may also be inhibited by 
the peptide (Jackson et al., 1996) after a prolonged incubation period. In addition 
to haematopoietic stem cells, AcSDKP inhibits the proliferation of lymphocytes 
isolated from both mammals and birds (Volkov et al., 1996a).
AcSDKP is active at the Go or early Gi phases as shown by the response of 
CFU-S to Ara-C and AcSDKP (Monpezat & Frindel, 1989). AcSDKP inhibits the 
proliferation of hepatocytes after partial hepatectomy in vivo (Lombard et al., 
1990) but has no such effect on the proliferation of the same cells in vitro (Lauret 
et al., 1989). Lymphocytes have been ruled out as intermediary cells in AcSDKP 
inhibitory pathway (Monpezat & Frindel, 1989). However, AcSDKP inhibits the 
cytotoxic effects of lymphocytes if added to mixed lymphocyte cultures from 
different donors (Lavignac et al., 1992). In mice, AcSDKP decreases the mixed 
lymphocyte reaction induced by H-2 incompatible allogeneic spleen cells (Frindel 
et al., 1992). The tetrapeptide has no inhibitory effect on the cell lines, 3T3, FDC- 
P2 and K562 in vitro (Lauret et al., 1989). However when continuous cell lines
are partially synchronised into cell cycle by low seium concentration or serum 
deprivation, AcSDKP blocks or retards their entry into S-phase from early Gi 
(Volkov et al., 1996).
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AcSDKP does not affect tlie cycling of the HL-60 cell line and fresh 
ieukaemic cells from patients with either chronic myeloid leukaemia (CML) or 
acute myeloid leukaemia (AML) (Bonnet et al., 1992b). Tliis effect is independent 
of the dose of AcSDKP or the use of growth factors such as IL-3 or GM-CSF. No 
inhibitory effect of AcSDKP on neoplastic cells has been observed so far at 
concentrations which inhibit normal cell proliferation (Bonnet et al., 1992b, 
Cashman et al., 1994; Resnitzky et al., 1995; Defard et al., 1997). However very 
high doses of AcSDKP (lO'5M) may inhibit the proliferation of leukaemic cells in 
vitro (Defard et al., 1997). Therefore AcSDKP can achieve suppression of normal 
cells without affecting tumour cell proliferation, thereby potentially aiding 
intensification of cytotoxic therapy.
1.7,3 Effect of AcSDKP on long-term bone marrow cultures
Addition of AcSDKP at weekly intervals to long term bone marrow 
cultures has no effect on the proliferation of progenitor cells. However daily 
addition of the peptide to LTBMCs induces a reversible inhibition of the 
proliferation of non-adherent progenitor cells with no effect on the adherent layer 
cells (Bonnet et al., 1992a; Hong et al., 1995; Jackson et al., 1996). In addition 
AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures 
from the effects of mafosfamide (Genevay et al., 1996). Studies using long term 
bone marrow cultures have demonstrated that addition of MIP 1(3 to cultures 
antagonises the inhibitory effect of AcSDKP on normal primitive cycling human 
progenitor cells (Cashman et al., 1994). Addition of > 50 ng/ml AcSDKP to long 
term cultures of human normal cells at the time of media change induces a 
selective and reversible decrease in the proportion of high proliferative potential
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erythroid and granulopoietic progenitors in the adherent layer that are in S-phase 
(Cashman et al., 1994).
Using stromal lines, an increased rosette formation between stromal cells 
and haematopoietic cells was observed in the presence of AcSDKP (Aizawa et al., 
1992; Lenfant et al., 1989a). Pre-incubation of stromal cells but not 
haematopoietic cells with AcSDKP increases haematopoietic cell binding to 
stromal cells (Aizawa et al., 1992). Moreover, stromal cell proliferation is 
inhibited but its production of growth factors is not affected (Lenfant et al., 1989).
Establishing LTBMCs in the presence of AcSDKP from bone marrow 
cells of dogs that have been treated with AcSDKP in vivo, showed that 7 days of 
AcSDKP treatment to LTBMCs had a marked effect on progenitor cell 
proliferation. When AcSDKP was added to cultures at weekly intervals, no effect 
was observed at 10'7 M AcSDKP with only 20 to 25% inhibition at 10'6 M (Hong 
et al., 1995).
1.7.4 Quantification ofAcSDKP in vivo
Using an enzyme immunoassay, AcSDKP has been detected in 
lymphocytes, and in low concentrations in granulocytes (Pradelles et al., 1990). 
The mean value of AcSDKP in human serum is 1.5 ± 0.47 picomoL/ml and there 
is no variation between age and sex (Liozon et al., 1993). There is an increase in 
the peptide levels in myeloproliferative disorders and in acute myelogenous 
leukaemia (Liozon et al., 1995). There is an early and sharp increase in the peptide 
during induction treatment in some patients with acute myeloid leukaemia 
(Liozon et al., 1995). The variations of the endogenous AcSDKP levels in patients 
are dependent on type, doses and schedule of chemotherapy following solid
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tumour treatment (Comte et al., 1997b). In Xenopus laevis, the concentration of 
AcSDKP decreases during the final oocyte maturation and during the initial 15 
hour period of exponential cell division of the embryo (Volkov et al,, 1995). 
Interestingly AcSDKP has no clinical side effects in dogs when it is administered 
continuously through indwelling catheters and the serum chemistry remains 
normal (Hong et al., 1995). Surprisingly, some dogs show rebound 
thrombocytosis following discontinuation of AcSDKP (Hong et al., 1995).
1.7.5 Comparison of the inhibitory effect of AcSDKP, TNFa, TGF-
P, MIP la andpEECDK
As demonstrated by Bonnet et al., (1995), AcSDKP, TNF a, TGF-p and 
MIP la all inhibit BFU-E and CFU-GM numbers in CD34+ subpopulation. 
However TNFa reduces the number of CFU-GM present in CD34+DRh,gh cells 
more than other substances. AcSDKP and MIP la require daily addition to cell
cultures to exert their inhibitory effect while TNFa and TGF-p inhibit cells 
regardless of the procedure used to administer them. AcSDKP is less inhibitory 
for CD34+HLA-DRhigh than for CD34++HLA-DR|OW. MIP la has the opposite 
effect to AcSDKP on the same cell population. TNFa and TGF-p inhibit both 
CD34+ populations equally.
Just as with AcSDKP, pEEDCK decreases myeloid progenitor cells and 
CFU-S in a reversible manner and inhibits cell populations from entering DNA 
synthesis induced by chemotherapy (Paukovits et al., 1991; Aidoudi et al., 1996). 
Interestingly, both pEEDCK and AcSDKP inhibit non-haematopoietic cells 
(Volkov et al., 1996b; Reichelt et al., 1987; Elgjo et al., 1986). Both AcSDKP and
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pEEDCK inhibit malignant ceils (Paukovits et al., 1990; Defad et al., 1997). 
However, the crucial difference between AcSDKP and other proliferation 
inhibitors is that AcSDKP inhibits Ieukaemic cells at very high concentrations that 
have no inhibitory effect on normal progenitor cell proliferation (Defard et al., 
1997). AcSDKP has however no inhibitory effect on tumour cells at 
concentrations that affect normal cell cycling (Resnitzky et al., 1995; Bomiet et
al., 1993).
From these studies it can be concluded that at present the only negative 
haematopoietic stem cell proliferation regulator known that shows differential 
effect on the proliferation of normal and Ieukaemic cells is AcSDKP. TGF-p and
TNFca both inhibit the proliferation of normal and Ieukaemic cells (Sing et al., 
1988; Broxmeyer et al., 1986). MIP la has a variable effect on the proliferation of 
myeloid leukaemia and in some cases it inhibits their proliferation (BroKmeyer et
ah, 1993).
1.8 AcSDKP AIND TUMOUR THEERAPY
The concept of using stem cell proliferation inhibitors to protect normal 
cells from cytotoxic effects of tiunour cell cytotoxic agents is a feasible one. It is 
based on the ability of inhibiting normal cell proliferation without affecting the 
proliferation of neoplastic cells. In this way phase specific cytotoxic agents can 
kill proliferating neoplastic cells while sparing normal non-proliferating cells 
(Tubiana et al., 1993).
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1.8.1 Physical cytotoxic agents
There are many ways by which physical cytotoxic agents can be used with 
AcSDKP to kill tumour cells while protecting normal haematopoietic cells. One 
way is by using phototherapy. Tumour cells selectively accumulate the 
hematoporphyrin derivative, photofrin 2, and merocyanine-540 which are very 
unstable to light of specific wave lengths (Bohmer & Morstyn, 1985; Atzpodien et 
al., 1987). Using this method it has been shown that the ability of AcSDKP to 
inhibit noimal GM-CFC proliferation protects this cell population from the 
cytotoxic effects of photofrin-2 sensitiser and phototherapy. Leukaemic cells are 
neither inhibited nor protected from sensitiser and phototherapy (Coutton et al., 
1994).
The other way of using physical agents and AcSDKP in protecting 
haematopoietic cells is to use heat treatment. Cycling haematopoietic cells are 
sensitive to heat treatment of about 43°C. This sensitivity is reduced in the 
presence of AcSDKP and normal progenitor cells are spared from hyperthermic 
damage while murine leukaemic cells are destroyed both in the presence and 
absence of the peptide (Wierenga & Konings, 1996; Wierenga et al., 1997).
Dogs given AcSDKP before and during 300cGy whole body iiradiation 
are protected from the myelotoxic effects of iiradiation (Deeg et al., 1997). 
AcSDKP however has no effect at higher doses of irradiation. Interestingly, 
AcSDKP has a protective effect on murine bone marrow myelotoxicity if given 
for 3 days beginning 24 hours before sublethal irradiation. Addition of G-CSF for 
10 days after AcSDKP produces an increase in platelet numbers which is not 
observed in the presence of AcSDKP alone (Watanabe et al., 1996b).
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1,8,2 Chemical cytotoxic agents
Administration of AcSDKP together with chemical cytotoxic agents may 
inhibit the proliferation of normal haematopoietic cells and give them a survival 
advantage over neoplastic cells. Indeed, giving mice low molecular weight 
extracts from foetal calf bone marrow 2 hrs before a lethal dose of Ara-C, protects 
animals with some surviving up to 8 months after treatment (Guigon et al., 1982).
While a maximum number of animals survive Ara-C treatment when AcSDKP is
given either simultaneously or 2 hrs after Ara-C, the same protective effect is 
noticed when AcSDKP and cyclophosphamide (CTX) are given 8 hrs apart 
(Bogden et al., 1991). The combination of AcSDKP with G-SCF induces an 
increase in the total numbers of leukocytes following Ara-C treatment without 
reducing the carboplatin-induced haematotoxicity (Li et al., 1998). Moreover 
AcSDKP and GM-CSF accelerate the recovery from leukopenia following three 
cycles of Ara-C with an increase in the white blood cells in general and 
granulocytes in particular (Bogden et al., 1998). AcSDKP also reduces 
doxorubicin-induced mortality in mice and protects cells responsible for long-term 
reconstitution, HPP-CFC and GM-CFC from doxorubicin-toxicity (Masse et al., 
1998). Masse et al.,(1998), also found that the recovery of the GM-CFC 
population in the AcSDKP-doxorubicin treated mice was optimised by the 
subsequent administration of G-CSF. AcSDKP with platelet factor 4 (PF4) given 
to mice before 5 FU accelerated the recovery in vivo of HPP-CFC, CFU-GM and 
BFU-E (Aidoudi et al., 1996).
AZT an antiviral agent used in the treatment of Acquired Immunity 
Deficiency Syndrome (AIDS), induces anaemia due to its toxic effects on 
erythroid progenitor cells (Dainiak et al., 1988). Pretreatment of bone marrow
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cells with AcSDKP in vitro induces a significant reduction in the toxicity of 3'- 
Azido-S-Deoxythymidme (AZT) to both human erythroid and myeloid progenitor 
cells (Grillon et al., 1993b). Moreover, AcSDKP prevents CFU-GM inhibition 
induced by HIV-infected cell-derived conditioned medium (Coutton & Chennann,
1997).
1.9 STAJBT1LTY OIF AcSDKP UN SERUM AND PLASMA
1.9.1 Angiotennin 1-converting ennyrne degrades AcSDKP
A comparative study of the stability of AcSDKP in human, horse, foetal 
calf serum and bone marrow cells revealed that the peptide had a very short t!4 in 
serum. The t% of AcSDKP in human serum is 45 minutes, in horse serum is 30 
minutes and the peptide has a tVz of 80 minutes in human plasma. The degradation 
of AcSDKP in horse serum is 4 times higher than foetal calf serum. Addition of 
captopril, a metalloprotease and angiotensin 1-converting enzyme inhibitor, 
increases the WZ of AcSDKP in vitro (Grillon et al., 1993a). Interestingly, plasma 
from leukaemic mice degrades this tetrapeptide faster than plasma from normal 
mice, with leukaemic bone mamow cells degrading it only after 4 hours of in vitro 
incubation (Wdzieczak-Bakala et al., 1993).
The short tVz of AcSDKP in plasma / serum has been attributed to the 
ability of angiotensin 1-converting enzyme (ACE) to degrade this peptide (Rieger 
et al., 1993). ACE cleaves the peptide bond Asp-Lys to release the C-terminal 
dipeptide Lys-Pro that is further degraded to Lys. The second step in AcSDKP 
degradation is under the control of leupeptin and E-64, HgCE' insensitive enzyme. 
There is a marked inhibition of AcSDKP degradation in the presence of captopril
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(10* M) while in the presence of the same concentration of iisinopril and 
enaiapriiat, the activity of the enzyme on AcSDKP hydrolysis remains at 20% and 
15% respectively (Rieger et ai., 1993). Plasma that has been extensively dialysed 
degrades the peptide to a lesser extent (Rieger et al., 1993).
1.9l Biology of ACE
Angiotensin 1-converting enzyme is a zinc dipeptidyl carboxypeptidase 
with endopeptidase activity on certain substrates. It is also known as peptidyl 
dipeptidase A, kininase II and EC3.4.15.1. Its primary specific fmction is to 
cleave the C-terminal dipeptide from angiotensin 1 to produce angiotensin II a 
vasopotent octapeptide (Bakhle, 1968). In general the enzyme cleaves the C- 
terminal dipeptides from oligopeptide substrates with free C-terminus in the 
absence of a penultimate proline residue or a terminal dicarboxylic amino acid 
(Hooper & Turner, 1987). ACE also performs endopeptidase activity on substrates 
that are amidated at their C termini where it cleaves a C-terminal dipeptide amide 
and/or a C-terminal tripeptide (Dubreuil et al., 1989). As shown by the activity of 
ACE on luteinising hormone-releasing hormone, ACE has activity on both the 
COOH and NH2 terminal peptides on some substrates (Skidgel & Erdos, 1985).
1.9.3 Novd. aa^itviiy ofACE
ACE hydrolyses several peptides with a differential effect on each peptide.
In addition to the hydrolysis of angiotensin 1, ACE also hydrolyses substance P, 
bradykinin and luteinising hormone-releasing hormone (Skidgel & Erdos., 1985; 
Bakhle et al., 1968; Dorer et al., 1974; Hooper & Turner, 1987). The hydrolysis of
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bradykinin and its higher homologues shows an inverse relationship of the 
hydrolysis rate with size and charge of the peptide (Dorer et al., 1974). ACE 
hydrolyses cholecystokinin and gastrin analogues by attacking the penultimate 
peptide bond that generates the C-terminal amidated dipeptide. It subsequently 
releases di-or-tri-peptides from the remaining N-terminal fragments (Dubreuil et 
al., 1989). As already stated, ACE is important in the first rate-limiting step in 
AcSDKP degradation (Rieger et al., 1993).
The activation of ACE to catalyse the hydrolysis of the peptides depends 
on the pH and presence of ions. It has been demonstrated using furanacryloyl-Phe- 
Gly-Gly that the hydrolysis of this molecule by ACE is activated by monovalent
anions in the order Cf>Br>F>N O3 >CH3 COO Anions are essential activator of
ACE at both acidic and alkaline pHs (Bunning & Riodan, 1983).
1.9.4 CCaructensation ofACE
Angiotensin 1-converting enzyme is membrane bound, but soluble ACE 
has been found in the body fluids such as lymph, plasma, amniotic fluid 
cerebrospinal fluid, seminal plasma, homogenates of prostate and epididymis 
(Erdos, 1990). Organs which contain ACE include kidney, intestine, placenta, 
choroid plexus (Erdos, 1990). ACE is bound to cell plasma membranes through its
intracellular C terminus. The secreted form is derived from the membrane boimd
form by post-translation proteolytic cleavage of the C-terminal region (Wei et al., 
1991; Soubrier et al., 1988).
ACE has a number of isoenzymes. For example there is an ACE 
isoenzyme found in the testes. This isoenzyme has a molecular weight of 90KDa 
while ACE from the rest of the tissues has a molecular weight of 140KDa. Both
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ACEs have the capability of cleaving dipeptide residues from carboxylic termini 
of angiotensin 1, bradykinin, met-encephalin, and ACE inhibitors have identical 
effects on both isoenzyme activities (Lanzillo et al., 1985). Indeed ACE isoforms
have also been found in the brain tissues. The two isoforms of ACE in the striatal
part of the brain have molecular weights of 180KDa and 170KDa. The variation 
has been found to be due to differential glycosylation of the same enzyme in 
different cell types of the brain. Just as the isoenzyme from the testes, these brain 
isoforms also have similar properties with regards to enzymic activity and 
inhibitor sensitivity. They are both able to hydrolyse substance P (Hooper & 
Turner, 1987).
A single gene encodes for ACE in the human genome. The differences in 
the expression of isoenzymes are under the control of an internal promoter that is 
tissue specific. The study on the structure of the gene for the testicular ACE 
isoenzyme, using the A, phage human DNA library showed that the large ACE 
mRNA is transcribed from exon 1 to 26 excluding exon 13 from which the small
testicular ACE is transcribed. The two isoenzymes have an identical sequence 
near their 3’-ends with unique sequences on the 5’-ends. The unique sequence of 
the large enzyme precedes that of the small enzyme which in turn precedes the 
sequence common to both enzymes by splicing introns from the primary mRNA 
(Hubert et al., 1991; Kumar et al., 1991).
1.9.5 Two homologous domains of ACE
Two putative active centres in human ACE have been deduced from the 
structure of cDNA. A highly hydrophobic sequence is located near the carboxylic 
terminal which anchors the enzyme to the cytoplasm of cells and the other region,
Chapter 1 - Introduction 50
also displaying hydrophobicity, is classified as the signal peptide. Glutamic acid 
and histidine that are implicated in the catalytic processes of other enzymes are 
found in both domains (Soubrier et al., 1988). There is a high degree of homology 
between the two domains. The C-domain is located in the carboxylic terminal 
region and the N-domain is in the amino terminal region of ACE. Ileal-fluid ACE 
contains a single N-domain while geiminal ACE contains a single C-domain 
(Deddish et al,, 1994). The rest of ACE in other organs contains both domains.
These domains have individual high affinity inhibitory binding sites. At 
high chloride concentrations, the chloride effect is much greater on the C-domain 
than the N-domain. The inhibitory constants for captopril, enalaprilat and 
Iisinopril are all in the nanomolar range on both domains (Wei et al., 1992). While 
some ACE inhibitors are site selective, a lot are not site selective. Lisinopril and 
delaprilat are C-site potent inhibitors while cilazapril, trandolaprilat ramiprilat, 
quinaprilat and enalaprilat are not site selective (Bevilacqua et al., 1996; Wei et 
al., 1992; Deddish et al., 1996; Rousseau-Plasse et al., 1996). On the other hand 
captopril and fosinopril are N-site potent inhibitors (Wei et al., 1992; Michaud et 
al., 1997). This site-specific action is influenced by the pH and chloride anion 
concentration. N-domain active site acts independently of chloride concentrations 
and loses it action at high chloride concentration (Wei et al,, 1992, Deddish et al., 
1996). Organ-specific glycosylation affects the binding characteristics of ACE 
inhibitors to N-or C-site of human tissue ACE (Bevilacqua et al., 1996)
Both the N and the C active sites of ACE exhibit dipeptidyl activity 
towards AcSDKP but the N-active site hydrolyses the peptide 50 times faster than 
the C-active site. Addition of monoclonal antibody directed towards the N-active 
site, results in inhibition of hydrolysis of AcSDKP by ACE, AcSDKP is therefore
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a specific substrate for the N-domain of ACE (Rousseau et al., 1995; Deddish et 
al., 1996). Captopril a known N-site potent inhibitor of ACE increases the serum 
levels of AcSDKP both in vivo and in vitro (Azizi et al., 1996). However lisinopril 
and other known C-site potent inhibitor of ACE also inhibit AcSDKP degradation 
(Rousseau-Plasse et al., 1996; Rousseau et al., 1995; Azizi et al., 1997).
1.9.6 ACE expression by pathological and haematopoietic cells
Macrophages are some of the haematopoietic cells known to produce ACE 
(Costerousse et al., 1993). High levels of ACE are also found in alveolar 
macrophages of smokers (Hinman et al., 1979). Levels of ACE are elevated in the 
alveolar macrophages of people with sarcoidosis (Silverstein et al., 1976). 
Culturing human normal monocytes for 6 hours induces cells to produce high 
levels of ACE and enzyme levels are increased in the presence of autologous 
serum and dexamethasone (Friedland et al., 1978). Cells exhibiting lymphoblastic 
leukaemia antigen have an increased ACE activity with substantial ACE activity 
levels in the pre-B phenotype (Beaumont et al., 1989).
1.10 ACE INHIBITORS
1.10.1 General mode of action ofACE inhibitors
As reviewed by Erdo, (1990), ACE is an important enzyme involved in the 
regulation of blood pressure. There are two pathways in the regulation of blood 
pressure. These are the renin-angiotensin pathway and the kininogen-bradykinin 
pathway. Renin cleaves angiotensinogen to angiotensin I that is further cleaved to
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angiotensin IL Angiotensin II is a vasoconstrictor and it also stimulates 
aldosterone release resulting in sodium retention and hence elevations of blood 
pressure. Kininogen is cleaved by kallikrein to bradykinin, which is a vasodilator 
in its own right. However ACE degrades bradykinin to inactive fragments. 
Bradykinin is a potent stimulator of endothelial prostaglandins and nitric oxide 
(Furchgott, 1983). Bradykinin also stimulates release of tachykinms and 
neurokinin A (Umemura et al., 1997). Therefore ACE inhibitor effects are 
mediated by increase in both bradykinin and its by products and also the 
suppression of angiotensin II production (Campbell et al., 1995). There is also 
evidence that ACE inhibitors may inhibit a kininase other than ACE (Campbell, 
1995).
Angiotensin 1-converting enzyme inhibitors were first isolated from the 
venom of a snake called Borthrops jararaca (Ondetti et al., 1971). Subsequently a 
few have been synthesised. ACE inhibitors are valuable therapeutic agents for the 
management of hypertension, myocardial infarction, congestive cardiac failure 
and diabetic nephropathy (Campbell, 1995). All ACE inhibitors have a common 
2-methyl propanalol-L-proline moiety (Barr & Cohen, 1992). The current 
clinically studied ACE inhibitors inhibit tissue located ACE. They differ in that 
some incorporate sulfhydryl group like captopril and zofenopril, the others have 
carboxyalkyl dipeptides like enalapril, lisinopril, ramipril, benazepril, cilazapril, 
peridopril, and quinapril, and others have the phosphinic acid for example 
fosinopril (Herman, 1992). The differences in the structure of ACE inhibitors may 
contribute to the differences in absorption, metabolism, distribution, and 
elimination of the drug in vivo. Moreover, it may also affect the affinity of the 
drug to ACE and therefore the observed effects and side effects of the drugs
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(Herman, 1992). Some of ACE inhibitors are prodrugs (Opie, 1994). The binding 
of ACE inhibitors to ACE involves specific molecular interactions. For example 
captopril incorporates a sulfhydryl group that binds to a zinc atom in the enzyme 
(Opie, 1994).
1.10.2 Side effects ofACE inhibitors
Most common ACE inhibitor side effects are: First-dose hypotension, 
acute renal impairment, hyperkalemia, cough, skin rashes, dysgeusia, bone 
marrow suppression, hepatotoxicity, angio-oedema, and foetopathy (Alderman, 
1996). Factors which predispose to first dose hypotension following ACE 
inhibitor therapy include sodium depletion, diuretics, vomiting, diarrhoea, old age, 
congestive cardiac failure and severe or complicated hypertension (Alderman, 
1996). Hyperkalemia results horn increased sodium excretion following ACE 
inhibitor therapy. Low levels of aldosterone following ACE inhibitor therapy can 
explain this side effect. ACE inhibitor therapy increases renal blood flow and 
glomerular filtration rate in normal kidney. However in renovascular disease there 
is a reduction in glomerular filtration rate and renal blood flow following ACE 
inhibitor therapy which makes kidney disease worse (Textor, 1997). Cough 
production has been attributed to inhibition of substance P degradation in the 
airways (Tomaki et al., 1996) and imbalance between thomboxane A2 and 
prostaglandin I2 (Umemura et al., 1997). Skin rashes may be explained by 
inhibition of kininase rather than ACE and autoimmune reactions to the sulphur 
moiety which forms part of captopril structure (Alderman, 1996). Hepatoxicity 
may also be attributed to the ability of ACE inhibitors to deplete liver glutathione 
levels. Reduced glutathione is an important substrate for the reductive
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detoxification of reactive intermediates such as hydrogen peroxide or 
hydroperoxides produced by glutathione peroxidase (Golik et al., 1995). 
Bradykinin, substance P or angiotensin II reduction and autoimmunity to these 
drugs may mediate ACE inhibitor-induced angio-oedema. Since ACE is found in 
amniotic fluid and it regulates prostaglandin synthesis, it is not surprising that 
ACE inhibitors cause foetopathy (Shotan et al., 1994; Barr& Cohen, 1991).
Captopril administration to rats and dogs has been shown to induce 
haematological changes consistent with haemolytic anaemia (Imai et al., 1979). 
However, the most common haematological side effect of captopril is neutropenia 
with or without pancytopenia (aplastic anaemia) (Cooper at al., 1983, Israeli et al., 
1985; van Brummelen et al., 1980). This side effect was first observed on 
hypertensive patients with systemic lupus erythematosis (Amann et al., 1980), 
renovascular hypertension (Staessen et al., 1980), chronic renal failure (Israeli et 
al., 1985), chronic obstructive uropathy (Strair et al., 1985) and on elderly patients 
(Kim et a!., 1989). In hypertensive chronic haemodialysis patients, captopril 
induces anaemia necessitating frequent blood transfusions (Hachache et al., 1995). 
In some cases a high dose of captopril was given for the treatment of hypertension 
and this high dose induced anaemia (Amann et al., 1980; Staessen et al., 1980). 
However, pancytopenia induced by captopril has been observed in hypertensive 
patients without other complications (Kim et al., 1989). In addition to humans, 
pancytopenia has been observed in a dog with normal renal function (Holland et 
al., 1996). At times pancytopenia caused by captopril can be fatal as was observed 
in an elderly patient with diabetes mellitus and chronic renal failure receiving 
normal doses of captopril (Gavras et al., 1981).
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All in all, the aim of this work is study the regulatory role of ACE on 
haematopoietic stem cell proliferation. By inhibiting ACE using captopril or 
lisinopril, the role of ACE on haematopoiesis will be evaluated. These 
investigations will indirectly analyse the role of the individual ACE domains on 
haematopoiesis. Therefore this work will emphasise the link between AcSDKP 
and ACE inhibitors in order to understand the underlying mechanism of ACE
inhibitor induced bone mareow failure. The work will also concentrate on the
beneficial effect of using ACE inhibitors with cytotoxic treatment with the aim of 
preserving stem cell integrity during neoplastic treatment. AcSDKP and its 
analogue made resistant to ACE degradation will also be studied. Studies will be 
done both in vivo and in vitro on mice. To understand the significance of ACE 
inhibitors and AcSDKP on haematopoiesis, long-term bone marrow cultures will
also be studied with these substances.
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CHAPTER 2
MATERIALS AND METHODS
2.1 SAMPLING OF HAEMATOPOIETIC CELLS
2.1.1 Mice
Eight to twelve week old female CD1, CBA/H, and a cross breed between CBA/H 
and C57BL/6 mice (CBA/H x C57BL/6) FI were used for these investigations. Some 
animals were purchased from Charles River, UK. In-house mice were bred and housed at 
the University of St. Andrews, Scotland, UK. They were kept in controlled conditions 
and fed on a diet of chlorinated water and RMI chow (Special Dietary Services, UK).
2.1.2 In vivo recruitment of haematopoietic stem cells into cell cycle
Mice were used in groups of three or four individuals per experiment unless 
otherwise stated. Haematopoietic stem cells were induced into cell cycle in vivo by 2 Gy 
whole body y-irradiation (CIS Biolnternational IBL 437C 137Cs y-irradiation source.
Dose rate 4.66 Gy/minute), 1-p-D-arabinofuranosylcytosine (cytosine arabinoside 
intraperitoneal injection (i.p) (Ara-C)) (Sigma, UK) at a dose of 100 mg/kg or 5 
fluorouracil intravenous injection (i.v)(5 FU) (Sigma, UK) at a dose of 150 mg/kg. Ara-C 
and 5 FU are both S-phase specific cytostatic agents (Millard & Okell, 1975; Kerr, 1989). 
Mice were killed by cervical dislocation and the femoral marrow was harvested 24 hour 
after 2 Gy whole body irradiation and Ara-C administration. Following in vivo 5 FU 
treatment bone marrow cells were sampled on day 4.
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2X3 Medium
The media used were made up from concentrates of either Dulbecco’s lOx (Gibco 
BRL, UK) or Fischer’s lOx (Gibco BRL, UK) supplemented with 50 iu/ml penicillin 
(Sigma, UK); 50pg/ml streptomycin sulphate (Sigma, UK); 2mM L-glutamine (Flow 
Lab, UK); NaHCOa (BDH, UK) according to manufacturer’s recommendation. 
Dulbecco’s medium routinely contained either 10% or 20% horse serum (Globepharm, 
UK) or 30% foetal calf serum (Globepharm, UK). These are referred to as either D10% or 
D 20% HS PS/G or D 30% FCS PS/G. In the case of Fischer’s medium, 20% horse serum 
as well as hydrocortisone 10'6M (Sigma, UK) were included in the medium. This is 
referred to as F 20% HS PS/G Hydro. Fisher’s medium that contained 10% horse serum 
without hydrocortisone was also used. This is referred to as F 10% HS PS/G. All media 
were made up with sterile distilled deionized water in a laminar horizontal flow hood 
(Bassaire, John Bass, UK).
2.1.4 Bone marrow single cell suspension
As soon as the mice were killed, the abdominal skin was swabbed with 70%
alcohol and a lower abdomen transverse incision was made. The cut skin was reflected
exposing the femurs and sometimes the tibias, which were removed with a pair of sterile 
scissors and put in 90-mm petri dishes (Sterilin, UK). Tissues were then carried into a 
sterile laminar horizontal flow hood where excess muscle tissue was scraped away using 
a sterile surgical blade (Swann-Morton, UK). The heads of the femurs were removed by 
cutting the neck of the femurs. The knee joints were disarticulated to reveal the soft 
cartilaginous articular surface. Using sterile forceps to hold the femurs, a 1 ml syringe 
(Becton Dickson, Ireland) with blue tip microlance needle (23G) (Becton Dickson, 
Ireland) containing 1 ml of appropriate medium was used to gently bore a hole through
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the remaining cartilaginous part of the knee joint into the marrow cavity, and the medium 
was gently forced into the femur. This method was used to wash out bone marrow cells 
into a 5 ml plastic vial (Teklab, Sacristone, UK). The femur was flushed in the opposite 
direction using the same amount of medium by inserting the needle in the cut end of the 
neck of femur and the whole procedure was repeated as with the knee part of the bone. 
The femoral shaft was washed through in this manner twice. This process was carried out 
on all femurs. In cases where tibias were used, both ends of the tibias were cut and the 
proximal end only was used to flush cells out of the bones. A single cell suspension was 
made by progressively aspirating the bone marrow cell suspension through a 23G blue 
tipped microlance needle followed by a 25G orange tipped microlance needle (Becton 
Dickson, Ireland). Cells were then ready for assaying. Before assaying, cells were first
counted.
2.1.5 Cellularity determination
Cell numbers in tubes were counted on a Coulter coimter model ZM (Coulter 
Electronics, UK)' according to the manufacturer’s recommendations. Pooled cells were 
routinely suspended in 2 mis of medium in a 30 ml universal tube (Sterilin, UK). The 
cellularity of the single cell suspension was determined by diluting 40 pl of cell 
suspension into 20 mis of Isoton II (Coulter Euro Diagnostics, UK) in a 20 ml clear 
plastic vial (Coulter Euro Dignostics, UK) with three drops of red cell lysing agent called 
Zaponin (an acetic acid based lysing agent) (Coulter electronics, UK). The Coulter 
counter setting was determined after calibration such that this dilution gave the number of 
nucleated cells per millilitre (see Table 2.1). The contents of each femur were routinely 
suspended in 1 ml of D20%HS PS/G. Therefore the femur cellularities were determined 
by diluting 20 pl from the cell suspension in half of the Isoton II solution used for pooled
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ceils. The average of three Coulter readings was determined as the number of cells per
millilitre.
Table 2.1 Coulter Settings were;
Tissue Haematopoietic cells Long term cultured hone 
marrow cells
PARAMETER O.5mls O.5mls
current 130 700
Lower threshold" 30 21
Full scale 10 1
polarity + +
attenuation 1 1
Pre set gain 2 2
2.2 Assays
2.2.1 Colony assays
a. Growth Factors
Conditioned medium was used as a source of growth factors in some experiments. 
Conditioned medium was derived from the WEHI-3B myelomonocytic leukaemic cell 
line and the L929 fibroblast cell line. WEHI-3B is a source of interleukin-3 (IL-3) (Ihle et 
al., 1982) and L929 cells produce macrophage colony stimulating factor (M-CSF) 
(Stanley & Heard, 1977).
Recombinant growth factors were also used. These were:
1. Recombinant murine granulocyte-macrophage colony stimulating factor (Immunex, 
U.S.A) at 40 Units/ml (r mu GM-CSF).
2. Recombinant murine interleukin-3 (R&D Systems, UK) at 10 ng/ml (r mu IL-3).
3. Recombinant human interleukin-1p (Immunex, U.S.A or R&D Systems, UK)
at 10 units/ml (r hu IL-lp).
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4. Recombinant murine macrophage colony stimulating factors (R&D Systems, UK) at 
20 ng/ml (r mu M-CSF).
b, Granulocyte-Macrophage Colony Forming Cells Assay
Progenitor cells were investigated using the granulocyte-macrophage colony
forming cell (GM-CFC) assay. Cells (5 x 105 cells/ml) were suspended in D20%HS PS/G
in 30 ml universal tubes (Sterilin, UK) and kept in a water bath at 37°C. 8 mis of
D20%HS PS/G were aliquoted into each of the 30 ml universal tubes and these tubes
were placed in a water bath at 37°C. A bijoux bottle of 3% (v/v) agar (Bacto Agar; Difco
Labs; Detroit, MI) was melted in boiling water in 100 ml glass beaker (Pyrex, UK). Eight
30 mm triple vent nontissue culture grade petri dishes (Sterilin, UK) per investigation
were laid out in the hood and labelled. To each petri dish, 40-units r mu GM-CSF were
added to give a final concentration of 40 units in the agar/cell mixture. The warmed
universal tubes containing cells and the ones containing medium alone were removed
from the water bath and placed into the laminar flow cabinet. 1 ml of melted agar was
added to the universal tubes containing media followed by 1 ml of cell suspension and
thoroughly mixed by gentle inversion. 1 ml of a mixture containing 5x104 cells/ml and
0.3% agar was pipetted into each of the eight petri dishes. Dishes were gently swirled
around to spread the mixture out over the entire surface of the plate and allowed to gel for
approximately five to ten minutes.
Semi-solid cultures were placed into cleaned plastic container that had been
swabbed with 70% alcohol and placed in an incubator (Heraeus instruments, Germany). 
They were incubated at 37°C, in 10% CO2 in a fully humidified atmosphere for 7 days.
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Fig. 2.1 The GM-CFC assay
1ml Cells 
1ml 3% Agar
8ml D20%HS PS/G
1ml of the mixture pipetted 
in 30mm non tissue culture 
grade petri dishes
▼ containing rmGM-CSF
(colonies of 50 or cells were counted)
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After 7 days dishes were removed from the incubator and colonies counted using a dark 
field microscope (Kyowa, Japan). Colonies containing 50 or more cells were counted. 
Different types of colonies were recorded. All colonies regardless of shape were 
considered. Fig. 2.1 summarises the general protocol for GM-CFC assay.
C. High Proliferative Potential- Colony Forming Cell Assay 
(HPP-CFC-1).
Two layers of semi-solid agar cultures are required for this assay. These layers are 
called the feeder and cellular layers. The basal layer is the feeder layer to which growth
factors are added.
Feeder layers
8 mis of D20%HS PS/G were aliquoted into 30 ml universal tubes (Sterilin, UK).
1 ml of a mixture of r mu M-CSF at 200ng/ml, r mu IL-3 at lOOng/ml and r hu IL-lp at 
100 units/ml suspended in D20%HS PS/G was added to each tube. When conditioned 
medium was used as a source of growth factors, 7 mis of D20%HS PS/G were aliquoted 
into 30 ml universal tubes and 1 ml of conditioned medium from WEHI-3B (10% v/v) 
and L929 (10% v/v) each separately was added to each tube. Tubes were then placed in a 
water bath at 37°C for approximately five minutes to be warmed. 5% (v/v) agar (Bacto 
Agar; Difco Labs; Detroit, MI) in a bijoux bottle was melted in boiling water in a 100 ml 
glass beaker (Pyrex, UK). Four 60 mm nontissue culture grade triple vent petri dishes per 
group were laid out in the horizontal laminar flow hood. Universal tubes were then 
removed from the water bath and 1 ml of 5% agar was added. Before the agar could gel,
2 mis of the agar-growth factors medium mixture, thoroughly mixed were pippetted into 
each of the petri dishes. Dishes were kept in the hood for approximately five minutes
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Fig. 2.2 The HPP-CFC assay
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until they gelled. To avoid pH changes they were then placed in the incubator until the
cellular layer was ready to be added.
Cellular layers,
10 mis of single cell suspensions containing 2.5 x 105 cells/ml were suspended in 
D20% HS PS/G in 30 ml universal tubes. This was done under sterile conditions in the
laminar flow hood. These universal tubes were then placed in a water bath at 37°C. 8 mis 
of D20%HS PS/G were pippetted in 30 ml universal tubes, 3% (v/v) agar was melted in 
boiling water in a 100 ml glass beaker. Feeder layer petri dishes were removed from the 
incubator and placed in the hood. Single cell suspensions and universal tubes containing 
media were removed from the water bath and taken to the hood, 1 ml of 3% (v/v) agar 
was then added to universal tubes containing media followed by 1 ml of single cell 
suspensions and the mixture was thoroughly mixed by gentle inversion of universal tubes. 
2 mis of single cell suspension with 0.3% (v/v) agar mixture was then very gently 
pipetted over the feeder layer taking great care not to puncture the feeder layer. The 
cellular layer finally contained 0.3% (v/v) agar and 5x104. Cultures were allowed to gel. 
Gelled cultures were stored in a 70% alcohol wiped plastic container and incubated at 
37°C in 10% CO2 in a fully humidified atmosphere for 14 days.
Staining and counting
On day 13 of incubation, cultures of HPP-CFC colonies were removed from the 
incubator and laid out in the laminar flow hood. 0,8 mis of an autoclaved solution of 1 mg 
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride (INT)/ml 0.9% (w/v) 
NaCl (BDH, UK) was added to each petri dish (Bol et al., 1977). Petri dishes were then 
replaced in plastic containers and returned to the incubator for a final 24 hrs of
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incubation. INT gets metabolised by viable cells from colourless to a red tetrazolium salt. 
This makes viable colonies appear dark red in colour thus making macroscopic counting 
possible. Colonies greater than 2 mm in diameter were counted when WEHI-3B and 
L929 were used as sources of growth factors. However, smaller colonies of 1 mm in 
diameter visible to the naked eye were counted when recombinant growth factors were 
used. Fig.2.2 summarises the way HPP-CFC were cultured.
2.2.2 S-phase suicide assay
Suicide assay was performed to determine the proportion of haematopoietic cells 
in S-phase of the cell cycle. This was done on whole bone marrow cell suspension. This 
assay involved incubating half of the cell suspension with Ara-C (25 gg/ml) and the other 
half with media alone prior to clonogenic semi-solid agar assays. This killed cells that 
were in S-phase of cell cycle at the time of incubation. This is observed as a loss of 
colony forming potential when these incubated cells are plated in semi-solid agar 
cultures. Cell cycle specific cytotoxic agents either bind to enzymes required for DNA 
replication or get incorporated into DNA bases, stopping DNA replication and thus 
resulting in cell death. Therefore indirectly it was possible to assess the proportion of the 
tested haematopoietic cells that were in S-phase after cells were subjected to various 
treatments in vivo or in vitro. (Fig. 2.3 summarises the general protocol for the S-phase 
assay).
The general procedure for S-phase suicide assay involved two single cell 
suspensions in 30 ml universal tubes (Sterilin, UK). Ara-C was routinely dissolved in the 
medium used for cell incubation. To the first single cell suspension 25 pg/ml Ara-C was 
added with equal volume of incubation medium added to the other cell suspension. Cell 
suspensions were either incubated for 1 hr at 3 7°C in a water bath or when Ara-C was
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added at the end of incubation period, cell suspensions were kept for 1 hour in the
incubator. At the end of any incubation period, cell suspensions were washed twice in 20 
mis of D20%HS PS/G by chill spinning at 1000 r.p.m (approximately 140G) for 10 
minutes in a centrifuge (Fisons-MSE, UK) to remove all Ara-C in the supernatant.
Fig. 2.3 The S-phase suicide assay.
2ml single cell 
suspension incubated
with 25p,g/ml Ara-C
for I hr at 31° °C
2ml cell suspension 
incubated in medium 
alone for llir at 37°C
Washed twice in a chilspin centrifuge at 
1000 r.p.m
▼
A single cell suspension made 
and cellularity adjusted to 
either 5x105 or 2.5x105 
cells/ml
A single cell suspension made
and cellularity adjusted to 
either 5x105 or 2.5x10)5 
cells/ml
Plated for either HPP-CFC 
or GM-CFC or Both
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Afterwards cells were resuspended as a single cell suspension by gently passing them 
through a 25G yellow needle a few times using a 1 ml syringe. They were then ready to 
be counted and plated for haematopoietic stem cell or progenitor cell assays.
Colony numbers derived from cells incubated with Ara-C prior to the GM-CFC or 
HPP-CFC-1 assays and colony numbers from control cell suspensions determined the 
approximate percentage of cell in S-phase. The computer program calculated the 
difference in colony numbers derived from Ara-C incubated cell suspensions and control 
cell suspension. The difference in colony numbers was divided by control cell suspension 
colony numbers multiplied by 100 to give the proportion of cells in S-phase.
2.2.3 ASBJTP asa
Single cell suspensions were incubated in D30%FCS PS/G for up to 24 hours. 
AcSDKP levels were assayed before rn vitro incubation and at 24 hours following 
incubation. For the initial measurements of AcSDKP, 2 mis of 5x1044 cells/ml in 
D30%FCS PS/G were transferred to two pairs of 10 mis plastic tubes (Sterilin, UK). 
Tubes were immediately centrifuged at 1000 r.p.m for 10 minutes. From each tube, 0.5 
ml of the supernatant was aliquoted into three 2 mis polypropylene cryotubes (Corning, 
Cambridge, Canada). All cryotubes were kept at -20°C until needed.
AcSDKP levels in regenerating bone marrow following 2 Gy and cytotoxic drug 
treatment were measured after incubation. Single cell suspensions in D30%FCS PS/G 
were transferred to each of the four 30 mm non tissue culture grade petri dishes. Petri 
dishes were then placed in the incubator at 37°C in 10% CO2 fully humidified 
atmosphere. After 24 hours cell suspensions were transfeiTed to labelled 10 mis plastic 
tubes. As above cells were centrifuged and the supernatant was aliquoted into 
polypropylene cryotubes and stored at -20OC until needed for assay. Supernatants placed
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on ice were transported to Institut de Chimie des Naturelles in France where AcSDKP 
assay was performed.
Assays were done by diluting samples 1 in 3 with methanol and incubated for 1 
hour at 4°C. The samples were centrifuged at 5000G for 15 minutes. The protein pellet 
was discarded and the collected supernatants were submitted to an enzyme immimoassay 
after evaporation according to the procedure described by Pradelles et al., 1990. In brief 
the supernatant was aliquoted into microtitre plates washed with 10'° M phosphate buffer 
pH 7,4 containing 0.05% Tween 20. The reagents were dispensed as follows: 50 pi of
standard AcSDKP or biological samples, 50 pi of diluted enzymatic tracer (1,3 Ellman
units/ml) and 50 pi of AcSDKP diluted antiserum (Lot TP 13, 1/30,000). Plates were then 
covered with adhesive sheet and left for 18 hrs at 42C. Afterwards, plates were washed 
again and 200 pi of enzymatic substrate (Ellman’s reagent) was added to each well. After 
90 minutes of gentle shaking at room temperature in half-light, the absorbance at 414 nm 
in each well was measured automatically.
2.3 ACETYL-SER-ASP-LYS-PRO (AcSDKP) AND ANGIOTENSIN 1 
CONVERTING ENZYME INHIBITORS (ACEI).
Two types of AcSDKP were used in this work: the natural synthetic peptide and a 
further peptide that has been rendered resistant to degradation by proteases at the Asp- 
Lys bond by replacing it with an aminomethylene vj/ bond (Gaudron et al., 1997). These
are referred to as AcSDKP and AcSD\j/KP respectively. AcSDKP (Mw = 487) (IPSEN-
Biotech; Paris, France) and AcSDyKP (CNRS, Gif-sur-Yvette, France) were supplied as 
lyophilised samples and stored at -20°C. The peptides were dissolved in sterile distilled 
water, aliquoted in polypropylene cryotubes (Corning; Coming Costar Corporation,
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Cambridge, Canada), and stored at -20°C. Each peptide was used once at a final 
concentration of 10'° M.
Two angiotensin 1-converting enzyme inhibitors (ACEI) were studied. These 
were captopril and lisinopril, both purchased from Sigma, UK. The drugs were dissolved 
in the same medium used for cell incubation and tissue culture. Both were used at a final
concentration of IpM (Grillon et al., 1993a). However for in vivo injection, they were 
dissolved in saline (0.9% NaCl) (Antigen Pharmaceuticals, Ireland) and injected 
intraperitoneally (i.p) at either 10 mg/kg or at 100 mg/kg mouse body weight.
2.4 METHOD FOR COLLECTING PLASMA AND SERUM
Mice were killed by schedule 1 method and the abdominal skin was swabbed with 
70% alcohol. Chest wall was cut in V-neck using a pair of sterile scissors. The chest 
organs were pushed to one side and the tips of scissors were passed to the posterior 
thoracic wall. An incision was made through the aorta without searching for it. Following 
which blood filled the chest cavity. Using cooled pasteurpippettes, blood was transferred 
into 1.5 mis Eppendorf tubes (Nunc, Denmark) with or without 20 microlitres of heparin 
(100 units) (CP Pharmaceuticals Ltd., UK) which were placed on ice. Samples were 
transferred into a microcentrifrige (Denver, UK) which was kept at 4°C and centrifuged at 
7000 rpm for 10 minutes. Plasma was sampled from blood collected in the presence of 
heparin. Serum was collected from blood sampled in the absence of heparin. These 
samples were taken off as supernatants with a pasteurpipette after centrifuging. Samples 
were placed into 30 ml universal tubes ready for in vitro incubation. Approximately 3 
mice produced 1 ml of sample.
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2,5 METHOD FOR ASSAYING ACE ACTIVITY
A sigma kit method was used for this assay. This is a spectrophotometric method 
which utilises the synthetic tripeptide substrate N-[3-(2-furyl)acryloyl]-L- 
phenylalanylglycylglycine (FAPGG). ACE catalyses FAPGG to form FAP and 
Glycylglycine. Hydrolysis of FAPGG results in a decrease in absorbance at 340 nm. ACE 
activity in the sample is determined by comparing the sample reaction rate to that 
obtained with the ACE calibrator. The procedure measures the catalytic rate of the
COOH domain of ACE.
The Sigma kit used was kept at 4°C. ACE calibrator was reconstituted according 
to the instructions in its package insert. 200pl of ACE reagent solution was pipetted into 
each of two cuvettes (UV range, disposable; Merck, UK) labelled ‘Test’ and ‘Calibrator’. 
20pl of plasma or serum to be tested was added to the test cuvette and 20pl of ACE 
calibrator was added to the calibrator cuvette. Samples were mixed by inversion. 
Cuvettes were placed in a water bath at 37°C for approximately 5 minutes. Following this 
initial incubation, cuvettes were placed in a spectrophotometer (Cecil Instruments, CE 
594 Double Beam, UK) and absorbance of test and calibrator were determined at 340nm. 
After the initial reading, samples were immediately transferred back to the water bath. 
Approximately 5 minutes later a second set of absorbances was recorded. ACE activity 
was determined by the difference in absorbance of the test sample over 5 minutes divided 
by the difference in absorbance of ACE calibrator multiplied by activity of calibrator. 
The assigned value of activity of calibrator at 37°C was 40 units/1.
!
'3
.1
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2.6 IN VITRO INCUBATIONS
2.6.1 The effect of AcSDKP and captopril on GM-CFC proliferation
Bone marrow cells were flushed from femurs of CDl mice using D30%FCS 
PS/G. A single cell suspension was suspended in the same medium and 2 mis was 
aliquoted into each of four 30 mm triple vent non tissue culture grade petri dishes. Dishes 
were then incubated at 37°C in 10% CO2 in a fully humidified atmosphere for 7 hours. 
Ara-C suicide assay was carried out after 7 hours, making a total in vitro incubation time 
of 8 hours. At the end of the incubation period cells were transferred into 30 ml universal 
tubes and washed twice with D20%HS PS/G at 1000 r.p.m.(approximately 140G). A 
single cell suspension was made and the cellularity was adjusted to 5x10° cells/ml. The 
single cell suspension was plated for GM-CFC.
2.6.2 ACE inhibitors and AcSDKP on HPP-CFC-1 proliferation
Following in vivo recruitment of haematopoietic stem cells into the cell cycle by 
2 Gy-y-irradiation, Ara-C (lOOmg/kg) i.p injection or 5 FU (150mg/kg) i.v injection, 
mice were killed and femoral bone mairow cells were sampled at appropriate times using 
D30%FCS PS/G. A single cell suspension was suspended in the same medium and 
samples containing 5x10° cells/ml were incubated. Control bone marrow cells taken from 
mice that were not given cytotoxic insults were included.
A control short incubation period was initially done (T = 0). 2 mis of bone 
marrow cell suspensions in D30%FCS PS/G were transferred to each of the four 
universal tubes. An S-phase suicide assay was then performed. At the end of the suicide 
assay, cell suspensions were washed twice with D20%HS PS/G by centrifuging at 1000 
r.p.m. (140G). A single cell suspension was made and cells were counted. After counting
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Fig. 2.4 In vitro incubation of regenerating bone marrow 
cells with drugs.
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the cellularity was adjusted to the number required for HPP-CFC-1 assay and cells were 
then plated.
The proportion of HPP-CFC-1 in S-phase was assessed after 24 hours of in vitro 
incubation (T = 24). 2 mis of bone marrow cell suspension in D30%FCS PS/G was 
transferred to each of four 30 mm triple vent nontissue culture grade petri dishes. Dishes 
were incubated at 37OC in a 10% CO2 fully humidified atmosphere. After 23 hours of 
incubation, petri dishes were removed from the incubator and taken to a flow cabinet. 
Ara-C S-phase suicide assay was performed according to the general protocol. Dishes 
were then replaced in the incubator and incubated for a further 1 hour. At the end of the 
S-phase suicide assay, cell suspensions were transferred to 30 ml universal tubes and 
washed twice with D20%HS PS/G by centrifuging them. After washing a single cell 
suspension was made and cells were counted. The cellularity was adjusted for HPP-CFC- 
1 assay.
Supernatant from bone marrow incubated with drugs and their controls were 
assayed for AcSDKP concentration at the beginning and at the end of the incubation 
period. Cell suspensions were washed once at 1000 r.p.m and 0.5 mis from each of 
supernatants were aliquoted into 3 cryotubes and stored at -20°C and sent to France. The 
method used for in vitro incubation is summarised in Fig.2.4.
2.7 METHOD FOR INCUBATING SA2 JMBl MYELOID 
LEUKAEMIC CELL LINE.
The myeloid leukaemic cell line (SA2 JMBl) was developed at the University of 
St. Andrews. Primary myeloid leukaemias were induced in 13 week old CBA/H male 
mice following exposure to whole-body doses of 3 Gy X-irradiation (250 kVp 14mA, 0.5 
mm Cu at dose rate of 0.8 Gy/min). This is one of the clones developed after serial
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passaging leukaemic cells in further groups of mice following i.p. injection of 1.5 x 106 
cells (Hepburn et al., 1987), This cell clone is kept in liquid nitrogen at the University of
St. Andrews.
SA2 JMBl (SA2) at 106 cells/ml in cryotubes were thawed and drop by drop 
transferred into a 25-cm4 tissue culture flask (Nunc, Denmark). 10 mis of F10%HS PS/G 
were slowly added to the flask. The flask was gassed with 5% C02/air to adjust pH and 
was incubated at 37°C for three days. This enabled cells to divide. After 3 days cells were 
counted on the Coulter counter. Due to the absence of red cells, no zaponin was added to 
Isoton-II. The Coulter settings were Current 700, Lower Threshold 30, Full Scale 1 and
Attenuation. 8.
SA2 were also incubated in vitro for (T = 0) and (T = 24). For control (T = 0), 2 
ml of cell suspension (4 x 106 cells/ml) in D30%FCS PS/G were transfeiTed to two pairs 
of universal tubes. 25pg/ml Ara-C for the S-phase assay was added to one tube of each 
pair. Cells were then incubated at 37°C in a water bath for 1 hour. After the incubation 
period cells were washed twice with D20%HS PS/G. Cells were counted and cellularity 
adjusted for the colony assay.
For in vitro incubation (T = 24), 2 mis of SA2 cell suspension (4 x 104 cells/ml) in 
D30%FCS PS/G were placed in each of four 30 mm nontissue culture petri dishes. Cells 
were incubated at 37°C /10% CO2 in fully humidified air. After 23 hours of incubation, 
cultures were removed from the incubator and placed in a laminar flow hood. An Ara-C 
S-phase suicide assay was performed. After this, cell suspensions were transferred to 
labelled 30 ml universal tubes. They were washed twice with D20%HS PS/G and the 
cellularity was adjusted. They were then ready for plating in semi-solid agar cultures.
For agar cultures, cells were suspended in D20%HS PS/G (5 x 104 cells /ml) in 
30-ml universal tubes. These were placed in a water bath at 37°C. 8 mis of D20%HS
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PS/G was pipetted into each 30 ml universal tube and also placed in a water bath at 37°C. 
A bijoux bottle of 3 % (v/v) agar (Bacto Agar; Difco Labs; Detroit, MI) was placed in a 
100 ml beaker with boiling water to melt the agar. 30 mm nontissue culture grade petri 
dishes (8 per group) were labelled and placed in the hood. Universal tubes containing 
medium alone were removed from the water bath and 1 ml of 3% agar was added to the 
universal tubes containing media followed by 1 ml of cell suspension. Cells and agar 
were thoroughly mixed by gentle inversion of the universals. 1 ml of the mixture was 
pipetted into each of the 30 mm nontissue culture grade petri dishes. Dishes were swirled 
around to spread the mixture equally over the base. No growth factors were used in this 
procedure. The 5 x 10° cells per dish with 0.3% agar were allowed to solidify for 
approximately 5 minutes. Incubation and counting procedure was identical to the one 
performed for GM-CFC assay in the general protocols.
2.8 IN VIVO EFFECTS OF ACE INHIBITORS ON 
HAEMATOPOEITIC STEM CELL PROLIFERATION
To test the effect of ACE inhibitors on haematopoietic stem cell cycling in vivo,
two groups of animals were selected. Haematopoietic stem cell proliferation was induced
in one group of mice by 2 Gy-y-irradiation, Ara-C (lOOmg/kg) i.p injection or 5 FU
(150mg/kg) i.v injection, the other group of mice did not receive cytotoxic stress. In
general six animals were used per group. Three animals in each group received normal
saline intraperitoneally (0.9% NaCl) at a dose proportional to the weight of the animal.
The other three mice received ACE inhibitors that were dissolved in normal saline at the
human therapeutic recommended dose for each ACE inhibitor. Therefore to test the effect 
of lisinopril or captopril on HPP-CFC-1 proliferation, mice received either a single dose 
at 10 mg/kg (Goa et al., 1996) orlOOmg/kg (Martin et al., 1984) 1-hour after irradiation. 
Animals were killed 24 hours following irradiation or Ara-C and at day 4 following 5 FU.
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Femurs were removed and their contents flushed into 5 ml vials using D20%HS PS/G by 
the method described in the general protocol for sampling haematopoietic cells. Single 
cell suspensions were made in D20%HS PS/G and an S-phase suicide assay was 
performed. After 1 hour in vitro incubation, cells were washed twice in D20% HS PS/G, 
the cellularity adjusted to 2.5 x 105 cell/ml for HPP-CFC-1 assay.
2.9 CAPTOPRIL AND AcSDKP LEVELSJWFLFO
Captopril was administered 1 hour after 2 Gy y-irradiation or Ara-C in the same 
way as performed in the HPP-CFC-1 in vivo assay. Plasma was sampled 1 5, and 23 
hours after captopril administration, which was 2, 6, 24 hours following cytotoxic insult. 
The method for plasma collection was the same as described for the in vitro ACEI 
studies. All plasma samples were collected on ice and stored at -20°C in polypropylene 
cryotubes. They were then sent to France where AcSDKP concentrations were assayed. 
This assay was performed in the same way as the in vitro experiments described in the 
section for investigating the short and long-teim effects of ACEI on HPP-CFC-1 cycling 
following cytotoxic insults to the bone marrow.
2.10 HIGH OR LOW FRACTIONATED Ara-C DOSES
Six groups of mice each consisting of three mice per group were selected for this 
experiment. For low dose Ara-C fractionation, all animals received two doses of Ara-C at 
200mg/kg body-weight 24 hours apart, making a total dose of 400mg/kg body-weight of 
Ara-C. Drugs were given intraperitoneally (i.p.). Three groups of mice received 
lOOmg/kg body-weight captopril i.p. 1 hour after the first dose of Ara-C. The other three 
groups received normal saline (i.p.) at a dose equivalent to weight by volume. Animals
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were killed at days 3, 7 and 10. The spleen from each mouse was excised after opening 
the abdomen in layers using sterile instruments and it was placed in a 5 ml tube and 
weighed on a scale (Sartorius, Germany). Afterwards, femurs were sampled. One femur 
from each mouse was initially made into a single cell suspension in D20%HS PS/G as 
described. Femur cellularities were determined for each femur as already described in 
section 2.1.5, Then all single cell suspensions were pooled from femur contents of each 
group of mice. Cells from each group were divided into two universal tubes. One tube
was used for both GM-CFC and HPP-CFC-1 numbers and the other was used for
determining the percentage of HPP-CFC-1 in S-phase for both GM-CFC and HPP-CFC-1 
on a pooled cell suspension using methods already described in the colony assay section 
and the Ara-C S-phase suicide assay section.
To test the effect of a high-fractionated dose of Ara-C, Ara-C was administered in 
two doses of 400mg/kg (i.p) body-weight to make a total dose of 800mg/kg body weight 
Ara-C. The second dose was given 24 hours after the first dose to all six groups of mice. 
Captopril at lOOmg/kg body-weight (i.p.) was given to three groups of mice 1 hour after 
the first dose. The three other groups received saline i.p. at the same time as the other 
mice received captopril. As in the previous investigation of low dose Ara-C, spleen 
weights, femur cellularity and the proportion of both HPP-CFC and GM-CFC in S-phase
were assessed.
2.11 ESTABLISHMENT OF LONG-TERM BONE MARROW 
CULTURES
All haematopoietic cells for establishing long-term bone maiTow cultures were
taken from femurs of eight to twelve year old crossbred mice (CBA/H x C57BL) FI. 
Animals were killed by cervical dislocation and their femurs were dissected out. The
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femur cellularity was approximately 1.2 x 10° nucleated cells per femur. One femur was 
used to set up one flask of LTBMC.
In a laminar flow hood with sterile instruments excess muscle was removed from 
femurs and the marrow of each femur flushed with F20%HS PS/G Hydro mto 25-cm° 
conical flask, using a syringe with a 21 gauge blue tipped needle. No attempt was made 
to make a single cell suspension. Six flasks were set up for each protocol. To adjust pH, 
all flasks were gassed with 5% CO2 for approximately 2 minutes and incubated at 33°C. 
Total media change, addition of fresh drugs, and gassing was performed once a week. 
Establishment of the adherent layer was observed with an inverted microscope. Cells 
from each protocol were pooled and transferred into 100 ml conical glass beakers (Pyrex, 
UK) for analysis. Hie adherent layer cells were scraped from the bottom of the flasks by 
a disposable cell scraper (Greiner, UK). They were then suspended in 10 mis F20%HS 
PS/G hydro and transfereed to a conical glass flask and analysed.
The procedures for determining flask cellularity in the non-adherent layers were 
the same as for counting bone marrow cells described in section 2.1.5. A sample of 
pooled cells from each group was put in 20 ml Isoton-II in plastic vials ready for Coulter 
counting. Coulter settings were different from those described with fresh bone marrow 
cell (see table 2.1) and no Zaponin was added in the 20 ml clear vials since there were no 
red cells to be destroyed. Adherent layer cells were counted in the same way as the non­
adherent layer cells.
After counting, 2 mis taken from each pooled sample were transferred to each of
the six universal tubes. Four universal tubes were used for HPP-CFC and GM-CFC
suicide assay in the same way as described in the general protocol. One of the other two 
universal tubes was used for the HPP-CFC colony numbers and the other for GM-CFC 
colony numbers. The feeder layer for HPP-CFC was made up with conditioned medium
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(10% v/v WEHI and L929 combined) and the GM-CFC were done in the same way as
the rest of the investigations.
2.12 DATA ANALYSIS.
The data are presented in tables followed by bar graphs with standard eiTors of the 
means throughout. Each investigation was done in the presence of a control that was 
treated in the same way as the experimental sample. All in vivo experiments included 
animals that were not given any cytotoxic insults except for experiments where 
fractionated doses of Ara-C were used. In this group only 1 set of normal mice was used 
to compare all experiments. The testing of AcSDKP in vivo levels relative to cytotoxic 
insults and captopril entailed injecting control mice with saline before giving them 
captopril or saline. This controlled the effect of general stress on animals on AcSDKP 
before or after captopril.
Cell counting on a Coulter counter was performed three times from each sample. 
For Ara-C fractionated experiments three spleens per group were measured for weight. 
Four individual experiments were carried out for each investigation throughout all
experiments.
For the GM-CFC Ara-C S-phase assay, eight individual petri dishes were plated 
from control cells and eight petri dishes from cells incubated in the presence of Ara-C. 
Individual colony numbers from each of eight petri dishes were entered into a computer 
programme. Control colony numbers were entered first followed by colony numbers 
obtained from Ara-C incubated bone marrow. The computer calculated the proportion of 
cells in S-phase from these colony numbers by dividing the difference in colony numbers 
by control colony numbers and multiplying the result by 100. Four individual repeats 
were done per investigation. Therefore, there were 64 petri dishes tliat were pooled from 
four different experiments for any GM-CFC S-phase investigation and about 32
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individual petri dishes were pooled when GM-CFC numbers were evaluated. The same 
procedure was executed with SA2 leukaemic cells. However, no absolute numbers of 
SA2 cells were evaluated, GM-CFC numbers were calculated as follows: A = Y x 
P/SxlO4 . Where A = GM-CFC numbers, Y = number of colonies and P = either mean 
femur cellularity or mean flask cellularity.
For the HPP-CFC Ara-C S-phase assay, four individual petri dishes were 
routinely set up from the control cells and a further four from the cells incubated with 
Ara-C. To assay HPP-CFC numbers, eight petri dishes were used. All individual 
experiments were repeated four times. Therefore 32 individual petri dishes were made 
from both control and Ara-C incubated cell suspension per investigation. In addition 32 
dishes in all from four individual experiments were prepared where HPP-CFC numbers 
were assayed. The HPP-CFC numbers were calculated by the following formula. Z = Y x 
P/Sxl06. Where Z = HPP-CFC numbers, Y = number of colonies and P = either mean 
femur cellularity or mean flask cellularity.
Four independent repeat experiments were also carried out for the analysis of 
ACE activity following in vitro incubation of plasma or semm with ACEI. For in vitro 
haematopoietic cell incubation with ACEI or AcSDKP, AcSDKP levels were analysed in 
three individual experiments. In each experiment, samples were collected in three 
ciyotubes. Three individual repeat experiments were carried out for in vivo regulation of 
AcSDKP levels following insults and captopril. Two cryotubes were routinely analysed
for AcSDKP.
2.12.1 Statistics
For any S-phase assay, the values from each experiment were fed into a special 
statistical computer program which calculated the percentages of cells in S-phase. The
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number of colonies from control petri dishes were initially fed into the computer followed 
by those from Ara-C treated petri dishes. The computer calculated the means of both sets 
of values ± standard errors. The percentages of cells in S-phase were also printed out. The 
programme assumed that values were normally distributed. The percentage in S-phase 
was calculated as a proportion of the difference between control (A) values and the 
values from Ara-C treated (B) values divided by the control values multiplied by 100 
{(A-B)/A x 100}. In the result sections, the proportions in S-phase and numbers of both 
GM-CFC and HPP-CFC assays are presented together with standard errors. This final 
mean was calculated from the pooled means of all four experiments.
Two statistical tests were routinely performed in these investigations. These were 
the two-tailed Student t-test and Analysis of Variation (ANOVA). The significant p-value 
was set at less than 0.05. The two-tailed Student t-test was routinely used to determine the 
significance of the difference between the effect of a drug (i.e, ACEI or AcSDKP) 
relative to the controls. This test was used when 2 groups of samples needed to be 
compared. The student t-test was also used to analyse the changes in AcSDKP levels 
following in vitro incubation of regenerating bone marrow cells in the presence of 
captopril. The Student t-test was calculated with the aid of Excel for Windows 1995
Version 8.
In the long-term bone marrow cultures, AcSDKP, captopril and the combination 
of the two were investigated to see if each individual treatment had an effect relative to 
saline control and between different treatments. The test used to analyse these differences 
was ANOVA. If the means were foimd to be statistically significant after carrying out 
ANOVA, the Tukey test was done. ANOVA was also used to analyse the differences in 
AcSDKP levels following in vivo administration of captopril in mice after Ara-C and 2 
Gy irradiation. ANOVA was carried out also with the aid of the Excel computer program.
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CHAPTER 3
3.0 IN VITRO STUDIES ON THE EFFECT OF ACE ON
HAEMATOPOIESIS
Serum and plasma from CBA/H mice was analysed to study the efficiency of 
ACE inhibitors in blocking ACE activity in vitro. This was done to establish a basis 
for studying their effects on haematopoietic cell proliferation. In vitro incubation with 
bone marrow cell suspension was performed in the presence of D30%FCS PS/G. This 
concentration of FCS was chosen because it reduced the in vitro cell loss following 
incubation. D30%FCS PS/G was not investigated for ACE activity as it was assumed 
that the levels of ACE activity would be modified by presence of macrophages in the 
bone marrow cell suspension. Macrophages are known to produce both ACE 
(Costerousse et al., 1993) and AcSDKP (Li et al., 1997).
It is well established that AcSDKP prevents the transition from Go-Gi into S- 
phase in proliferating cells (Mopezat & Frindel, 1989). It has been shown previously 
that AcSDKP has no effect on GM-CFC proliferation following a short in vitro 
incubation in serum free medium (Robinson et al., 1992). An investigation was 
carried out to determine if in vitro incubation with AcSDKP and captopril together in 
the presence of D30%FCS PS/G would affect the cycling status of GM-CFC from 
normal bone marrow. As AcSDKP is degraded by the N-domain ACE active site 
(Rousseau et al., 1995), captopril was used to prevent AcSDKP degradation. It has 
been shown previously that captopril on its own has no effect on the proliferation of 
GM-CFC after several days of incubation (Hammond et al., 1988). Therefore, a 
control incubation with captopril alone was not performed.
After studies on GM-CFC proliferation were performed a single bone marrow 
cell suspension was incubated from mice that had not received any insults and from
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mice treated with 2 Gy-y-in'adiation, Ara-C (100 mg/kg i.p) and 5 FU (150 mg/kg 
i.v). 2 Gy-y-irradiation is the standard dose used to recruit HPP-CFC-1 into cell cycle 
in our laboratoiy (Rousseau et ai., 1998). Ara-C (100 mg/kg) produced least 
myelotoxicity and 5 FU (150 mg/kg) (Bartelmez et ai., 1989) enriches for the HPP- 
CFC-1 population. ACE inhibitors were investigated on their ability to influence the 
proportion of HPP-CFC-1 in S-phase in normal bone marrow cells in order to 
determine if they could alter the proliferative status of this cell population. Cytotoxic 
insults increase the levels of stimulatory factors m vivo (All et al., 1989; Frindel et al., 
1976). These stimulatory factors recruit HPP-CFC-1 into S-phase. By this method, 
inhibitors of stem cell proliferation can be studied. Therefore, the ability of ACE 
inhibitors to modify stem cell kinetics was studied following in vivo cytotoxic insults. 
The supernatant of bone marrow cell suspension incubated with captopril was 
analysed for endogenous AcSDKP concentration before and after incubation.
To determine whether captopril might have differential effects on normal and 
neoplastic cell populations, this drug was incubated with SA2 neoplastic cells. SA2 
cells were chosen because they were easily accessible. This investigation was 
performed to assess the feasibility of using captopril to protect normal haematopoietic 
cells while making neoplastic cells vulnerable to cytotoxic agents during tumour 
therapy.
Because AcSDKP has been found to inhibit CFU-S proliferation only if given 
2 hours following Ara-C, it has been suggested that AcSDKP given at this point 
blocks GO-Gi/S transition (Monpezat & Frindel, 1989). However, this has not been 
previously elucidated. Therefore an investigation was carried out to test the mode of 
action of AcSDKP in vitro and to confirm the fact that the peptide may be active at 
the Gi/S boundary. This hypothesis was tested using proliferating HPP-CFC-1.
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3.0.1 Ace activity in murine serum and plasma
Procedure
The ability of ACE inhibitors to inhibit background ACE activity was 
analysed before these drugs were studied for haematopoiesis. This was investigated in 
vitro by incubating plasma or serum with ACE inhibitors. Plasma or serum samples 
collected from CBA/H mice were incubated with captopril or lisinopril both at 1 pM 
final concentration for 2 hours in a water bath at 37°C. Control samples that were 
incubated with medium alone were included. After 2 hours samples were placed on 
ice to stop the enzymatic activity. Samples were then analysed for ACE activity using 
a kit ftom Sigma Diagnostics as described in materials and methods.
Results
As shown in Fig 3.1, ACE activity was high and identical in serum and plasma 
from normal mice after 2 hours of in vitro incubation (p = 0.75). Incubating both 
serum and plasma in the presence of ACE inhibitors resulted in a significant reduction 
in the activity of ACE (p<0.00001). However both ACE inhibitors equally inhibited 
ACE activity in plasma with no observable difference between captopril and lisinopril 
(p = 0.34). In contrast, there was a difference between captopril and lisinopril on ACE 
activity in serum. Lisinopril had a greater inhibitory effect on serum ACE than 
captopril. While only 28.6 ± 6.3 units of ACE activity was observed after 2 hours of 
serum incubation with lisinopril, 198.7 ± 24.3 units of ACE activity was observed 
when serum was incubated with captopril (p = 0.00001). While lisinopril had no 
differential inhibitory effect between serum or plasma ACE activity, captopril showed
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FIG. 3.1 ACE activity in serum and plasma following incubation with ACE 
inhibitors
Units (l,uM FAP/minute)
plasma serum
control 392.9 ±43.3 453.3 ±36.0 P = 0.75, n = 4
lisinopril 63.2 ±19.9 28.6 ± 6.6
captopril 86.0 ±24.5 198.7 ±24.3
P = 0.34, n = 4 P = 0.00001, n = 4
a reduced inhibitory effect on serum ACE when compared to plasma ACE. From 
these observations, AcSDKP levels were routinely analysed from plasma in all the in 
vivo experiments.
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3.0.2 AcSDKP and GM-CFCproliferation
Procedure
2 mis of bone marrow single cell suspensions suspended in D30%FCS PS/G
from untreated CDl mice were aliquoted into four universal tubes at 5 x 10° cells/ml. 
AcSDKP (10"° M) together with captopril (IpM) was added to one pair and the other 
pair was used as a control. Cells were incubated at 37°C for 7 hours. After 7 hours of 
incubation an S-phase suicide assay was performed making a total incubation time of 
8 hours. At the end of incubation period cells were washed and the cellularity was 
adjusted for GM-CFC assay. AcSDKP that has been made resistant to degradation by 
ACE by replacing the DK bond with an aminomethylene bond (AcSDj/KP) (Gaudron 
et al., 1997) was also investigated without the addition of captopril.
Results
As shown in Fig 3.2, (28.9 ± 1.5)% of GM-CFC were in S-phase in the 
control groups and this percentage was reduced to (16.0 ± 2.4)% (p = 0.0011) when 
bone marrow cells were incubated with AcSDKP and captopril together after 8 hours. 
In the experiments where AcSDj/KP was investigated, (29.3 ± 2.5)% of GM-CFC 
were in S-phase in the control group. This percentage was reduced to (14.7 ± 3.3)% (p 
= 0.004) in the presence of AcSDj/KP after 8 hours. There was no difference 
between the percentage of GM-CFC in S-phase in the presence of AcSDKP together
with captopril and with AcSDj/KP alone.
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FIG. 3.2 The proportion of GM-CFC in S-phase following incubation of bone 
marrow cells with captopril together with AcSDKP or AcSDvyKP alone
Normal bone
marrow
AcSDKP 
+ Captopril
Resistant
AcSDKP
(28.9 ± 1.5)%
(29.3 ± 2.5)%
(16.0 ±2.4)%
(14.7 ±3.3)%
P = 0.0011, n = 4
P = 0.004, n = 4
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3.0.3 Discussion
3.0.3.1 Differential effects of captopril and lisinopril on serum and 
plasma ACE activity
These investigations showed that both captopril and lisinopril were potent 
inhibitors of plasma ACE activity. Lisinopril had no differential effect on inhibiting 
ACE in both plasma and serum while captopril was less efficient at inhibiting serum 
ACE (see Fig 3.1). The superiority of lisinopril to captopril as an inhibitor of serum
ACE activity from rats and humans has also been observed by others (Nguyen et al.,
1994, Small Jr et al., 1997). This difference in potency between lisinopril and
captopril in inhibiting ACE activity in serum and plasma is not well understood.
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However, it is known that there is a difference between the relative capacity of ACE 
inhibitors to inhibit ACE in different organs (Bevilacqua et al., 1996). As reviewed by 
Herman (1992), the affinity of the ACE inhibitor for a particular enzyme is not only 
determined by the structure of the inhibitor, but also by the structure of the enzyme. 
ACE isoenzymes from different tissues may be slightly different, varying with regard 
to their molecular weight, amino- and carboxyl-terminal amino acids in their structure 
and also their degree of glycosylation.
Different active ACE isoenzymes in plasma and serum samples might explain 
the observed differential inhibitory effects of captopril and lisinopril on serum ACE. 
Heparin used in the collection of plasma may alter the glycosylation of this enzyme. 
Lisinopril and fosinopril have been found to have a more consistent effect on 
inhibiting ACE from all tissues (Herman, 1992). Lisinopril could be exhibiting an 
equal potency on isoenzymes in plasma and serum while captopril may affect these 
isoenzymes differently.
As reviewed by Beneteau-Brunat and Baudin (1991), ACE is mostly located 
on the luminal surface of the endothelial cells as an ectoglycoprotein. ACE activity 
measured in plasma is mostly of endothelial origin. Endothelial ACE may have the 
same affinity for both captopril and lisinopril. This may be one factor that brings 
about their equal potency in inhibiting plasma ACE. In addition ACE inhibitors have 
different tissue bioavailability making them show differential effects on tissue ACE in 
organs (Herman, 1992). There is also a difference in structure between captopril and 
lisinopril in that captopril uses its sulfhydryl group to bind to the zinc atom in the 
enzyme. Nevertheless, lisinopril has a greater affinity for ACE than captopril 
(Herman, 1992) resulting in equal inhibition of ACE activity in both serum and 
plasma in the present investigations.
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There is also a possibility that lisinopril might exhibit a dual effect of 
inhibiting other enzymes that may be involved in FAPGG catabolism in addition to 
mouse ACE, This hypothesis is strengthened by the fact that lisinopril and peridopril 
inhibit a kininase that is neither ACE nor aminopeptldase P (Campbell et al., 1995). 
Captopril is a more potent inhibitor of the N-domain ACE active site while lisinopril 
favours the COOH domain ACE active site (Wei et ah, 1992, Rousseau et al., 1995, 
Bevilacqua et ah, 1996). It is possible that the physiological nature of serum means 
that the required electrolyte balance in the assay favours the inhibition of COOH 
domain ACE active site compared to the N-domain ACE active. Since bradykinin has 
an approximately 100 fold affinity for ACE compared to angiotensin-1 and is mainly 
cleaved by the COOH domain active site (Campbell, 1995, Dorer et ah, 1974), 
lisinopril may be binding to the ACE active site that may be responsible for both 
FAPGG and bradykinin hydrolysis. This may reveal the strength of lisinopril as an 
inhibitor of ACE activity in plasma and serum.
3.0.3.2 AcSDKP and GM-CFC proliferation
In the present investigations AcSDKP reduced the proportion of GM-CFC in 
S-phase in bone marrow cells taken from untreated mice after 7 hours of in vitro 
incubation. In this investigation, the AcSDKP inhibitory effect on GM-CFC 
proliferation was shown not be related to captopril by the equal potency of GM-CFC 
inhibition in the presence of AcSDKP and captopril when compared to AcSD\|/KP 
alone. Therefore the reduction in the proportion of GM-CFC in S-phase in both cases 
was thought to be due to the effect of AcSDKP on GM-CFC proliferation. Others 
have shown that AcSDKP inhibits human progenitor cell proliferation in vitro 
(Guigon et al., 1990). It is not surprising that a short incubation period with AcSDKP
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did not inhibit GM-CFC proliferation in previous investigations. The reason for this 
may be two fold. Firstly, the fact that AcSDKP acts exclusively at the Go-Gi/S 
boundary (Mopezat & Frindel, 1989) means that its effect on cell proliferation would 
be noticed after proliferating cells have exited S-phase. Secondly the short Xm of 
AcSDKP in serum prompted Robinson et al., (1992) to use serum free medium which 
may have retarded the progression of cells that were already in S-phase out of this 
phase.
Despite no observable effect of AcSDKP on the proliferation of GM-CFC 
both in vitro following a short incubation period and in vivo from murine bone 
marrow cells (Robinson et al., 1992, Monpezat & Frindel, 1989), some investigators 
observed an effect of the peptide on murine GM-CFC proliferation after cells were 
incubated for extended periods of time in vitro (Jackson et al., 1996, Wierenga et al., 
1996). While Wierenga et al., (1996) used nonnal bone marrow cells without growth 
factors for a 24 hour-incubation period, Jackson et al., (1996) incubated normal bone 
maiTow cells in the presence of growth factors for up to 72 hours. Wierenga et al., 
(1996) found a maximum inhibitory effect of AcSDKP and captopril (1 pM) after 8 
hours of incubation. Jackson et al., (1996) found that addition of growth factors 
during incubation reduced the concentration of AcSDKP needed to inhibit GM-CFC 
proliferation from 10'** M to lO*14 M.
30% of GM-CFC are in S-phase at any one time (Blackett et al., 1974; 
Wierenga et al., 1996). In addition, GM-CFCs are inhibited by a higher concentration 
of inhibitory factors than CFU-S in vitro (Tejero et al., 1984). From these 
observations it is clear that a long duration is needed for AcSDKP to inhibit GM-CFC 
proliferation. Moreover, the length of the cell cycle of GM-CFC will determine the 
time it takes for the peptide to show its effect. In these investigations the proportion of
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GM-CFC in S-phase was reduced after 7 hrs. Wierenga et aL, (1996), also observed a 
decrease in the proportion of GM-CFC in S-phase with AcSDKP to (9 ± 3)% at 8 
hours. The proportion of GM-CFC in S-phase had increased to (18 ± 3)% after 16 
hours incubation and remained so up to 24 hours of in vitro investigation. This 
suggests that the block of Go-Gi/S transition on GM-CFC by AcSDKP is weak or 
reaches a peak. This means that any additional incubation time does not affect GM- 
CFC proliferation. Therefore the effect of AcSDKP on GM-CFC may be more 
complicated than previously thought.
In vivo studies on haematopoietic cell proliferation have shown that AcSDKP 
is a better inhibitor of CFU-S than GM-CFC when administered to mice following 
Ara-C treatment. Monpezat & Frindel, (1989) found that Ara-C recruits CFU-S into 
S-phase after 12 hours and administration of AcSDKP 6 hours after Ara-C prevents 
CFU-S recruitment into S-phase but not GM-CFC and no inhibitory effect was 
observed when AcSDKP was given 8 hours after Ara-C on both cell populations. In 
addition, Bogden et al., (1991), showed that AcSDKP protected mice when it was 
administered simultaneously with Ara-C or 2 hours after Ara-C treatment. The 
findings of Bogden et al., (1991) and Monpezat & Frindel, (1989), demonstrate the 
specificity of AcSDKP action at the Go-Gi/S transition and the specific response of 
haematopoietic stem cells to AcSDKP inhibitory effects.
It is possible that AcSDKP may affect the Go-G|/S transition of 
haematopoietic cells by down regulating growth factor receptors or by blocking 
intracellular signalling pathways critical at the Gi/S transition (Yip & Levy, 
1996). AcSDKP seems to function by interacting with glycoproteins on some 
responsive cells and the sequence SDK may be important in this interaction 
(Thierry et al., 1990; Robinson et al., 1993). Furthermore AcSDKP may inhibit
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cells by influencing the release of inhibitory factors by accessory cells (Cashman 
et al., 1995). It has been found that AcSDKP enhances engraftment of 
intravenously transplanted haematopoietic stem cells into bone marrow of 
irradiated mice (Suzuki et al., 1998) an effect that involves accessory cells.
3.1 IN VITRO EFFECT OF AcSDKP AND ACE INHIBITORS ON 
HPP-CFC-1 PROLIFERATION
3.1.1 Normal bone marrow
Procedure
A bone marrow single cell suspension sampled from 3 untreated CDl mice 
was suspended in D30%FCS PS/G. Some cells were immediately incubated with 
captopril or lisinopril both at lpM separately for (T = 0) together with controls. The 
remaining cell suspension was aliquoted into each of the four petri dishes for (T = 
24). Captopril or lisinopril were added to two petri dishes. The other dishes were used 
as controls. Control bone marrow cell suspensions were incubated with medium 
alone. An S-phase assay was performed according to the in vitro incubation methods 
already described. At the end of the incubation periods, the cellularity was adjusted 
and cells were plated for the HPP-CFC-1 assay as described.
Results
As shown in Fig 3.3, (8.1 ± 2.6)%, (13.6 ± 2.6)% and (13.9 ± 4.4)% of HPP- 
CFC were in S-phase in the control samples, in the presence of captopril and lisinopril 
respectively at the beginning of incubation period (T = 0). This proportion was not 
significantly altered after 24 hours (T = 24) of incubation. (12.3 ± 4.7)% of HPP- 
CFC-1 were in S-phase in control samples, (14.7 ± 3.5)% of HPP-CFC-1 were in S-
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FIG. 3.3 The proportion of HPP-CFC-1 in S-phase following in vitro incubation 
of bone marrow cells from untreated mice with ACE inhibitors
Normal bone
marrow
% HPP-CFC-1 in S-phase
T = 0 T = 24
control ( 8.1 ±2.6)% (12.2 ±4.7)% P = 0.58,n = 4
lisinopril (13.9 ±4.4)% (10.1 ±7.7)% P = 0.72, n = 4
captopril (13.4 ±2.6)% (14.7 ±3.5)% P = 0.84,n = 4
ffllNBM
□ NBMKisinopril
□ NBM+Captopril
phase in the presence of captopril and (10.1 ± 7.7)% of HPP-CFC-1 were in S- phase 
in the presence of lisinopril (p>0.5) after 24 hours of incubation. Therefore in vitro 
incubation of nonnal bone marrow cells in the presence of ACE inhibitors showed no 
influence on the proliferation of HPP-CFC-1 in normal bone marrow cells.
Chapter 3 - In vitro effects of ACE inhibitors & AcSDKP 94
3.1.2 Regenerating hone rmiar^ow HPP-CFC-1 prollfeeafion
Procedure
Bone marrow ceils from mice that had received 2 Gy y-irradiation, Ara-C 
(l^OO^jg/kg-body weight i.p injection.) and 5 FU (150mg/kg-body weight i.v 
injection.) in vivo were sampled with D30%FCS PS/G at appropriate times. A single 
cell suspension was made with the same medium and an S-phase suicide assay was 
immediately performed on half of the cells in the presence or absence of ACE 
inhibitors with or without AcSDKP. The other half were aliquoted into four 30-mm 
petri dishes. Following 2 Gy y-irradiation, bone marrow cells were incubated with 
AcSDKP (lO'6M) alone or in combination with one of the ACE inhibitors (IpM), 
captopril or lisinopril alone both at IpM individually were added to one pair. The 
other pair was used as a control to which medium alone was added. Bone marrow
cells taken from mice treated with Ara-C or 5 FU were incubated with ACE inhibitors
alone. Cells were incubated for (T = 0) and (T = 24) according to the described 
method. At the end of the incubation period, an S-phase was camed out and cells
were washed and plated for HPP-CFC-1.
Results
L 2 Gy regenerating bone marrow
As shown in Fig 3.4, (34.6 ± 1.9)% HPP-CFC-1 were in S-phase in 2 Gy bone 
marrow at beginning of incubation (T = 0). In the presence of lisinopril and captopril, 
(38.6 ± 1.7)% and (45.2 ± 6.2)% of HPP-CFC-1 were in S-phase at the same time 
respectively. In the presence of AcSDKP alone, (40.2 ± 2.6)% of HPP-CFC-1 were in 
S-phase at the beginning of the incubation period. After 24 hours of incubation
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(T = 24), (31.5 ± 4.0)% of HPP-CFC-1 were in S-phase in 2 Gy regenerating bone 
marrow cell suspension (p = 0.34) and (43.1 ± 3.4)% of HPP-CFC-1 were in S-phase 
in the presence of lisinopril (p = 0.28). (47.7 ± 5.4)% and (31.8 ± 3.0)% of HPP-CFC- 
1 were in S-phase in the presence of captopril (p = 0.46) and AcSDKP (p = 0.09)
FIG. 3.4 The proportion of HPP-CFC-1 in S-phase in bone marrow cells taken 
from mice treated with 2 Gy following in vitro incubation with ACE inhibitor 
and AcSDKP
% HPP-CFC-1 in S-phase
2 Gy regenerating
bone marrow
T = 0 T = 24
Medium alone (34.6 ± 1.9)% (31.5 ±4.0)% P = 0.34, n = 4
+Captopril (45.2 ± 6.2)% (47.7 ± 5.4)% P = 0.46, n = 4
+Lisinopril (38.6 ± 1.7)% (43.1 ±3.4)% P = 0.28, n = 4
+AcSDKP (40.2 ± 2.6)% (31.9 ±3.0)% P = 0.09, n = 4
+AcSDKP&Lis. (33.2 ± 0.8)% (25.7 ±4.4)% P = 0.06, n = 4
+AcSDKP&Cap. (42.1 ±31.7)% (10.3 ± 1.9)% P = 0.005, n = 4
NB: Lis. = lisinopril, Cap. = captopril
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respectively at the end of the incubation period (T = 24). Thus no significant 
inhibitory effect was observed on 2 Gy regenerating bone marrow HPP-CFC-1 when 
AcSDKP or ACE inhibitors were investigated individually. Therefore both AcSDKP 
and ACE inliibitors showed no direct inhibitory effect on 2 Gy irradiation when they
were used separately.
Both ACE inhibitors were incubated in combination with AcSDKP for 24
hours. As shown in Fig. 3.4, there was no significant reduction in proportion of HPP- 
CFC-1 in S-phase at the end of incubation period when lisinopril and AcSDKP were 
combined. The initial proportion of HPP-CFC-1 in S-phase was (33.2 ± 0.8)%, and it 
was (25.7 ± 4.4)% after 24 hours of incubation (p = 0.06). In the presence of captopril 
and AcSDKP, the initial proportion of HPP-CFC-1 in S-phase was (42.1 ± 3.7)%. 
This proportion was significantly reduced after 24 hours of incubation to (10.3 ± 
1.9)% (p = 0.005). Therefore AcSDKP was crucial in inhibiting HPP-CFC-1 in 2 Gy 
regenerating bone marrow cells. Captopril was able to restore the AcSDKP inhibitory 
activity.
iL Ara-C regenerating bone marrow
(44.0 ± 5.9)% of HPP-CFC-1 were initially in S-phase from bone marrow cell 
suspension of Ara-C treated mice. In the presence of lisinopril the proportion of HPP- 
CFC-1 in S-phase was (52.3 ± 1.8)% at time 0. In the presence of captopril, (43.2 
±3.2)% were in S-phase at the same time (see Fig.3.5). At the end of 24 hour 
incubation period the proportion of HPP-CFC-1 in S-phase in Ara-C regenerating 
bone marrow control cell suspension was reduced to (26.5 ± 1.8)% (p = 0.0009) and 
to (25.6 ± 3.3)% (p = 0.00012) in the presence of lisinopril. While incubation alone 
reduced the cycling proportion of HPP-CFC-1 in both controls and lisinopril petri
Chapter 3- In vitro effect of ACE inhibitors & AcSDKP 97
FTG. 3.5 The proportion of HPP-CFC-1 in S-phase in bone marrow cells taken 
from mice treated with Ara-C following in vitro incubation with ACE inhibitors
% HPP-CFC- 1 in S-phase ---- ---
Ara-C regenerating
bone marrow
T = 0 T = 24
Medium alone (44.0 ±5.9)% (26.5 ± 1.8)% P = 0.0009, n = 4
+Lisinopril (52.3 ± 1.8)% (25.6 ±3.3)% P = 0.00012, n = 4
4Captopril (43.2 ± 3.2)% (4.9 ± 0.8)% P = 0.000003, n = 4
Control & Lisinopril P = 0.17
Control & Captopril P = 0.00034
Lisinopril & Captopril P = 0.00004
dishes, no significant reduction was observed between Ara-C controls and Ara-C 
lisinopril incubated petri dishes after 24 hours (p = 0.17). Ara-C regenerating bone 
marrow cell suspension incubated in the presence of captopril had only (4.9 ± 0.8)% 
of HPP-CFC-1 in S-phase after 24 hours of incubation (p = 0.000003). This indicated 
that captopril reduced the proportion of proliferating HPP-CFC-1 when compared to 
both Ara-C controls (p = 0.00034) and Ara-C lisinopril incubated bone marrow cells 
(p = 0.00004). In addition captopril prevented HPP-CFC-1 entry into S-phase as 
shown by the low proportion of HPP-CFC-1 in S-phase.
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iii. 5 FU regenerating bone marrow
At the beginning of the incubation period, (44.9 ± 5.0)% of HPP-CFC-1 were 
in S-phase in 5 FU regenerating bone marrow control cell suspension. The proportion
FIG. 3.6 The proportion of HPP-CFC-lin S-phase in bone marrow cells from 
mice treated with 5 FU following in vitro incubation with ACE inhibitors
5FU
Regenerating bone 
marrow.
% HPP-CFC-1 in S-phase
T = 0 T = 24
Medium alone (44.9 ± 5.0)% (24.9 ± 7.2)% P = 0.004,
+Lisinopril (41.0 ±9.6)% (33.1 ±4.1)% P = 0.21,
±Captopril (43.6 ±4.8)% (8.9 ± 1.6)% P = 0.00008,
Control & Lisinopril P = 0.14
Control & Captopril P = 0.0005
Captopril & Lisinopril P = 0.0015
of HPP-CFC-1 in S-phase with lisinopril was (41.0 ± 9.6)% at time 0. (43.6 ± 4.8)% 
of HPP-CFC-1 were in S-phase with captopril initially. The proportion of HPP-CFC-1 
in S-phase in the 5 FU control regenerating bone marrow cell suspension was reduced 
to (24.9 ± 7.2)% (p = 0.004) after a 24 hour incubation and to (33.1 ± 4) (p = 0.21)
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when 5 FU regenerating bone marrow cell suspension was incubated with lisinopril. 
In contrast 5 FU regenerating bone marrow cell suspension incubated with captopril 
had only (8.9 ± 1.6)% (p = 0.00008) of HPP-CFC-1 in S-phase after 24 hours of 
incubation. Captopril significantly reduced the proportion of HPP-CFC-1 in 5 FU 
regenerating bone marrow cell suspension when compared to 5 FU controls (p = 
0.0005) and to 5 FU lisinopril treated bone marrow cell suspensions (p = 0.002). 
Captopril also inhibited HPP-CFC-1 S-phase entry. Hence the effect of captopril was 
the same on the proliferation of HPP-CFC-1 following the two drugs studied. There 
was no difference in the proportion of HPP-CFC-1 in S-phase between 5 FU controls 
and bone marrow cell suspension incubated with lisinopril (p = 0.14) after 24 hours of 
incubation (see Fig 3.6).
3.2 The effect of Captopril on AcSDKP concentration after in vitro 
incubation with normal bone marrow, 2 Gy and Ara-C 
regenerating bone marrow cells
Procedure
Supernatants from normal and regenerating bone marrow treated with 2 Gy y- 
irradiation, Ara-C (lOOmg/kg-body weight i.p.) and 5 FU (150mg/kg-body weigh i.v) 
were analysed for AcSDKP concentrations before incubation and after 24 hrs of 
incubation. No supernatant from lisinopril incubated bone marrow was analysed. 
After sampling control bone marrow cells and regenerating bone marrow cells from 
CDl mice treated with each of the three studied insults at appropriate times, a single 
cell suspension was made. Cells were suspended in D30%FCS PS/G. Half of the cell 
suspensions were immediately analysed for AcSDKP in the presence of captopril (T = 
0) and the other half was aliquoted into 30 mm-petri dishes. Captopril (IpM) alone 
was added to cell suspensions. All experiments were performed with controls. For T =
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0, cell suspensions were immediately centrifuged after sampling and supernatants 
were aliquoted into cryotubes. For T = 24, Petri dishes were incubated for 24 hour in 
10% CCVfully humidified air at 37°C. At the end of the incubation period cell 
suspensions were centrifuged and the supernatant was aliquoted into cryotubes. The 
general method of cell sampling, storage of samples and AcSDKP assay was carried 
out as already described.
Results
As shown in Fig.3.7, the concentration of AcSDKP in the supernatants of 
normal bone marrow cell suspensions incubated with saline at the beginning of 
incubation period (T = 0) was 0.68 ± 0.06 nM. The concentration of AcSDKP 
remained unchanged at 0.70 ± 0.03 nM (p = 0.77) after 24 hours. On the other hand 
0.58 ± 0.06 nM of AcSDKP was obtained in the supernatant of normal bone mairow 
cell suspension incubated with captopril at the beginning of the incubation period (T = 
0). This concentration was significantly increased to 1.16 ± 0.08 nM (p = 0.000014) 
after 24 hours in the presence of captopril. Neither saline (p = 0.3) nor captopril (p = 
0.19) influenced the production of AcSDKP following incubation with 2 Gy 
regenerating bone marrow cell suspension after 24 hours. On the contrary, captopril
had a marked effect on AcSDKP concentration when it was incubated with Ara-C
regenerating bone marrow cell suspension. AcSDKP levels significantly increased 
from 0.55 ± 0.02 nM at the beginning of the incubation period (T = 0) when captopril 
was added to Ara-C regenerating bone marrow cell suspension to 0.84 ± 0.09 nM (p = 
0.00064) after 24 hours of incubation. Interestingly in the absence of captopril there 
was a significant reduction in AcSDKP levels in Ara-C regenerating bone manow cell
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suspension. At time 0, Ara-C regenerating bone marrow had 0.54 ± 0.06 nM AcSDKP 
in the presence of saline. This value was significantly reduced to 0.43 ± 0.02 nM (p =
FIG. 3.7. AcSDKP concentration following in vitro incubation of bone marrow- 
cells with captopril
AcSDKP concentration 
(nM)
T = 0 T = 24
NBM + Saline 0.68 ± 0.06 0.70 ± 0.03 P = 0.77, n = 3
NBM + Captopril 0.58 ± 0.06 1.16±0.08 P = 0.000014, n = 3
2 Gy + Saline 0.88 ± 0.40 0.61 ±0.12 P = 0.3, n = 3
2 Gy + Captopril 0.88 ± 0.20 1.22 ±0.40 P = 0.19, n = 3
Ara-C + Saline 0.54 ± 0.06 0.43 ± 0.02 P = 0.02, n = 3
Ara-C + Captopril 0.55 ± 0.02 0.84 ± 0.09 P = 0.00064, n = 3
5 FU + Saline 0.62 ±0.12 0.58 ± 0.04 P = 0.59, n = 3
5 FU + Captopril 0.56 ± 0.08 0.66 ± 0.09 P = 0.15, n = 3
C NBM -saline 
0 NBM -captopril
□ 2 Gy-saline 
0 2 Gy-captopril
□ AraOsaline
□ Ara-Ocaptopril 
@ 5 FU-saline
S 5 FU-captopril
0.02). Neither saline (p = 0.59) nor captopril (p = 0.15) significantly influenced 
AcSDKP production in 5 FU regenerating bone marrow cell suspension after 24 hours
of incubation.
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3.3 The response of SA2 leukaemic call lime to in viiro incubation wiih 
captopril.
Procedure.
SA2 were suspended in D30%FCS PS/G at 4 x 104 cells/ml. Captopril was 
added to cell suspensions and they were incubated for (T = 0) and (T = 24) according 
to the general method used in these investigations. However saline was added to the 
control cell suspensions. After incubation and an S-phase assay, cells were washed 
and the cellularity was adjusted. They were plated in semi solid agar cultures 
according to the described methods for SA2 semi-solid agar cultures.
Results
(59.5 ± 8.0)% and (58.2 ± 12.0)% of SA2 leukaemic cells were in S-phase in 
the presence of saline and captopril at the beginning (T = 0) of incubation
FIG. 3.8 The proportion of SA2 myeloid leukaemia cell line following in vitro 
incubation with captopril
SA2 cells
% SA2 in S-phase
T = 0 T = 24
+Saline
+Captopril
(59.5 ± 8.0)%
(58.2 ±12.0)%
P = 0.87, n = 4
(59.1 ±5.1)% 
(61.1 ± 1.9)%
P = 0.69,n = 4
P = 0.97, n = 4
P = 0.77, n = 4
□ SA2+Saline 
■ SA2+Captopril
T = 0 T = 24
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respectively. The proportion of SA2 leukaemic cells in S-phase was not affected by 
either incubation alone or with captopril. As shown in Fig 3.8, (59.1 ± 5.1)% and 
(61.1 ± 1.9)% were still in S-phase in the presence of saline (p = 0.97) and captopril 
(p = 0.77) respectively after 24 hours of incubation. Therefore captopril’s inhibitory 
effect was observed to be specific to normal HPP-CFC-1 at the doses used.
3.4 The in vitro effect ofAcSDKP on the HPP-CFC A proliferation
Procedure
Bone marrow cell suspension in D10%HS PS/G prepared fiom CDl mice 24 
hours after 2 Gy "/-irradiation and Ara-C (lOOmg/kg) i.p. injection and 4 days 
following 5 FU (150mg/kg) i.v injection were initially incubated with Ara-C 
(25pg/ml) for 1 hour to deplete all cells that were in S-phase in vivo. Following this 
initial incubation period, cells were washed twice with D20%HS PS/G to remove 
Ara-C. Clots that formed after centrifuging were dispersed with a 25G orange needle 
to make a single cell suspension. This single cell suspension was resuspended in 
DiO%HS PS/G. 2 mis of the same cell suspension was aliquoted into each of the four 
30 ml universal tubes. Captopril (IpM) and AcSDKP (lO^M) together were added to 
one pair of universal tubes and the other pair had medium alone and placed in a water 
bath at 37°C. They were incubated for 3 hours and an Ara-C S-phase suicide was 
performed making a total incubation period of 4 hours. At the end of the second 
incubation period cells were again washed twice with D20%HS PS/G. A single cell 
suspension was made again and cells were counted. The cellularity was adjusted to 
2,5x106 cells/ml and cells were then plated for the HPP-CFC-1 assay. Fig. 3.9 
summarises the experimental procedure.
Chapter 3- In vitro effect of ACE inhibitors & AcSDKP 104
Fig. 3.9 AcSDKP mode of action
Bone marrow cells in 
D10%HS PS/G taken
from mice following 
2Gy, Ara-C and 5 FU in 
vivo administration.
Cells were incubated with 
25pg/ml Ara-C at 37°C for lhr 
to kill all cells that were in S- 
phase in vivo
Cells were washed twice with 
D20%HS PS/G and aliquoted 
into 30-ml universal tubes. ,
Cells were further incubated for 3 hrs 
in D10%HS PS/G. Ara-C suicide
assay was then performed thus making 
4 hrs of incubation all together.
Cells were washed and 
cellularity adjusted to
2.5x104 cells/ml
▼
Ceils plated for HPP-CFC-1 assay
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Results
As shown in Fig 3.10, (28.4 ± 2.5)%, (35.6 ± 3.5)% and (38.8 ± 3.1)% of 
HPP-CFC-1 had entered into S-phase after 3 hrs in the 2 Gy, Ara-C and 5 FU control
FIG. 3.10 The proportion of HPP-CFC-1 in S-phase following Ara-C depletion of
the in vivo S-phase cell population from regenerating bone marrow cells 
incubated in vitro with AcSDKP and captopril
Regenerating
bone marrow % HPP-CFC-1 in S-phase
cells.
Control AcSDKP + Captopril
2 Gy (28.4 ±2.5)% (5.4 ±1.4)% P = 0.00019, n = 4
Ara-C (35.6 ±3.5)% (13.3 ± 4.8)% P = 0.009, n = 4
5FU (38.8 ±3.1)% (16.1 ±3.7)% P = 0.0033, n = 4
□ Control
■ +AcSDKP+captoprll
regenerating bone marrow cell suspensions respectively. However when AcSDKP and 
captopril were incubated with these bone marrow cell suspensions, (5.4 ± 1.4)% (p = 
0.00019), (13.3 ± 4.8)% (p = 0.009) and (16.1 ± 3.7)% (p = 0.0033) of HPP-CFC-1 
had entered into S-phase from 2 Gy, Ara-C and 5 FU regenerating bone marrow cell 
suspension respectively. Therefore AcSDKP and captopril prevented Gi/S transition 
thus confirming the previous observation that AcSDKP acts at the Gi/S boundary in 
CFU-S (stem cells).
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3.5 Discussion
3.5,1 In vitro effect of ACE inhibitors on haematopoietic cell
proliferation
The HPP-CFC-1 cell population from normal bone marrow cells is quiescent 
with only a small proportion of cells in S-phase. A normal bone marrow cell 
suspension was incubated for up to 24 hour in the presence of captopril, lisinopril and 
without ACE inhibitors. As expected ACE inhibitors had no effect on the proliferation 
of normal quiescent haematopoietic stem cells (see Fig.3.3). This is due to the fact 
that haematopoietic stem cell inhibitory factor influence is already at its peak in 
quiescent HPP-CFC-1. Moreover, inhibitory factors are thought to act by antagonising 
the production of stimulatory factors by stromal cells this maintains a balance on the 
proportion of HPP-CFC-1 in cell cycle (Lord et al., 1979). To increase the levels of 
stimulatory factors, mice were given 2 Gy, Ara-C and 5 FU cytotoxic insults. 
Following in vivo redmitment of bone marrow HPP-CFC-1 into S-phase, cells were 
sampled and these proliferating haematopoietic stem cells were incubated in vitro in 
the presence of AcSDKP, ACE inhibitors with or without AcSDKP. This was 
performed in order to investigate whether prevention of AcSDKP degradation would 
inhibit HPP-CFC-1 proliferation. In addition, the investigations were also carried out
in order to observe the differences between the two ACE inhibitors on HPP-CFC-1
cell proliferation. A short incubation time was used as a control and a 24 hour in vitro 
incubation time was used to study these effects.
L 2 Gy y-irradiation
Bone marrow cells prepared from mice that were given 2 Gy irradiation were 
incubated with either captopril, lisinopril, AcSDKP or ACE inhibitors combined with
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AcSDKP, This was done to evaluate a direct or indirect inhibitory effect of AcSDKP 
on 2 Gy regenerating HPP-CFC-1. No inhibitory effect on cell proliferation was 
observed when all three substances were used separately (see Fig 3.4). It is not 
surprising that AcSDKP was unable to inhibit HPP-CFC-1 proliferation because it has 
a very short half-life in serum and plasma (Grillon et al., 1993a). Moreover, the 
peptide shows its inhibitory effect on haematopoietic progenitor cell proliferation at 
optimum concentrations. Thus doses higher than 1O'4m or lower than 10*14M have no 
effect on the proportion of these cells in S-phase from both mice and human bone 
marrow cells (Jackson et al., 1996; Bonnet et al., 1995). The fact that the peptide is 
thought to act at only one cmcial specific point in the cell cycle (Monpezat & Frindel, 
1989), also means that it may only affect a small number of proliferating cells at any 
one time. Therefore, the length of the peptide bioavailability directly relates to the 
potency of the inhibitory action. Others have shown that ACE inhibitors increase 
plasma concentration of AcSDKP both in vivo and in vitro (Azizi et al., 1996, Azizi et 
al., 1997). It can therefore be hypothesised that haematopoietic stem cell proliferation 
can be inhibited in the presence of ACE by up regulating AcSDKP levels.
The fact that captopril and lisinopril have no individual inhibitory effect on 
HPP-CFC-1 proliferation from 2 Gy regenerating bone marrow cell suspension rules 
out the involvement of angiotensin-ll as a contributor to 2 Gy regenerating HPP-CFC- 
1 proliferation in this assay. AcSDKP when incubated together with captopril reduced 
the proportion of HPP-CFC-1 in S-phase. The proportion of HPP-CFC-1 in S-phase 
was not reduced when 2 Gy regenerating bone maiTow cells were incubated with 
AcSDKP and lisinopril together. Therefore it can be assumed that captopril was able 
to synergise with AcSDKP to reduce the proportion of HPP-CFC-1 in S-phase in 2 
Gy regenerating bone marrow cell suspensions. This observation possibly suggests
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that captopril prevents AcSDKP degradation. It also demonstrates an indirect 
mechanism of captopril in bringing about its inhibitory effect on cell proliferation.
Since macrophages are responsible for AcSDKP production in vitro (Li et al., 
1996), the incubation medium of bone marrow cell suspension was sampled after 
incubation in the presence of captopril alone. The incubation medium was evaluated 
for any changes in AcSDKP concentration following incubation to analyse the 
balance between production and degradation of the peptide. This study was also 
performed to verify that AcSDKP levels influenced the proportion of HPP-CFC-1 in 
S-phase following incubation. Secondly this investigation was performed in order to 
show whether the inability of ACE inhibitors alone to reduce the proportion of HPP- 
CFC-1 in S-phase in 2 Gy regenerating bone marrow cell suspension was due to lack 
of endogenous AcSDKP production in the incubation dishes. 2 Gy regenerating bone 
marrow cells had very high levels of AcSDKP at the beginning of the incubation with 
no significant increase in the peptide levels in the presence of captopril after 24 hours 
of incubation (see Fig 3.7). The reason behind this finding is unknown. However, 
there are several possibilities that might lead to initial high AcSDKP levels following 
2 Gy irradiation. One reason may be cell death. AcSDKP may leak from the 
cytoplasm into the serum following irradiation injury since there are high levels of 
AcSDKP in the cell cytoplasm (Volkov et al., 1995; Volkov et al., 1997). An 
alternative explanation may rest on the cytotoxic nature of irradiation. Since 
irradiation kills only radiosensitive cells, there may be an imbalance between the 
number of cells that are responsible for AcSDKP production and those that are 
responsible for its degradation. Cells responsible for the production of stimulatory 
factors may be spared from irradiation injury because these cells are thought to be 
radioresistant(Wright & Lorimore, 1987). These cells may exert an increase in
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stimulator production. An increase in stimulator production may activate a negative 
feed back loop that may increase the production of AcSDKP by some viable cells 
responsible for AcSDKP production. These high levels of AcSDKP have no 
inhibitory effect on the proliferation of HPP-CFC-1 in this cell suspension probably 
due to a high concentration of stimulators. The inability of captopril to increase levels 
of AcSDKP after 24 hours of incubation in 2 Gy bone marrow cell suspension might 
also mean that the system responsible for AcSDKP production is working at a 
maximum capacity.
Since HPP-CFC-1 in 2 Gy regenerating bone marrow were already cycling in 
the presence of high AcSDKP levels might suggest that these high levels of AcSDKP 
were achieved by a feed back loop in vivo which could not be maintained in vitro. 
Higher concentrations of AcSDKP may be required to inhibit HPP-CFC-1 
proliferation following 2 Gy irradiation probably due to the increased levels of 
stimulatory factors. The inhibitory concentration of AcSDKP on cell proliferation is 
achieved by exogenous addition of the peptide to incubation dishes. Assuming that 
ACE activity is not at its saturation point, addition of exogenous AcSDKP would 
activate ACE thereby increasing the degradation of AcSDKP. This might explain the 
inability of lisinopril and AcSDKP to inhibit the proliferation of HPP-CFC-1 
following 2 Gy irradiation. This hypothesis is strengthened by the fact that lisinopril is 
a weak inhibitor of the N-domain ACE active site (Wei et al., 1992, Rousseau et al.,
1995).
Therefore, irradiation either disrupts the integrity of molecules involved in 
AcSDKP production and inhibitory mechanisms or it increases the concentrations of 
stimulators of stem cell proliferation to high levels that can not be opposed by the 
initial observed levels of AcSDKP in vitro. Hence no inhibitory effect on HPP-CFC-1
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proliferation following 2 Gy irradiation is observed in the presence of captopril alone 
but in the presence of captopril together with AcSDKP. The ability of captopril to 
prevent the degradation of AcSDKP in vitro ensures high levels of AcSDKP that can 
directly inhibit HPP-CFC-1 proliferation. Moreover, these results suggests that 
captopril on its own is not an inhibitor of cell proliferation following 2 Gy irradiation.
ii. Ara-C regenerating bone marrow
The effect of AcSDKP on Ara-C regenerating bone marrow cell suspension 
was investigated previously by Robinson et al., 1992. AcSDKP alone was unable to 
reduce the proportion of HPP-CFC-1 in S-phase in Ara-C regenerating bone marrow 
cell suspension in their investigations. Therefore AcSDKP alone was not investigated 
with regenerating bone marrow cell suspensions from Ara-C drug treated mice. In 
contrast to 2 Gy regenerating bone marrow HPP-CFC-1, the HPP-CFC-1 population 
is switched out of cycle in the presence of captopril in Ara-C regenerating bone 
marrow cell suspension after 24 hours of incubation (see Fig. 3.5). Surprisingly, 
incubation alone also reduced the proportion of HPP-CFC-1 in S-phase following 
Ara-C treatment. Lisinopril reduced the proportion of HPP-CFC-1 in S-phase to the
same levels as control bone marrow cells. This demonstrates that there was an
endogenous production of inhibitors of cell proliferation following incubation. 
Captopril had a synergistic effect with the endogenously produced inhibitors of cell 
proliferation, while lisinopril was unable to synergise with these endogenously 
produced inhibitory factors. Since Ara-C kills cells that are specifically in S-phase, 
differentiated cells responsible for inhibitor production are not compromised 
following Ara-C treatment. This is in contrast to irradiation, which affects 
differentiated as well as proliferating cells and it therefore compromises the functional
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integrity of ceils that may be involved in the production of factors that regulate cell 
proliferation. Indeed, levels of AcSDKP were significantly increased when captopril 
was added to Ara-C regenerating bone marrow cell suspensions after 24 hours of 
incubation (see Fig. 3.7). Interestingly, incubation alone significantly decreased the 
levels of AcSDKP in Ara-C treated bone marrow cell suspension. This may contradict 
the inhibitory effect observed on HPP-CFC-1 proliferation by incubation alone. 
However, the presence of uninjured bone marrow macrophages in the cell suspension 
may lead to the production of other stem cell proliferation inhibitors such as MIP la
and TGF-P (Maltman et al., 1993) that may reduce AcSDKP levels.
Incubation alone may also increase the endogenous production of
prostaglandin-Ez (PG-Ei) (Goodwin et al., 1978). Prostaglandins are produced by the 
action of the enzyme cyclooxygenase (COX) on arachidonic acid liberated from 
membrane phospholipids. There are two forms of COX called COX-1 and COX-2. 
COX-2 is produced following lipopolysacchride (EPS) stimulation on alveolar 
macrophages while COX-1 is present only in resisting macrophages and is not 
affected by LPS (Lee et al., 1992). Therefore an increase in prostaglandins in LPS- 
stimulated macrophages (Humes et al., 1977) results from selective expression of 
COX-2. PG-E2 sthnulates production of cyclic-3’,5’adenosine monophosphate 
(cAMP) which decreases the production of IL-2 and IFN-y by T cells (Phipps et al., 
1991). The increase in intracellular cAMP may interfere with signal transduction 
cascades involving MAP kinase because cAMP stops the physical association of Ras 
and Raf-1 (Wu et al., 1993). IFN-y induces la (class II major histocompatibility 
complex (MHC)) expression on macrophages by rapid exchange of Na+ and H+ by 
means of the Na+/FT antiporter (Prpic et al., 1989). Therefore PG-E2 is an indirect 
potent inhibitor of the expression of la-antigens on macrophages (Snyder et al., 1982;
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Figuekedo et al., 1990). Macrophages expressing la-antigens are essential in the 
production of stimulatory factors (All et al., 1982). In addition to its effect on IL-2 
and IFN-y, PG-E2 is potent inhibitor of IL-12 production and a potent stimulator of 
IL-10 production (van der Pouw Kraan et al., 1995; Strassman et ai., 1994). PG-E2 
also inhibits lipopolysaccharide (LPS)-production of TNF-a and IL-6 by an autocrine 
feedback mechanism involving up regulating the levels of IL-10 (Strassmann et al., 
1994). IL-1 and TNF-a in combination increase PG-E2 production (Topley et al., 
1989). TNF alone stimulates the production of IL-1 and PG-E2 in resting 
macrophages (Bachwich et al., 1986). Interestingly anti-inflammatory cytokines (IL-4 
and IL-10) both decrease levels of TNFa, IL-1, and PG-E2 (Hart et al., 1989; Niho et
ah, 1998).
Therefore PG-E2 may bring about its suppressive effect by up regulating the
levels of IL-4 and IL-10. Indeed both IL-4 and IL-10 inhibit LPS-induced COX-2 
expression thus leading to down-regulation of PG-E2 production (Niiro et al., 1995). 
Therefore PG-E2 regulates a feed back loop on cytokine production which in turn 
regulates its own production. It is sensible to suggest that an increase in PG-E2 
production results in a reduction in cytokines that may have some stimulatory activity 
on the proliferation of stem cells. The net result is inhibition of stem cell proliferation.
Interestingly, dose dependently captopril but not lisinopril suppresses IL-lp- 
induced synthesis of TNF and IL-1 a (Schindler et al., 1995). However both captopril 
and lisinopril suppress production of interleukin-12 by human peripheral blood 
mononuclear cells stimulated by LPS (Constantinescu et al., 1998). Excitingly, 
lisinopril suppresses production of IL-12 at lO"3M with little effect at low 
concentrations, while captopril suppresses IL-12 at concentrations as a low as lO'7M. 
In these investigations we used 1O'7m for all investigations since this concentration
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was shown to inhibit ACE activity. Therefore these results are in agreement with the 
hypothesis that reduced levels of stimulatory factors may be behind the effects of 
ACE inhibitors on HPP-CFC-1 proliferation. The high concentration of lisinopril 
required to suppress IL-12 production may also suggest that AcSDKP levels may 
influence IL-12 production. Captopril is 50 times better at inhibiting the N-domain 
ACE active site and preventing AcSDKP degradation (Rousseau et al., 1995) than 
lisinopril. Therefore higher levels of lisinopril are needed to inhibit the N-domain 
ACE active site than captopril. However, in addition to an increase in AcSDKP 
concentration due to reduced degradation as observed in Ara-C generating bone 
marrow cell suspension incubated with captopril, captopril also increases PG-E2 
production (Swartz et al., 1980). The inhibitory effect of captopril on T lymphocyte 
proliferation has been shown to involve an increase in PG-E2 production (Johnsen et 
al., 1997). Therefore, it can be concluded that captopril might be working in concert 
with most of the mechanisms involved in the inhibition of haematopoietic stem cell 
proliferation to bring about its inhibitory effect on Ara-C proliferating HPP-CFC-1.
Since the mode of action of AcSDKP is unknown it can not be ruled out that
AcSDKP may utilise the same pathway in its inhibitory effect on HPP-CFC-1 
proliferation as captopril. It is plausible to suggest that captopril may influence cell 
proliferation by increasing the endogenous levels of AcSDKP which may in turn 
increase the endogenous levels of PG-E2, IL-10 or IL-4 resulting in the reduction in 
the production of stimulatory factors. The fundamental difference between the 
inhibitory effects observed in the presence of Ara-C and 2 Gy can therefore be 
attributed to cell damage that is incurred by these two cytotoxic agents. The absence 
of damage to differentiated cells in the presence of Ara-C results in tlie normal feed 
back loops which are involved in the regulation of stem cell proliferation. Tliis is not
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observed following 2 Gy because cells may be experiencing the late effect of 
irradiation on cell function. The above hypothesis suggests that the ability of captopril 
to influence HPP-CFC-1 from Ara-C regenerating bone marrow is likely to be 
indirect. This mechanism requires the involvement of accessory cells. AcSDKP also 
shows the need for accessory cells for its cell proliferation inhibitory effect (Lauret et 
al., 1989). Therefore the observed effect of captopril may not due to the drug alone.
5 FU regenerating bone marrow
Regenerating bone mairow cell suspensions from 5 FU treated mice were also 
incubated with or without ACE inhibitors. This was done for three reasons, firstly to 
evaluate whether the captopril effect on Ara-C regenerating HPP-CFC-1 cycling was 
unique to Ara-C. Secondly, to investigate the response of very primitive HPP-CFC-1 
which responds to the three recombinant growth factors used in these investigations 
following 5 FU treatment in vivo. Thirdly to evaluate whether cytotoxic drug induced 
HPP-CFC-1 proliferation would respond in the same way to ACE inhibitors 
regardless of the type of drug used to induce insult.
While incubation alone reduced the proportion of HPP-CFC-1 in S-phase in 
control bone marrow after 24 hours, no such effect was observed with lisinopril. In 
contrast, captopril significantly reduced the proportion of HPP-CFC-1 in S-phase 
when compared to controls (see Fig. 3.6). Furthermore, no increase in the levels of 
AcSDKP was observed in the presence of captopril after 24 hours of incubation of 5 
FU regenerating bone marrow cells (see Fig. 3.7). This is rather surprising. However, 
5 FU enriches for HPP-CFC-1 after 4 days in vivo (Bartelmez et al., 1989). The HPP- 
CFC population needs low concentrations of inhibitory factors to be inhibited 
(Pragnell et al., 1988). The fact that 5 FU metabolites also kill cells (Hodgson et al.,
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1982; Donowitz & Quesenberry, 1986) means that there is a marked cell death 
following 5 FU treatment with reduction in cells that may be involved in inhibitor 
production. Therefore, it is not surprising that the levels of AcSDKP do not increase 
in the presence of captopril after 24 hours. Lisinopril may antagonise inhibitor 
production as shown by its inability to inhibit IL-ip production of IL-1 a and TNF 
(Schindler et al., 1995). Moreover, endogenous PG-E2 also greatly enhances the 
synthesis of GM-CSF and it may upregulate the expression of IL-1 receptors on 
monocytes (Phipps et al., 1991). It follows then that the concentrations of stimulators 
are not significantly reduced in the presence of lisinopril. The small amount of 
inhibitor produced manages to slightly inhibit HPP-CFC-1 proliferation in the absence 
of ACE inhibitors. Despite no change in AcSDKP levels, captopril significantly 
reduced the proportion of HPP-CFC-1 in S-phase. This can be attributed to the 
inherent property of captopril in addition to its effect on cytokine production.
Captopril’s inhibitory effect may involve the scavenging of free radicals 
(Bagchi et al., 1989). For example, TNF stimulates superoxide (O2') release directly in 
human granulocytes in a dose-dependent manner (You et al., 1989). This granulocyte 
activation may also activate other cells with a net increase in the production of 
cytokines. Therefore, the ability of captopril to scavenge free radicals induced by TNF 
may inhibit the production of cytokines that utilise this mechanism. As discussed by 
Wang et al., 1995, antioxidants and free radical scavengers inliibit NFkB activation. 
Therefore captopril by its ability to scavenge free radicals, may inhibit the production
of stimulatory factors by inhibiting NFkB. In addition there is evidence that captopril 
inhibits GM-CFC proliferation in the presence of copper, a mechanism that has been 
attributed to free radical scavenging (Hammond et al., 1988). Moreover, captopril has 
marked anti-inflammatory activity as shown by its ability to inhibit delayed
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hypersensitivity reactions in rodents (Wang et ai., 1996). Since inflammatory 
processes are regulated by cytokines, captopril is therefore a potent inhibitor of 
cytokine production. To conclude, captopril may in general inhibit cell proliferation 
by mechanisms that may involve ACE inhibition, inhibition of cytokine production 
and the free radical scavenging mechanism. All these mechanisms may be involved in 
captopril inhibitory effect following cytotoxic drugs.
From the in vitro investigation, it seems that angiotensin-II is not involved in 
HPP-CFC-1 proliferation in vitro. This is shown by the fact that lisinopril had no 
effect on HPP-CFC-1 proliferation in all the three models tested. Moreover, high 
levels of foetal calf serum were used in all these investigations and lisinopril was 
demonstrated to be more effective on ACE inhibition in serum. Therefore, if the 
inhibitory effect of ACE inhibitors was mediated by reduction in angiotensin-II levels, 
then lisinopril should have preferentially inhibited HPP-CFC-1 proliferation.
While AcSDKP is a strong candidate in the inhibitory effect imposed by 
captopril, angiotensin-II mechanism can not be ruled out. Indeed AcSDKP and 
angiotensin-II may share some common characteristic in that they both inhibit 
immunological reactions brought about by cells that may be involved in immime 
regulatory mechanisms and reactions (Dezso & Foris, 1981; Foris et al., 1983; Thierry 
et al., 1990, Frindel et al., 1992a; Lavignac et al., 1992; Aizawa et al., 1992). 
Therefore by inhibiting one molecule captopril may up regulate the other hence 
revealing the common pathways of AcSDKP and angiotensin-II. Interestingly, 
angiotensin-II has both stimulatory and inhibitory effects on cell proliferation. 
However, stimulatory effects of angiotensin-II are more marked than its inhibitory 
effects on cell proliferation. For example, angiotensin-II is a growth factor with 
receptors on haematopoietic (Dezso & Foris, 1991; Foris et al., 1983; Shimada &
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Yazaki, 1978) and on non haematopietic cells (Crabos et al., 1994; Sadoshima & 
Izumo, 1993). On the other hand, the response of peripheral blood T-lymphocyte 
stimulation to lectin is impaired in people with essential hypertension and is increased 
after captopril treatment (Shasha et al., 1991) suggesting that angiotensin-II may be an 
inhibitory factor on T-cell proliferation in these patients. Captopril enhances in vitro 
human lymphocyte thymidine incorporation stimulated by phytohaemagglutinin-P 
(PHA) and concovalin-A (Con-A) but not pokeweed mitogen (PWM) (Simon et al., 
1984). Simon et al, 1984 argue that this stimulatory effect is mediated by ACE 
inhibition since both PHA and Con-A are mitogens that are macrophage dependent 
and macrophages produce ACE (Costerousse et al., 1993). In addition, angiotensin-II 
inhibits active, and passive IgG2a-erythrocyte-antibody (EA) rosette formation on 
monolayers of rat peritoneal macrophages at a dose range of 10'5 to 5 x 10’7 M and 
stimulates them in the dose range of 10* to 10' M (Dezso & Foris, 1981, Foris et al., 
1983). Therefore this dual effect of angiotensin-II on cell proliferation makes it 
difficult to interpret the effects angiotensin-II may have in vitro in the present 
investigation. If angiotensin-II is acting as an inhibitor of cell proliferation, its 
reduction should recruit HPP-CFC-1 into cell cycle. Therefore, ACE inhibitors should 
have increased the proportion of HPP-CFC-1 into S-phase rather than reduce it. 
However, if it was acting as a stimulatory factor, its reduction following ACE 
inhibitors should have been shown by both captopril and lisinopril.
3.5.2 The effect of on SA2 cell proliferation
The observation that captopril inhibited HPP-CFC-1 proliferation in
regenerating bone marrow cell suspensions with or without AcSDKP was investigated 
further. The specificity of the captopril inhibitory action on normal haematopoietic
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ceils was evaluated using the SA2 myeloid leukaemia cell line. The main point was to 
find out whether captopril inhibits all cycling cells regardless of being normal or 
neoplastic. In these investigations captopril failed to inhibit the proliferation of 
neoplastic cells. This is in agreement with what has been observed by others before. 
The underlying cause of this effect is largely unknown. Interestingly, captopril 
inhibits glioma cell mvasion without affecting the motility or proliferation of these 
cells (Nakagawa et al., 1995). In addition, captopril in vivo retards the expansion of 
kidney tumours without affecting its cell proliferation (Hii et al., 1998). Therefore, the 
effect of captopril on tumour cell proliferation is a complex one. Some possible 
mechanisms involved in captopril’s ability to influence tumour cell proliferation will 
be discussed further in chapter 6.
3.5.3 The effect of AcSDKP on HPP-CFC-1 cell cycle
This was investigated by an initial incubation of regenerating bone marrow
cells with Ara-C followed by a second incubation of bone maiTow cells with AcSDKP 
and captopril together. The proportion of cells in S-phase following the second 
incubation time is an indication of cell entry into cell cycle following the second in 
vitro incubation. Moreover, this method synchronises cells in the cell cycle. The fact 
that AcSDKP inhibits CFU-S cycling following Ara-C is well-established (Monpezat 
& Frindel, 1989). It is also known that AcSDKP has an inhibitory effect on cycling 
HPP-CFC that is mediated by opposing the effect of stimulatory factors on cell 
proliferation (Robinson et aL, 1992). Since Ara-C is an S-phase specific agent and 
AcSDKP only inhibits CFU-S cycling if given 2 hours following Ara-C, it has been 
suggested that AcSDKP blocks Go-Gi/S transition. However, this has not been 
directly shown and the in vitro cell cycle mode of action of AcSDKP has not been
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elucidated. Therefore an investigation was carried out to test the mode of action of 
AcSDKP in vitro and to confirm the fact that the peptide may be active at the Gj/S 
boundary. This hypothesis was tested using cycling HPP-CFC-1. HPP-CFC-1 S-phase 
entry was inhibited in the presence of AcSDKP and captopril from all cytotoxic 
insults (see Fig. 3.8). Bone marrow cells prepared from mice following 2 Gy — 
irradiation showed the greatest reduction in S-phase entry, and bone marrow cells 
prepared from mice following 5 FU treatment showed the least potency in S-phase 
entry reduction. Moreover, the same results were demonstrated after only 1 hour of 
incubation following the initial Ara-C suicide (results not shown). From these results, 
it is confirmed that AcSDKP inhibits S-phase entry of stem cells regardless of the 
assay used. Moreover, it also confirms that the peptide has little or no effect on other 
phases of the cell cycle. This is so because 4 hours is not enough time for the 
completion of the cell cycle progression. Considering that there were no cells in S- 
phase during the second incubation, the proportion of HPP-CFC-1 in S-phase in 
control samples is very high thus suggesting that this pool of cells might have just 
been recruited into S-phase from Gj/S boundary. A high proportion of HPP-CFC-1 in 
S-phase would have been observed in AcSDKP and captopril incubated bone marrow 
cells if the peptide was acting at a different point in the cell cycle rather than the Gj/S 
boundary. This is due to specificity of Ara-C in killing cells that are in S-phase of the 
cell cycle. From the results presented in these investigation and the argument put 
forward, it is likely that AcSDKP and captopril inhibit S-phase entry in proliferating
cells.
The molecular mechanisms employed by AcSDKP in its inhibitory effect are 
unknown. There are several pathways by which inhibitors of cell proliferation can 
achieve their effect. An increase in the levels of inhibitory cytokines may be
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responsible for AcSDKP action. Other mechanisms may involve competitive 
displacement of growth factors from their receptors; down-regulating growth factor 
receptor expression; counter-acting one or more steps involved in the signal 
transduction pathways; disruption of cell communication by affecting the integrity of 
gap junctions, imbalance between cytoplasmic ions, like Ca77 and small molecules 
like cyclic adenosine monophosphate (cAMP). Very little information is available on 
the molecular mode of action of the most commonly known inhibitors of 
haematopoietic stem cell proliferation. However, there is evidence that AcSDKP 
causes an incomplete competitive inhibition of calmodulin-dependent 
phosphodiesterase (Voelter et al., 1995). It is thus possible that the AcSDKP 
inhibitory effect may involve cyclic nucleotide metabolism. In addition the findings of 
Voelter et al., 1995 suggest that Cat may be crucial in the AcSDKP induced cellular 
proliferation inhibitory effect. In addition, AcSDKP has no effect on neoplastic cell 
proliferation at concentrations that affect normal cell proliferation (Bonnet et al., 
1992a). This suggests that AcSDKP can only function if the cellular molecular 
integrity is preserved. The crucial step in the induction of S-phase progression in the 
cell cycle is the passage of proliferating cells at the restriction point, which is in the 
late Gi phase before they can progress into the S-phase. Neoplastic cells may by-pass 
this stage while normal cells can not. It therefore follows that the genetic integrity of 
the restriction point in the late Gi phase of cell cycle will have a tremendous influence 
on normal cell cycling. AcSDKP may exert its influence indirectly at this point by 
inhibiting the phosphorylation of the retinoblastoma gene protein. The molecular 
mechanisms involved in the AcSDKP inhibitory effect require further investigation.
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CHAPTER 4
4.0 IN VIVO EFFECT OF ACE INHIBITORS ON HPP-CFC-1 
PROLIFERATION
Having established the inhibitory effect of captopril on HPP-CFC-1 
proliferation in vitro, investigations were conducted to see whether ACE inhibitors 
might also reduce the proportion of HPP-CFC-1 in S-phase in vivo following 
cytotoxic treatments. The doses of insults given to mice were identical to the ones 
given for in vitro investigations. Since it was difficult to give a dose of ACE that 
would produce I pM drug concentration in vivo without pharmacokinetic studies, the 
recommended human therapeutic dose of each ACE inhibitor was chosen as the dose 
to be investigated for in vivo experiments. Thereafter the ability of captopril to 
regulate AcSDKP concentrations m vivo was studied. Captopril was further 
investigated on its potential ability to protect the haematopoietic system from 
myelotoxicity following cytotoxic agents.
Procedure
CDl mice were exposed to 2 Gy irradiation or injected with Ara-C (lOOmg/kg
i.p) or 5 FU (150mg/kg i.v). 1 hour after the insult they were injected i.p with saline, 
lisinopril or captopril. The doses chosen were 10 mg/kg-body weight for the lisinopril 
(Goa et al., 1996) investigation and 100 mg/kg-body weight for the captopril (Martin 
et al., 1984) investigation. Mice were killed after 24 hours following 2 Gy or Ara-C 
and after 4 days following 5 FU treatment. Bone marrow cells were pooled from mice 
and a single cell suspension produced in D20%HS PS/G. The proportion of HPP- 
CFC-1 in S-phase was estimated using an S-phase suicide assay. All experiments 
were performed with control mice that did not receive insults but received saline or
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ACE inhibitors. After an S-phase suicide assay, cells were washed twice and plated 
for HPP-CFC-1 assay according to the general methods.
Results
4.0.1 The effect of 10 mg/kg lisinopril following 2 Gy
As shown in Fig 4.1, HPP-CFC-1 in animals that did not receive irradiation 
were not in cell cycle. Lisinopril had no effect on the proliferation of this HPP-CFC-1
FIG. 4.1 Proportion of HPP-CFC-1 in S-phase following 2 Gy irradiation in vivo 
with lOmg/kg lisinopril
lOmg/kg ACE
ACE Inhibitor
% HPP-CFC-1 in S-phase
NBM + Saline
NBM + Lisinopril
2 Gy + Saline
2 Gy + Lisinopril 
NS & 2 GyS
NS & 2 GyL
(15.1 ±3.9)% 
(11.4 ±4.2)% 
(42.9 ± 4.7)% 
(27.2 ± 4.0)%
P = 0.63, n = 4
P = 0.05, n = 4
P = 0.002
P = 0.03
NB; NS = Normal bone marrow + saline, 2 Gy S = 2 Gy bone marrow + saline, 2 
GyL = 2 Gy bone marrow + lisinopril.
50 1
1
□ NBM + Saline 
0NBM + Lisinopril 
■ 2 Gy + Saiine 
B2 Gy+Lisinopril
cell population. Mice that received 2 Gy irradiation and saline had (42.9 ± 4.7)%
HPP-CFC-1 in S-phase and the proportion was slightly reduced to (27.2 ± 4.5)% in
mice that were given lisinopril following 2 Gy (p = 0.05). Therefore in vivo lisinopril
was unable to strongly reduce the proportion of HPP-CFC-1 in S-phase following 2
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Gy y-irradiation. Having established that lisinopril had a borderline effect on HPP- 
CFC-1 proliferation following 2 Gy, the same dose of captopril as lisinopril was 
investigated. Just as with the lisinopril experiments, normal bone marrow HPP-CFC-1 
proliferation was not affected by captopril (see Fig 4.2). Furthermore, captopril had 
no effect on HPP-CFC-1 proliferation at 10 mg/kg (p - 0.42). Hence, low doses of 
captopril did not affect HPP-CFC-1 proliferation following 2 Gy irradiation in vivo.
FIG. 4.2 The proportion of HPP-CFC-1 in S-phase following 2 Gy in vivo with 
captopril (lOmg/kg)
1 Omg/kg ACE
ACE Inhibitors
% HPP-CFC-1 in S-phase
NBM + Saline (6.1 ± 1.9)%
NBM + Captopril (7.5 ±4.1)% P = 0.74, n = 4
2 Gy ± Saline (44.7 ±2.1)%
2 Gy + Captopril (37.1 ±7.6)% P = 0.42, n = 4
NS & 2 GyS P = 0.00002
NC & 2 GyC P = 0.0004
NB: NC = normal bone marrow + captopril, 2 GyS= 2 Gy bone marrow ± saline, 2 
GyC = 2 Gy bone marrow + captopril
□ NBM+Saline
□ NBM+Captopril 
■ 2 Gy+Saline 
02 GY+Captopril
4.0.2 The effect of 1 Omg/kg ACE inhibitors following Ara-C
ACE inhibitors did not have an effect on HPP-CFC-1 proliferation from bone 
marrow cells of untreated mice (Fig 4.3). However (42.1 ± 3.5)% of HPP-CFC-1 were 
in S-phase in Ara-C treated mice followed by saline injection whereas lisinopril
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significantly reduced this proportion to (20.5 ± 4.4)% (p = 0.0084). Interestingly, 
captopril at a dose of lOmg/kg was unable to reduce the proportion of HPP-CFC-1 in 
S phase following Ara-C treatment. Ara-C treated mice that were given saline had
(38.4 ± 2.1)% of HPP-CFC-1 in S-phase while mice that were given captopril had
FIG. 4.3 The proportion of HPP-CFC-1 in S-phase following Ara-C treatment in 
vivo with lisinopril (lOmg/kg)
lOmg/kg ACE
ACE Inhibitors
% HPP-CFC-1 in S-phase
NBM + Saline
NBM + Lisinopril 
Ara-C + Saline 
Ara-C + Lisinopril 
NS& 2 GyS
NL & 2 GyL
(3.9 ± 6.2)% 
(4.3 ± 5.9)% 
(42.1 ±3.5)% 
(20.5 ± 4.4)%
P = 0.85, n = 4
P = 0.0084, n = 4
P = 0.00007
P = 0.0012
NB: NL = Normal bone marrow with lisinopril, 2 GyL = 2 Gy bone marrow with 
lisinopril.
□ FBMHSaline 
S FBMHJsincprrii 
■ Aaa-C+Saline 
OAc-C+Lisnoprrii
(35.2 ± 4.6)% of HPP-CFC-1 in S-phase (p = 0.55) (Fig 4.4). Therefore lisinopril 
reduced the proportion of HPP-CFC-1 in S-phase in Ara-C regenerating bone marrow
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at these low doses without affecting the proportion of HPP-CFC-1 in S-phase 
following 2 Gy. Lisinopril inhibitory effect on HPP-CFC-1 proliferation was 
incomplete in that a large proportion of HPP-CFC-1 was still in S-phase.
FIG 4.4 The proportion of HPP-CFC-1 in S-phase following Ara-C treatment in 
vivo with captopril (lOmg/kg)
l Omg/kg ACE
ACE Inhibitors
% HPP-CFC-1 in S-phase
NBM + Saline (11.0 ±2.8)%
NBM + Captopril (12.7 ±3.5)% P = 0.75, n = 4
Ara-C + Saline (38.4 ±2.1)%
Ara-C + Captopril (35.2 ± 4.6)% P = 0.55, n = 4
NS & AS P = 0.002
NC & AC P = 0.005
NB: AS = Ara-C bone marrow + saline, AC = Ara-C bone marrow + captopril
45
40
<u
|35
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o
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□ NBM+Saiine
□ INBM+CCptcpril 
■AraOSaline 
SABOCSptcprilI
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4.0.3 The effect of lOOmg/kg ACE inhibitors on 2 Gy regenerating bone 
marrow HPP-CFC-1
ACE inhibitors did not affect the proportion of HPP-CFC-1 in S-phase in 
untreated mice. 2 Gy followed by saline treated mice had (26.9 ± 3.5)% of HPP-CFC- 
1 in S-phase, this proportion was unchanged when 2 Gy was followed by lisinopril 
(lOOmg/kg) at (29.2 ± 2.2)% (p = 0.6) (see Fig 4.5). However, when mice that were
exposed to 2 Gy y-irradiation were injected with captopril (lOOmg/kg), there was a
significant reduction in the proportion of HPP-CFC-1 in S-phase. (35.9 ± 3.1)% of
HPP-CFC-1 were in S-phase following 2 Gy y-irradiation and saline. This proportion
FIG. 4.5 The proportion of HPP-CFC-1 in S-phase following 2 Gy irradiation in 
vivo with lisinopril
lOOmg/kg ACE
ACE Inhibitors
% HPP-CFC-1 in S-phase
NBM + Saline
NBM + Lisinopril
2 Gy + Saline
2 Gy + Lisinopril
NS & 2 GyS
NL & 2 GyL
(4.4 ±7.1)% 
(9.4 ± 4.0)% 
(26.9 ±3.5)% 
(29.2 ± 2.2)%
P = 0.87, n = 4
P = 0.6, n = 4
P = 0.003
P = 0.006
□ N BM +Saline 
S NBM + Lis inopril 
■ 2 Gy+Saline 
E32 Gy+Lisinopiil
0
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was reduced to (13.7 ± 2.5)% (p = 0.0013) when 2 Gy exposed mice were given 
captopril (Fig 4.6). Despite having no effect at low doses captopril reduced the 
proportion of HPP-CFC-1 in S-phase following 2 Gy irradiation at therapeutic doses
used in man in these mice.
FIG. 4.6 The proportion of HPP-CFC-1 in S-phase following 2 Gy irradiation in 
vivo with captopril (lOO^^/'kg)
l OOmg/kg ACE
ACE Inhibitors
% HPP-CFC-1 in S-phase
NBM + Saline
NBM + Captopril
2 Gy + Saline
2 Gy + Captopril
NS & 2 GyS
NC &2GyC
(12.6 ±4.0)%
(8.6 ±34)%
(35.9 ±3.1)% 
(13.7 ±2.5)%
P = 0.65, n = 4
P = 0.0013, n = 4
P = 0.002
P = 0.42
□ NBM+Saline 
0 NBM+Captopril 
■ 2 Gy+Saline 
Q 2 Gy+Captopril
4.0.4 The effect of lOOmg/kg ACE inhibitors on Ara-C regenerating 
bone marrow HPP-CEC-1
No difference in the proportion of HPP-CFC-1 was observed in the presence
of ACE inhibitors in untreated control mice. (30.8 ± 4.6)% of HPP-CFC-1 were in S-
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phase following Ara-C and saline which remained unchanged at (32.1 ± 2.0)% when 
mice received lisinopril (lOOmg/kg) following Ara-C treatment (p = 0.79) (see fig 
4.7). However captopril showed a significant reduction in the proportion of HPP-
CFC-1 in S-phase after
FIG 4.7 The proportion of HPP-CFC-1 in S-phase following Ara-C in vivo 
following ACE inhibitors (lOO^j^y/kg)
lOOmg/kg ACE
ACE Inhibitors
% HPP-CFC-1 in S-phase
NBM + Saline
NBM + Lisinopril 
NBM + Captopril
(13.6 ±5.1)% 
(11.7 ± 1.7)% 
(11.8 ±3.1)%
P = 0.81, n = 4
P = 0.73, n = 4
Ara-C + Saline-1 
Ara-C + Lisinopril
(30.8 ± 4.8)% 
(32.1 ±2.0)% P = 0.79, n = 4
Ara-C + Saline-2 
Ara-C + Captopril
(29.8 ± 1.5)% 
(7.8 ± 2.5)% P = 0.00024, n = 4
NS &AS-1
NS & AC
AC & AL
P = 0.003
P = 0.06
P = 0.00014
□ NBM+Saline 
El NBM+Llsinopril 
S NBM+captopril 
E3 Ara-C+Saline
□ Ara-C+Llsinopril
□ Ara-C+Captopril 
■ Ara-C+Saline
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Ara-C treatment (29,8 ± 1.4)% of HPP-CFC-1 were in S-phase when Ara-C and 
saline were administered and this proportion was significantly reduced to (7.8 ± 2.5)% 
(p = 0.00024)(Fig 4.7) when Ara-C and captopril (lOOmg/kg) were administered. The 
proportion of HPP-CFC-1 in S-phase observed after captopril was given to Ara-C 
treated mice was the same as the one observed in the control mice receiving only
saline or ACE inhibitors.
4.0.5 The effect of lOOmg/kg ACE inhibitors on 5 FU regenerating
bone marrow HPP-CFC-1 cycling
As shown in Fig 3.22, (60.5 ± 7.2)% of HPP-CFC-1 were in S-phase in 5 FU 
treated mice given saline and the proportion remained unchanged with lisinopril at
FIG. 4.9 The proportion of HPP-CFC-1 in S-phase following 5 FU treatment in 
vivo with ACE inhibitors (l OOmg/kg)
1 OOmg/kg ACE
ACE Inhibitors
% HPP-CFC-1 in S-phase
NBM+ Saline
NBM+ Lisinopril 
NBM+ Captopril
(4.1 ±6.5)%
(9.4 ± 5.0)%
(7.5 ± 3.6)%
P = 0.74, n = 4
P = 0.83, n = 4
5 FU + Saline
5 FU + Lisinopril
(60.9 ± 772)% 
(64.2 ± 2.4)% P = 0.64, n = 4
5 FU + Saline
5 FU + Captopril
(57.0 ± 2.0)% 
(22.3 ± 5.8)% P = 0.0013, n = 4
NS & 5 FUS
NS & 5 FUC
5 FUC & 5 FUL
P< 0.001
P = 0.032
P = 0.0004
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NB: 5 FUS = 5 FU bone marrow + saline, 5 FUC = 5 FU bone marrow + captopril, 5 
FUL = 5 FU bone marrow + lisinopril.
(64.2 ± 2.4)% (p = 0.64). On the other hand (57.0 ± 2.0)% of HPP-CFC-1 were in S-
□ NBM+Saline
El NBM+Captopril
□ NBM+Lisinopril 
■ 5 FU+Saline
□ 5 FU+Lisinopril 
05 FU+Captopril
□ 5 FU+Saline
phase in mice given saline after 5 FU treatment and captopril reduced this proportion
to (22.3 ± 5.8)% (p = 0.0013)(see Fig 4.9). Thus high levels of captopril inhibited
HPP-CFC-1 proliferation from 5 FU treated mice. However the inhibitory effect of 
captopril on HPP-CFC-1 proliferation following 5 FU treatment was incomplete. 
Captopril at its recommended therapeutic dose clearly had a suppressive effect on
HPP-CFC-1 proliferation in vivo regardless of the length of time following its in vivo
metabolism.
4.0.6 Effect of Captopril on AcSDKP concentration in vivo following 2 
Gy and Ara-C administration
Procedure
3 groups of CDl mice were given captopril 100 mg / kg-body weight an hour
after saline, 2 Gy-y-irradiation or Ara-C (1 OOmg/kg-body weight) treatments. The
procedure included control mice that received saline instead of captopril. Mice were
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killed at 2, 6, and 24 hours following insult in vivo. Plasma was collected and
samples were assayed for AcSDKP concentrations according to the methods already
described.
Results
As shown in fig 4.8 plasma levels of AcSDKP are highest at 2 hours and they 
dropped to normal levels after 24 hours in captopril treated mice regardless of 
whether they received cytotoxic insults or not. The concentration of AcSDKP in tlie 
plasma of untreated mice was 0.82 ± 0.20 nM of AcSDKP. When captopril was 
administered to mice that had received saline, AcSDKP concentration increased to
FIG. 4.8 The in vivo effect of captopril on AcSDKP levels
100mg/kg
Captopril
AcSDKP concentration 
(nM)
T = 24T = 2 T = 6
N-plasma 0.82 ± 0.20
NBM+ saline 1.53 ±031 1.10 ±0.50 0.90 ± 0.20 P = 0.126, n = 3
NBM + Captopril 4.62 ±1.06 4.20 ± 1.60 1.65 ±0.40 P = 0.023, n = 3
2 Gy + saline 0.92 ± 0.32 1.10 ±0.50 1.00 ±0.66 P = 0.886, n = 3
2 Gy + captopril 9.70 ± 1.70 4.20 ± 0.60 1.95 ±0.70 P = 0.000003, n = 3
Ara-C + saline 1.10 ±0.64 1.10 ±0.60 1.00 ±030 P = 0.97, n =3
Ara-C + captopril 7.85 ±2.20 4.14 ± 1.00 1.63 ± 0.35 P = 0.00027, n = 3
N-plasma & NS P = 0.03 P = 0.5 P = 0.77
N-plasma & NC P = 0.001 P = 0.03 P = 0.41
N-plasma & GyS P = 0.698 P = 0.41 P = 0.7
N-plasma &GyC P = 0.00006 P = 0.00003 P = 0.054
N-plasma & AS P = 0.56 P = 0.49 P = 0.48
N-plasma & AC P = 0.001 P = 0.001 P = 0.03
NB: N-plasma = Normal bone marrow plasma.
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a. In vivo effect of captopril on AcSDKP concentration following 
saline treatment
—Hl— NBM + Saline
Time after treatment (hrs)
NBM + Captopril
4.62 ± 1.06 nM after 2 hours, and were still high at 4.20 ± 1.60 nM after 6 hours. 
However after 24 hours the levels had decreased to 1.65 ± 0.40 nM (p = 0.023). No 
significant increase in AcSDKP levels was observed when saline treated mice 
received a second injection of saline. At 2 hours saline treated mice given saline had
1.53 ± 0.31 nM of AcSDKP and 1.10 ± 0.50 nM of AcSDKP were obtained at 6
hours. The levels of AcSDKP remained unchanged after 24 hours at 0.90 ± 0.02 nM 
(p = 0.12) in these mice. Thus saline did not influence AcSDKP production (see Fig
4.8a).
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b. In vivo effect of captopril on AcSDKP concentration following 2 Gy 
/-irradiation
Time after treatment (hrs)
2 Gy + Saline
Gy + Captopril
Following 2 Gy irradiation captopril significantly elevated AcSDKP levels after 2 
hours. 9.70 ± 1.70 nM of AcSDKP was obtained after 2 hours following 2 Gy and 
captopril and 4.20 ± 0.60 nM of AcSDKP was obtained after 6 hours. The levels of 
AcSDKP had dropped to 1.95 ± 0.70 nM after 24 hours (p = 0.0000034). On the other 
hand no such effect was observed with 2 Gy iiradiated mice that received saline. 'The 
values of AcSDKP were 0.92 ± 0.32 nM, 1.10 ± 0.50 nM and 1.00 ± 0.66 nM at 2, 6, 
and 24 hours respectively (p = 0.88) (see Fig. 4.8b).
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c. In vivo effect of captopril on AcSDKP concentration following Ara-C
treatment
-ir- Ara-C+ Saline
-^AaaO Captopril
0246 81012141618202224
Time after treatment (hrs)
Mice that were given captopril after Ara-C treatment had an increase in vivo AcSDKP 
production. The values of AcSDKP were 7.85 ± 2.20 nM, 4.14 ± 1.00 nM and 1.63 ± 
0.3 5nM at 2, 6, and 24 hours following Ara-C and captopril respectively (p = 0.0003). 
Therefore captopril had the same trend of AcSDKP production in Ara-C treated mice 
and 2 Gy irradiated mice. Just as with 2 Gy irradiation, no variation in AcSDKP 
endogenous production was observed when Ara-C treated mice were given saline. 
The values were 1.10 ± 0.64 nM, 1.10 ± 0.60 nM and 1.00 ± 0.3 nM at 2, 6, and 24
hours when saline was administered following Ara-C (see Fig.4.8c). These results
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clearly showed that the ability of captopril to inhibit HPP-CFC-1 proliferation fa vivo 
might partly involve the up-regnlation of the natural levels of AcSDKP.
4.1 THE EFFECT OF CAPTOPRIL ON THE FRACTIONATED 
DOSE OF Ara-C
Procedure
Mice were given two doses of Ara-C 24 hours apart and 1 dose of captopril an 
hour after the first dose. Studies were done in two parts, the first part was to 
investigate the effect of 200mg/kg Ara-C low dose fractionation. The second part was 
a fractionation of a higher dose of Ara-C at 400mg/kg Ara-C dose. Four parameters 
were investigated after 3, 7 and 10 days following the first dose. These parameters 
were femur celluiarity, spleen weights, GM-CFC and HPP-CFC-1 numbers per femur, 
and finally the proportion of GM-CFC and HPP-CFC-1 in S-phase at these times. 
These parameters were also studied on normal mice. Parameters from mice that did 
not receive any cytotoxic drug are included with each investigation. Femur celluiarity, 
spleen weights, GM-CFC and HPP-CFC-1 measurements were carried out according 
to the already described methods.
Results
4, LI The effect of two doses 200mg/kg Ara-C fractionation by captopril 
at lOOmg/kg or saline
As shown in Fig 4.10, there was no spleen weight difference between mice 
that received saline and those that received captopril in between the two Ara-C doses 
at days 3 (p = 0.09), 7 (p = 0.46) and 10 (p = 0.4). However two doses of Ara-C 
markedly reduced the spleen weight at day 3 compared to control mice regardless of 
whether mice received saline or captopril in between the two doses of Ara-C. The
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spleen size had recovered to normal weight on day 7. No difference in femur 
celluiarity was observed between saline or captopril treatment in between the two 
Ara-C dose treatments at day 3 (p = 0.48), day 7 (p = 0.74) and at day 10 (p = 0.54). 
However at day 3 there was a marked reduction in femur celluiarity between mice that 
received two doses of Ara-C compared to normal untreated mice (see Fig. 4.11). At 
day 7, however the difference in femur cellularity had disappeared between all 
groups. On the other hand, at day 10, the femur celluiarity was higher in the Ara-C 
treated mice compared to normal control mice. GM-CFC numbers were also the same
FlG. 4.10 Mean spleen weights following 2 doses of Ara-C (200mg/kg)
l00mg/kg Captopril 
with 2 doses of Ara-C 
(200mg/kg)
Mean Spleen weights
(Control) Saline Captopril
N-spleen (144.5 ± 14)
Day 3 89.5 ± 8.2 99.0 ± 9.3 P = 0.09, n = 4
Day 7 111.9± 10.7 119.0 ±21.2 P = 0.46, n = 4
Day 10 132.6 ±7^.2 126.5 ± 14.3 P = 0.4, n = 4
N-spleen & Day 3 (S +C) P < 0.05
NB: N-spleen = average normal spleen weight of 3 mice, S = saline, C = captopril
□ Untreated mice 
■ Saline 
H Captopril
Day 3 Day 7 Day 10
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between Ara-C saline and Ara-C captopril treated mice at day 3 (p = 0.86) day 7 (p = 
0.56) and at day 10 (p = 0.81). The absolute numbers of GM-CFC were markedly 
reduced following Ara-C treatment when compared to normal bone marrow control
GM-CFC at day 3. GM-CFC numbers however returned to the levels found in normal 
mice at day 7 and remained at this level at day 10 (see Fig.4.12). There was a 
difference in the proportion of GM-CFC in S-phase in Ara-C treated mice between 
mice that were given saline and those that were given captopril in between the two 
Ara-C doses. At days 3 and 7 significantly less GM-CFC were in S-phase in the
FIG. 4.11 Femur celluiarity following 2 doses of Ara-C (200mg/kg)
lOOmg/kg Captopril 
with 2 doses of Ara-C 
(200mg/kg)
Mean Femur celluiarity (n ± SEM) x IO6
(Control) Saline Captopril
NFc (13.4 + 1.2)
Day 3 9.4 ±0.8 8.2 ±2.1 P = 0.48, n = 4
Day 7 18.5 + 2.0 17.5 + 3.7 P = 0.74, n = 4
Day 10 19.8 + 2.3 21.0+ 1.5 P = 0.58, n = 4
NFc& day 3 (S+C) P < 0.05
NFc & day 7 (S+C) P > 0.05
NFc & day 10 (S+C) P > 0.05
NB: NFc = Normal femur celluiarity.
Day 3 Day 7 Day 10
Chapter 4 - In vivo effect of ACE inhibitors 138
captopril group compared to the saline controls (Fig 4.13). At day 3, (29.6 ± 2.1)% of 
GM-CFC were in S-phase in mice given Ara-C and saline. This proportion was 
significantly reduced to (10.1 ± 1.7)% (p = 0.00008) in mice that were given 
captopril. At day 7, (32.3 ± 2.4)% of GM-CFC were in S-phase with saline. A 
significantly reduced proportion was observed with captopril and Ara-C at (5.8 ± 
2.1)% (p = 0.00003). However, this difference was lost after 10 days. While saline
FIG. 4.12 GM-CFC numbers following 2 doses Ara-C (200mg/kg)
lOOmg/kg Captopril Mean GM-CFC nos (per femur)(n ± SEM) x 104
with 2 doses of Ara-C 
(200mg/kg)
(Control) Saline Captopril
NGM (2.7 ± 1.2)
Day 3 1.7 ±0.2 1.7 ±0.4 P = 0.48, n = 4
Day 7 2.4 ±0.4 2.1 ±0.6 P = 0.74, n = 4
Day 10 2.2 ± 0.4 2.3 ±0.3 P = 0.58, n = 4
NGM & day 3 (S) (C) P = 0.03, 0.03
NGM & day 7 (S) (C) P = 0.62, 0.34
NGM & day 10 (S) (C) P = 0.38, 0.47
NB: NGM = Normal GM -CFC numbers per femur, S = Saline, C = Captopril.
Day 3 Day 7 Day 10
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treated mice had (29.7 ± 2.1)%, captopril treated mice had (28.7 ±1.4)% of GM-CFC
in S-phase (p = 0.68). There was no difference between the proportion of unstressed
bone marrow GM-CFC in S-phase and those treated with two doses of Ara-C (see Fig
4.13).
FIG. 4.13 The proportion of GM-CFC in S-phase following 2 doses of Ara-C
(200mg/kg)
lOOmg/kg Captopril % GM-CFC in S-phase
with 2 doses of Ara-C
(200mg/kg)
(Control) Saline Captopril
NGM (28.2 ±3.6)%
Day 3 (29.6 ± 2.1)% (10.1 ± 1.7)% P = 0.00008, n = 4
Day 7 (32.3 ± 2.4)% (5.8 ± 2.1)% P = 0.00003, n = 4
Day 10 (29.7 ±2.1)% (28.7 ± 1.4)% P = 0.68, n = 4
NGM & day 3 (S) P> 0.5
NGM & day 7 (S) P>0.5
NGM & day10 (S +C) P> 0.5
HPP-CFC-1 numbers were same between Ara-C treated mice regardless of 
whether they were given saline or captopril in between the two Ara-C doses at days 3, 
7, and 10 (p = 0.24, 0.71, 0.66 respectively). HPP-CFC-1 numbers were not
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influenced by the two Ara-C doses unlike GM-CFCs whose numbers were reduced at 
day 3. (see Fig. 4.14). However fractionating 2 doses of Ara-C with captopril 
markedly reduced the proportion of HPP-CFC-1 in S-phase at all times investigated. 
Indeed HPP-CFC-1 S-phase entry was blocked at day 7 with captopril given in
FIG. 4.14 HPP-CFC-1 numbers following 2 doses of Ara-C (200mg/kg)
lOOmg/kg Captopril 
with 2 doses of Ara-C 
(200mg/kg)
Mean HPP-CFC-lnos (per femur)(n ± SEM) x 103
(control) Saline Captopril
NHPP (15.7 ± 2.7)
Day 3 17.0 ± 2.5 13.6 ± 3.0 P = 0.24, n = 4
Day 7 23.4 + 3.0 23.4 ± 7.1 P = 0.71, n = 4
Day 10 22.5 ± 2.8 21.4 ± 2.3 P = 0.66, n = 4
NHPP & day 3 (S+C) P > 0.05
NHPP & day 7 (S+C) P > 0.05
NHPP & day 10 (S+C) P > 0.05
NB: NHPP = Normal HPP-CFC-1 numbers per femur.
day 3 day7 day 10
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between the two doses of Ara-C (see Fig 4.15). At day 3, (21.7 ± 2.7)% of HPP-CFC-
1 were in S-phase with two Ara-C doses given saline and captopril reduced this 
proportion to (8.3 ± 2.7)% (p = 0.0027). At day 7, (27.8 ± 2.6)% of HPP-CFC-1 were 
in S-phase in the presence of saline. This was reduced to (2.1 ± 1.6)% with captopril 
(p = 0.00003). And finally at day 10, while (26.9 ± 2.6)% of HPP-CFC-1 were in S- 
phase in the presence of saline, only (6.2 ± 2.1)% of them were in S-phase with the 
two Ara-C doses separated by captopril (p = 0.00023).
FIG. 4.15 The proportion of HPP-CFC-1 in S-phase following 2 doses of Ara-C 
(200mg/kg)
lOOmg/kg Captopril 
with 2 doses of Ara-C 
(200mg/kg)
% HPP-CFC-1 in S-phase
(Control) Saline Captopril
NHPP (8.3 ± 3.6)%
Day 3 (21.7 ± 2.7)% (8.3 ± 2.7)% P = 0.0027, n = 4
Day 7 (27.8 ± 2.6)% (2.1 ± 1.6)% P = 0.00003, n = 4
Day 10 (26.9 ± 2.6)% (6.2± 2.1)% P = 0.00023, n = 4
NHPP & day 3 (Cap.) P> 0.5
NHPP & day 7 (Cap.) P < 0.05
NHPP & day 10 (Cap.) P>0.5
Da/3 Day7 Day 10
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4.1.2 The effect of two doses of 400mg/kg Ara-C fractionation by 
captopril at lOOmg/kg or saline
There was also no difference in the spleen weight between Ara-C fractionated 
with saline mice and those fractionated with captopril at days 3 (p = 0.05), 7 (p = 
0.87) and 10 (p = 0.9) (see Fig 4.16). A marked reduction in spleen weight was
FIG. 4.16 Mean spleen weights following 2 doses of Ara-C (400mg/kg)
lOOmg/kg Captopril with
2 doses of Ara-C 
(400mg/kg)
Mean Spleen weights (gms)
(Control) Saline Captopril
N-spleen (144.6 + 14.0)
Day 3 83.5 + 9.00 90.8+ 15.8 P = 0.052, n = 4
Day 7 143.0 + 31.9 139.3 + 25.1 P = 0.87, n = 4
Day 10 151.5 + 27.1 149.1 + 13.3 P = 0.9, n = 4
N-spleen & day 3 (S+C) P < 0.05
N-spleen & day 7 (S+C) P> 0.5
N-spleen & day 10(S+C) P>0.5
observed between normal spleen control weights and mice treated with two dose of 
Ara-C regardless of whether they were given captopril or saline at day 3. Spleen
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weights returned to levels equivalent to the weights found in control untreated mice at
day 7.
The femur cellularities were the same at all times between Ara-C fractionated
with saline or captopril at days 3 (p = 0.4), 7 (p = 0.45) and 10 (p = 0.37) (see Fig 
4.17). However 2 high doses of Ara-C reduced the femur celluiarity to less than half 
of the values found in femurs from untreated mice. The reduction in femur cellularity
FIG. 4.17 Mean femur celluiarity following 2 doses of Ara-C (400mg/kg)
lOOmg/kg Captopril Mean Femur celluiarity (n ± SEM) x IO6
with 2 doses of Ara-C 
(400mg/kg)
(Control) Saline Captopril
NFc
Day 3
Day 7
Day 10
NFc & day 3 (S+C)
NFc & day 7 (S+C)
NFc & day 10 (S+C)
(134.0+ 12.9)
4.8 + 0.5
16.3 + 1.1
18.4 + 1.2
4.4 + 0.4
17.4+1.6
19.1 + 0.1
P = 0.4, n = 4
P = 0.45, n = 4
P = 0.37, n = 4
P< 0.001
P < 0.05
P < 0.05
Day 3 Day 7 Day 10
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was the same in Ara-C treated mice regardless of whether saline or captopril was used 
for fractionation. The femur celluiarity returned to higher levels than normal femur 
cellularities at day 7 and remained high for the duration of the investigation. When the 
mean femur cellularities of low and high dose Ara-C are compared, high doses show a 
greater decrease in the number of nucleated cells per femur (see Figs 4.11 & 4.17).
As with low doses Ara-C treatments, GM-CFC numbers were not affected by 
captopril fractionation after high dose Ara-C treatment at day 3 (p = 0.13) day 7 (p =
FIG. 4.18 GM-CFC numbers following 2 doses of Ara-C (400mg/kg)
lOOmg/kg Captopril 
with 2 doses of Ara-C 
(400mg/kg)
Mean GM-CFC nos (per femur)(n ± SEM) x 103
(Control) Saline Captopril
NGM-CFC
Day 3
2.7 ± 1.2
7.0 ±0.4 9.6± 2.1 P = 0.13, n = 4
Day 7 19.7 ±2.6 22.1 ± 5.0 P = 0.57, n = 4
Day 10 21.4 ± 2.8 20.8 ± 2.2 P = 0.82, n = 4
NGM & day 3 (S) (C) P = 0.00025, 0.0012
NGM & day 7 (S) (C) P = 0.097, 0.44
NGM & day 10 (S) (C) P = 0.22, 0.15
Day 3 Day 7 Day 10
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0.57) and at day 10 (p = 0.82) (see Fig. 4.18). However there was a far greater 
reduction in GM-CFC numbers following two Ara-C high dose treatments when 
compared GM-CFC numbers found in mice that did not receive any Ara-C at day 3. 
GM-CFC numbers returned to levels equivalent to those found in femurs of mice that 
were not subjected to any treatment at day 7 and remained so at day 10.
However, high doses of Ara-C had a marked effect on the proportion of GM- 
CFC in S-phase when fractionated with saline at day 3. (51.9 ± 2.1)% were in S-phase 
at this time. At day 7, (33.7 ± 3.4)% of GM-CFC were in S-phase with saline treated 
and at 10, (42.8 ± 3.9)% of GM-CFC were in S-phase in the same saline group.
FIG. 4.19 The proportion of GM-CFC in S-phase following 2 doses of Ara-C 
(400mg/kg)
100mg/kg Captopril % GM-CFC in S-phase
with 2 doses of Ara-C
(400mg/kg)
(Control) Saline Captopril
NGM (29.7 ± 2.8)%
Day 3 (51.9 ± 2.1)% (15.7 ± 0.6)% P = 0.0000026, n = 4
Day 7 (33.7 + 3.4)% (10.7 ± 4.8)% P = 0.0079, n = 4
Day 10 (42.8 ± 3.9)% (31.2 ± 4.0)% P = 0.084, n = 4
NGM & day 3 (S) P < 0.05
NGM & day 7 (S) P > 0.05
NGM & day 10 (S+C) P > 0.05
Day3 Day7 Day 10
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Captopril significantly reduced the proportion of GM-CFC in S-phase at day 3 to 
(15.4 ± 0.6)% (p = 0.0000026) and to (10.7 ± 4.8)% at day 7 (p = 0.0079). However, 
only a slight non-significant reduction in the proportion of GM-CFC in S-phase was 
observed in the presence of captopril at (31.2 ± 4.0)% (p = 0.084) after 10 days. 
Interestingly, the proportion of GM-CFC in S-phase after 10 days in captopril treated 
mice was similar to the proportion of GM-CFC in S-phase observed from mice that
did not receive any insult (see Fig 4.19).
FIG. 4.20 HPP-CFC-1 numbers following 2 doses of Ara-C (400mg/kg)
100mg/kg Captopril 
with 2 doses of Ara-C 
(200mg/kg)
Mean HPP-CFC-1 nos (per femur)(n ± SEM) x 103
control Saline Captopril
NHPP-CFC-1 
Day 3
15.7 ± 2.7
6.2 ± 0.4 72 + 2.5 P = 0.52, n = 4
Day 7 17.6+1.3 15.7 ± 5.2 P = 0.58, n = 4
Day 10 18.8 ± 2.9 17.8 ± 6.4 P = 0.84, n = 4
NHPP & day 3 (S+C) P < 0.05
NHPP & day 7 (S+C) P > 0.05
NHPP & day 10 (S +C) P > 0.05
Day 3 Day7 Day 10
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Interestingly, high doses of Ara-C reduced the numbers of HPP-CFC-1 at day 
3 while this was not the case with low doses of Ara-C (see fig.4.14). However high
Ara-C fractionation showed no difference in HPP-CFC-1 numbers between saline and
captopril at all times investigated. There was no difference in HPP-CFC-1 numbers at 
days 3, 7 and 10 (p = 0.52, 0.58, 0.84 respectively) between captopril and saline
fractionations (see Fig 4.20). The reduction in HPP-CFC-1 numbers was observed at
day 3 between control mice and mice that received Ara-C. This difference was 
resolved at day 7 and the numbers remained at the same levels as those found in
FIG 4.21 The proportion of HPP-CFC-1 in S-phase following 2 doses of Ara-C 
(400mg/kg)
100mg/kg Captopril 
with 2 doses of Ara-C
% HPP-CFC-1 in S-phase
(400mg/kg)
(Control) Saline Captopril
NHPP-CFC-1 (9.9± 3.9)%
Day 3 (50.6 ± 3.1)% (14.7 ± 4.0)% P = 0.00038, n = 4
Day 7 (29.8 ± 2.7)% (3.5± 1.1)% P = 0.000094, n = 4
Day 10 (33.9 ± 2.8)% (3.1± 1.3)% P = 0.000065, n = 4
NHPP & day 3 (Cap.) P > 0.05
NHPP & day 7 (Cap.) P < 0.05
NHPP & day 10 (Cap.) P < 0.05
Day 3 Day 7 Day 10
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untreated mice for the duration of the investigations. High doses of Ara-C had a 
marked effect on the proportion of HPP-CFC-1 in S-phase. The proportion of HPP- 
CFC-1 in S-phase markedly increased to (50.6 ± 3.1)% at day 3 (see Fig 4.21) in Ara- 
C treated mice that were fractionated with the saline. With low doses at day 3, the 
proportion of HPP-CFC-1 in S-phase with Ara-C saline fractionation was only (21.7 ± 
2.7)% (see Fig 4.15). After 7 days (29.8 ± 2.7)% of HPP-CFC-1 were in S-phase in 
saline fractionated mice and after 10 days these mice had (33.9 ± 2.8)% of HPP-CFC- 
1 in S-phase. However at all these times captopril fractionation reduced the proportion 
of HPP-CFC-1 in S-phase following high dose Ara-C dose treatment (see Fig 4.21). 
At day 3, (14.4 ± 4.0)% of HPP-CFC-1 were in S-phase in Ara-C fractionated with 
captopril group (p = 0.00038) and only (3.5 ± 1.1)% (p = 0.000094) of HPP-CFC-1 
were in S-phase at day 7 in the presence of captopril. After 10 days, captopril still 
inhibited HPP-CFC-1 S-phase transition. The proportion of HPP-CFC-1 in S-phase at 
this time was (3.1 ± 1.3)% (p = 0.000065). Therefore regardless of the doses of Ara-C 
used, captopril was able to inhibit HPP-CFC-1 S-phase entry at all times but was 
unable to influence GM-CFC proliferation after 7 days.
4.2 Discussion
The normal clinical therapeutic dose of lisinopril is lOmg/kg (Goa et al., 1996) 
and that of captopril is from 50mg/kg to 150mg/kg (Martin et al., 1984). Therefore an 
average dose of 1 OGmg/kg for captopril was chosen as a dose used to investigate the 
effect of captopril on HPP-CFC-1 proliferation in vivo. The chosen dose of captopril 
to be investigated was a single dose given to mice 1 hour after the various insults.
HPP-CFC-1 recruited in S-phase by 5 FU are assayed after 4 days. The effects 
of ACE inhibitors were investigated after 4 days following 5 FU treatment. Animals
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were given insuits and ACE inhibitors in the same way as with 2 Gy or Ara-C. Due to 
a long lag period before HPP-CFC-1 suicide assays are performed following 5 FU, it 
was difficult to investigate the correlation between AcSDKP and ACE inhibitors 
following 5 FU treatment. Low doses of lisinopril were not investigated because they 
showed a discrepancy for their inhibition of HPP-CFC-1 proliferation between 2 Gy 
and Ara-C regenerating bone marrow cells. Due to a short t>/2 of ACE inhibitors in 
general, it may be difficult to interpret the effect of low dose lisinopril on HPP-CFC-1 
proliferation after 4 days. Therefore, it was decided to investigate the effects of 
captopril on HPP-CFC-1 proliferation using only high doses of ACE inhibitors 
following 5 FU treatment.
Plasma from animals which received 2 Gy or Ara-C with lOOmg/kg captopril 
was assayed for AcSDKP in vivo levels at 2 hrs, 6 hrs and 24 hours following the 
insult. No AcSDKP plasma levels from mice receiving lisinopril after insult was 
assayed because AcSDKP levels following 2 Gy and lisinopril have been investigated 
before (Rousseau et al., 1998). AcSDKP levels in vivo were not assayed following 5 
FU treatment because 5 FU bone marrow cells were sampled after 4 days. In addition, 
both 2 Gy and Ara-C treated mice showed normal levels of AcSDKP following 
captopril after 24 hour.
4.2.1 In vivo ACE inhibitor effect on stem cell proliferation
ACE inhibitors were given to mice following /« vivo administration of 2 Gy y- 
irradiation, Ara-C and 5 FU. At therapeutic doses lisinopril slightly inhibited HPP- 
CFC-1 proliferation following Ara-C (see Fig. 3.12). Lisinopril had no effect on HPP- 
CFC-1 proliferation when it was administered at high doses. At therapeutic doses 
lisinopril had a boarder line inhibitory effect on HPP-CFC-1 proliferation following 2
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Gy and it was unable to influence HPP-CFC-1 proliferation following 5 FU in vivo 
treatment at high doses. Both captopril and lisinopril did not affect the proliferation of 
HPP-CFC-1 in mice that did not receive insults. On the other hand, captopril at 
therapeutic doses inhibited HPP-CFC-1 proliferation regardless of the insult used. 
This is in agreement with the findings of Boyd et al., (1982). Boyd et al., (1982) 
found that captopril failed to produce myelotoxicity in normal Swiss mice but the 
same dose of captopril given to mice with busulfan-induced stem cell damage 
produced myelosuppression. They suggested that the suppressive action of captopril 
on neutrophilic progenitor cell proliferation in vivo might be caused by the 
suppression of an earlier myeloid progenitor cell rather than the GM-CFC population 
(Boyd et al., 1984). The fact that captopril inhibited RPP-CFC-1 proliferation 
following 5 FU in vivo also suggests an indirect mechanism of captopril induced 
inhibition of cell proliferation. 5 FU bone marrow was sampled after 4 days and the 
short duration of captopril in vivo (Duchin et al., 1982), suggests involvement of 
accessory factors in captopril’s inhibitory mechanism. The fact that captopril inhibits 
HPP-CFC-1 proliferation following 5 FU treatment after 4 days, suggests the strength 
of captopril as an inhibitor of haematopoietic cell proliferation
The differential effects of captopril and lisinopril on cell proliferation in the 
present investigations are unknown. These drugs may have a direct effect on cell 
proliferation or they may act indirectly by regulating endogenous production of 
inhibitors of cell proliferation. Captopril and lisinopril both down-regulate 
angiotensin-II levels in vivo. The fact that captopril was not able to inhibit cell 
proliferation at low doses and lisinopril inhibited Ara-C regenerating bone marrow 
HPP-CFC-1 at its therapeutic dose might however suggest that the degree of ACE 
inhibition may be crucial to the cellular inhibitory effects imposed by these drugs.
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However, if this was the only mechanism, an increase in the inhibitory influence 
should have been observed by lisinopril at high doses. Captopril is a weaker inhibitor 
of ACE and is nonnally given at least twice a day (Martin et al., 1984). In vivo 
captopril inhibitory effect on cell proliferation may involve other mechanisms other 
than an increase in AcSDKP levels. While partial involvement of angiotensin-II is a 
possibility, the effects of captopril on haematopoietic cell proliferation both in vivo 
and in vitro may also involve the up-regulation of some other natural inhibitors of 
stem cell proliferation. Lisinopril may not be able to influence the endogenous 
production of these unknown inhibitors. The present results in vivo, just as with in 
vitro results cast doubts on a direct involvement of angiotensin-II on the captopril 
inhibitory effect on HPP-CFC-1 proliferation. Captopril has the ability to inhibit the 
proliferation of a number of cells both in vivo and in vitro as will be discussed in 
chapter 6.
The noticeable effect of high doses of captopril to influence the proliferation 
of regenerating HPP-CFC-1 from 2 Gy and Ara-C regenerating bone marrow cells in 
vivo was investigated further to show whether captopril’s inhibitory mechanism was 
indirectly influenced by the endogenous production of AcSDKP. The correlation 
between the cycling status of haematopoietic stem cells and AcSDKP levels following 
captopril administration was studied. This was carried out using plasma but not on 
serum since captopril was a shown to be a weak inhibitor of ACE activity in serum. 
The control group of animals that received saline followed by captopril was also 
included. In the present investigations, the correlation between captopril and AcSDKP 
levels showed that captopril increased levels of AcSDKP to a peak after 2 hours 
following 2 Gy and Ara-C in vivo treatments (see Fig. 4.8a,b.c).
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4.2,2 The effect of captopril on Ara-C fractionated doses
Having established that captopril has inhibitory properties on the proliferation 
of HPP-CFC-1, an investigation was carried out to evaluate whether this effect would 
be employed to protect haematopoietic cells from cytotoxic insults in vivo. Cytotoxic 
drugs are generally given in fractionated doses in the treatment of neoplastic disease. 
In addition, more than one cytotoxic drug is administered at any one time in some 
treatment regimes. An investigation was carried out to find out whether captopril 
given with cytotoxic drugs would reduce the proportion of HPP-CFC-1 in S-phase 
following fractionated doses of cytotoxic drugs. This would protect HPP-CFC-1 from 
the subsequent doses of cytotoxic drugs. The study was conducted to mimic the 
therapeutic regimes in the treatment of neoplastic diseases. Since Ara-C has a short 
duration of action and is cytotoxic to cells in S-phase, it was ideal for this 
investigation. The parameters studied were spleen weights, femur cellularity, GM-
CFC and HPP-CFC numbers with their kinetics.
Since spleens are active haematopoietic organs in mice, spleen weights are a 
good indication of haematopoietic cell recovery in mice. The spleen weights were 
reduced in size following two doses of Ara-C but returned to nomial levels within 1 
week regardless of the doses of Aia-C used both in captopril treated mice and saline 
control mice. The same trend was observed with femur cellularities and GM-CFC 
numbers. However only high doses of Ara-C were able to reduce HPP-CFC-1
numbers with no observable effect on HPP-CFC-1 numbers with low dose Ara-C
fractionation. This signifies that mild insults may not affect the haematopoietic system 
while larger insults may injure the haematopoietic system. Regardless of the insult to 
the haematopoietic system, the system has a remarkable ability to recover. The fact 
that Ara-C is an S-phase cytotoxic specific drug (Crisp et al., 1996), means that only a
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small pool of haematopoietic stem cells is killed with the first Ara-C dose while about 
30 % of GM-CFC are killed. Since captopril inhibits HPP-CFC-1 proliferation, the 
second dose of Ara-C should have no effect on the stem cell pool. However, the 
number of GM-CFC affected by the second Ara-C dose will be greater because GM- 
CFC are actively cycling and a high concentration of inhibitory factors is needed to 
inhibit GM-CFC proliferation (Wright et al., 1985; Tejero et al., 1984). The reduction 
in haematological parameters observed at day 3 can be explained by this mechanism.
In these investigations captopril was not able to protect the numbers of both 
GM-CFC and HPP-CFC-1 per femur following high dose Ara-C treatments as shown 
by their reduced numbers on day 3. However, it was able to significantly reduce the 
proportion of both HPP-CFC-1 and GM-CFC in S-phase. Despite the inhibitory effect 
it imposed on GM-CFC proliferation on days 3 to 7 and HPP-CFC-1 proliferation for 
the duration of the investigations, femur celluiarity and HPP-CFC-1 numbers 
completely recovered at day 7. Captopril did not stop the regeneration of GM-CFC 
per femur since both captopril and saline had the same GM-CFC numbers for the 
duration of the investigation. In addition, the femur celluiarity which was low at day 3 
had recovered by day 7 and an over-shoot from the control levels was observed at day 
10 in both captopril and saline treated animals following Ara-C. Thus the progenitor 
cell generation was not inhibited in the presence of captopril. The ability of a small 
percentage of HPP-CFC-1 to recover haematopoietic cell numbers can mostly be 
explained by the quality of these stem cells. Stem cells following Ara-C and captopril 
have undergone few cell divisions and therefore, have a greater capacity of self­
renewal and cell division before they can differentiate to committed progenitor cells 
(Schofield et al., 1983). The net result is that a few cells are undergoing a lot of cell 
divisions. Moreover, the length of the both HPP-CFC-1 and GM-CFC cell cycle will
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also determine the total femur celluiarity. It is possible the time it takes for these cells 
to complete the cell cycle is reduced following captopril. This might also explain the 
discrepancy between the femur celluiarity and the number of both HPP-CFC-1 and 
GM-CFC in S-phase. The fact that cell recovery is the same in the presence of 
captopril and saline can be attributed to the feed back loop. There is a minimum 
number of haematopoietic cells required for the system to function and a lot of HPP- 
CFC-1 are recruited in the presence of saline to achieve this number while only a few 
HPP-CFC-1 in captopril treated mice can achieve the same numbers. Therefore, in 
this model captopril not only protected HPP-CFC-1 from cytotoxic insults but it also 
assured a long term recovery of the haematopoietic system. However, it is still 
intriguing that HPP-CFC-1 that were not cycling were able to rescue the 
haematopoietic system regardless of the doses of Ara-C used. In theory, mice treated 
with saline can easily develop long term bone marrow failure should they receive 
another high cytotoxic insult to the system because a lot of their stem cells have 
already undergone cell division (Mauch et al., 1988).
It is very unlikely that captopril was directly inhibiting both GM-CFC and 
HPP-CFC-1 proliferation after 1 week since it is known that one dose of captopril has 
a very short t 1 in vivo (Duchin et al., 1982). Therefore, an indirect mechanism is 
likely to be responsible for this inhibitory effect of captopril on haematopoietic 
progenitor cells. In this investigation captopril inhibited the Gi/S transition as shown 
by the low levels of HPP-CFC-1 in S-phase at all times investigated and GM-CFC in 
S-phase at days 3 to 7. This inhibition is consistent with the one observed with 
AcSDKP both in vivo and in vitro (Wierenga et al., 1996; Monpezat & Frindel, 1989; 
Jackson et al., 1996). It also confirms the observation that the effects of inhibitors of 
stem cell proliferation are not lost, so that once they have become effective, stem cells
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remain in a quiescent state until such time as they are switched on again by an 
increase in proliferation stimulators (Lord et ah, 1979). It seems that the second dose 
of Ara-C was not able to produce enough stimulators of stem cell proliferation to 
oppose the effect of captopril induced inhibitory factors. Tliis can be explained by the 
lack of the autologous effects of the second dose of Ara-C in the presence of 
captopril. However, in the absence of captopril, the second dose of Ara-C produces a 
marked increase in stimulator production as shown by the high proportions of HPP- 
CFC-1 in S-phase. Moreover, a high dose of Aia-C induced about 50% of HPP-CFC- 
1 in S-phase on day 3 (see Fig. 4.21) while low doses induced only about 20-30% of 
the same cell population in S-phase (see Fig. 4.15). On the other hand, low doses of 
Ara-C had the same proportion of GM-CFC in S-phase as control mice at day 3 (see 
Fig. 4.13) and high doses induced an increase to 50% of GM-CFC in S-phase (see 
Fig. 4.19). These results indicate that the loss of a small numbers of stem cells has a 
mild effect on the production of stimulators of stem cell proliferation, the small 
concentration of stimulatory factors produced might not affect tlie proliferation of 
committed progenitor cells. However, a greater stem cell loss will induce a marked 
increase in stimulator production that might effect progenitor cell proliferation (Lord, 
1986). The intriguing thing about these findings is the ability of haematopoietic HPP- 
CFC-1 to achieve a quiescent state at Ara-C high doses from 7 days onwards in the 
presence of captopril, while GM-CFC are induced back into cell cycle at day 10. An 
increase in celluiarity to normal levels is achieved within 1 week despite a low level 
of proliferating HPP-CFC-1 and GM-CFC in captopril treated mice.
The low levels of HPP-CFC-1 in S-phase in mice that did not receive any 
insult could explain the reason for the rare observation of pancytopenia with ACE 
inhibitors following hypertensive treatment. However at times of proliferative stress
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the demand for GM-CFC is increased since most of GM-CFC differentiate into
effector cells to combat infection, moreover, there is a massive death of mature 
haematopoietic cells. This induces the production of stimulators of stem cell 
proliferation in order to induce stem cells into a proliferative state so that destroyed 
progenitor and precursor cells can be replaced. ACE inhibitors may prevent the feed 
back loop on stem cell proliferation by opposing the stimulator effect or by up- 
regulating inhibitors of stem cell proliferation. The net result is no haematopoietic 
progenitor and precursor cell production. Therefore, the observed result is 
granulocytopenia or pancytopenia. Indeed, most reported cases of pancytopenia 
presented with infection that might have been primary or secondary after captoprii 
treatment (Gravras et al., 1981; Israeli et al., 1985; Holland et al., 1996).
Captopril has been used in the treatment of myeloproliferative disorders 
(Nomura et ai., 1996). Thus a possibility exists that administration of captopril in vivo 
antagonises the stimulatory effects on cell proliferation. Moreover, the ability of 
captopril to reduce LTC4 and LTB4 concentrations which synergies with GM-CSF on 
GM-CFC proliferation may account for the antagonism of stimulator effect on 
haematopoietic cell proliferation by captopril (Shindo et al., 1994; Stenke et al., 
1994). The most important characteristic of captopril induced-pancytopenia is its 
reversibility. This not only rules out permanent haematopoietic damage by captopril 
but it also provides a tool that can be used to temporarily suppress haematopoietic cell 
proliferation during cytotoxic therapy for the treatment of neoplastic disease. This 
investigation has shown that indeed captopril can be used as an adjuvant in 
chemotherapy, mainly in the treatment of leukaemia in which Ara-C is the main drug 
of choice (Crisp et al., 1996).
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Whatever the underlying mechanism of captopril induced-pancytopenia is, this 
side effect can be turned into a beneficial effect in the treatment of neoplastic disease. 
These results show that the inhibitory effect of captopril is reversible on GM-CFC and 
permanent on HPP-CFC-1, thus rendering them resistant to at least S-phase specific 
cytotoxic drugs and possibly to non specific cycle phase cytotoxic drugs too. The fact 
that GM-CFC can return to their normal proliferative state in the presence of captopril 
within 10 days, suggests that granulocytopenia may be prevented following 
chemotherapy. Moreover, only a short stay in the hospital may be necessary. 
However, administration of growth factors may accelerate this recovery with stem cell 
integrity intact as observed by the ability of AcSDKP to synergise with G-CSF 
(Masse et al., 1998) and GM-CSF (Bogden et al., 1998) in recovering mice from 
leucopenia following chemotherapeutic agents. Therefore, the use of captopril may 
prove very beneficial in the treatment of neoplastic disease. All in all, captopril may 
reduce the need for blood transfusions and reduce the incidences of long term bone 
maiTow failure following fractionated doses chemotherapy. The use of captopril not 
only provides a cheap adjuvant to the treatment of neoplastic disease, but it is also 
safe as ACE inhibitors rarely cause side effects in individuals without any other 
underlying disease, apart from hypertension (Alderman, 1996). Patients in countries 
with poor health care facilities might also benefit from this therapy.
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CHAPTER 5
5.0 THE EFFECT OIF AcSDyJKP AcSDKP AIN) CAPTOPWL UN 
LONG-TERM BONE MARROW CULTURES
Long-term bone marrow cultures are similar to the in vivo haematopoiesis 
requirements in that haematopoiesis is only achieved in the presence of stromal cells. 
The long-term bone marrow culture assay allows haematopoiesis to be maintained for 
many weeks. Captopril’s effect on LTBMCs was investigated for three reasons. 
Firstly, to see if captopril has any effect on the proliferation of haematopoietic 
progenitor cells in LTBMCs. Secondly, to investigate whether captopril could be 
toxic to the LTBMCs. Lastly to investigate whether captopril’s action on the LTBMC 
was similar to AcSDKP action in the same assay. To this purpose LTBMCs were 
cultured for 6 weeks in the presence of saline, AcSD\|/KP, captopril, and captopril 
plus physiological AcSDKP. AcSD\|/KP has been rendered resistant to proteases in 
serum by replacing the DK bond with the aminomethylene bond (Gaudron et al., 
1997).
Procedure
Bone marrow cells (1.2 x 107 cells/ml) prepared from femurs of cross bred 
mice ((CBA/H x C57BL) FI ) were suspended in F20%HS PS/G Hydro and put in 24 
100-cm7 flasks. Six flasks were used per protocol and four protocols were established 
in all. In the first protocol that was used as a control, 1 ml of saline was added to 9 
mis of cell suspension in each of the six flasks. In the second protocol, 1 ml of 
captopril dissolved in F20%HS PS/G Hydro was added to 9 mis of cell suspension in
each of the six flasks making a final concentration of 1 pM captopril. In the third
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protocol resistant AcSD\|/KP was added to 10 mis of cell suspension in each of the six 
flasks making a final concentration of 10’9 M AcSDj/KP. In the last protocol captoprii 
at 1 pM and conventional AcSDKP at lO*9M were added to each of the six flasks. 
LTBMC cultures were maintained for 6 weeks according to the already described 
method. Non adherent layer cells were sampled at the ends of week 2, 3 and 5. 
Adherent layer cells were sampled at the end of week 6. Flasks were analysed for 
celluiarity, GM-CFC numbers with their kinetics and finally HPP-CFC numbers also 
with their kinetics in both layers.
Results
5.0.1 AcSDWKP and Captopril do not affect cellularity in the non­
adherent layer
The celluiarity of the LTBMCs was determined over 5 weeks of culture. On 
week 6 the celluiarity of the adherent layers was also determined. There was no 
statistical significant difference between the celluiarity of non-adherent layer cells per 
week in the flasks of each treatment group. As shown in Table 5.1, at week 2 the 
number of cells per ml in the flasks treated with saline was (5.8 ± 1.0) x 105. Flasks 
treated with captoprii, AcSDj/DK, and captoprii together with AcSDKP had (7.5 ± 
1.5) xlO5, (7.8 ± 2.1) xlO, and (6.5 ± 2.4) x 105 (p = 0.79) cells per ml respectively. 
At week 3, the celluiarity varied between (7.2 ± 0.6) x 105 ^ps per mi in the flasks 
where captoprii was combined with AcSDKP' to (9.9 ± 2.3) x 105 cells per ml in the 
saline flasks (p = 0.87). The greatest increase in celluiarity was noticed at week 5 of 
culture. At this time the celluiarity ranged from (10.0 ±1.6) x 105 cells per ml in flasks 
where captoprii and AcSDKP were combined to (13.9 ± 1.1) x 105 cells per ml in the
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control flasks (p = 0.053). In general there was an increase in cellularity in each set as 
the weeks progressed.
Table 5.1 Total flask cellularities (xlO5cells/mi) In the non-adherent layers 
following different treatments
Time of LTBC Saline (±SE) Captoprii IpM
(±SE)
AcSDyKP
lO’9M
AcSDKP
(10*9 M) plus 
Captoprii IpM
Week2 5.8 ± 1.0 7.5 ±1.5 7.9 ±2.1 6.5 ± 2.5
Week3 9.9 ±2.3 8.3 ±1.3 8.0 ±0.8 7.2 ± 0.6
Week5 13.9 ±1.1 12.0 ± 1.7 11.1 ±2.0 10.0 ± 1.6
There is no signi'leant difference between each treatment group (p>0.05*
5.0.2 AcSDy/KP and Captopril increase the number of cells in the
adherent layer (week 6)
After 6 weeks in culture the celluiarity of the adherent layer was analysed. 
There was a statistically significant difference between cultures (p = 0.042) (see Table 
5.2). This significant difference was observed between cultures established in the
presence of AcSDvpKP or captoprii separately when compared to control saline flasks.
Table 5.2 Total flask cellularities (xlO6 cell/flak) in the adherent layers (week 6) 
following different treatments
Saline (±SE) 23.8 ±2.7
Captoprii (IpM) (±SE) 33.0 ±2.1 (p<0.05)
AcSDij/KP (10*9 M) (±SE) 31.8±3.4(p<0.05)
Captoprii (IpM) plus AcSDKP (lO^M)
(±SE)
25.0 ± 1.5 (p>0.05)
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Flasks established in the presence of captoprii together with AcSDKP had cell 
numbers equivalent to control saline treated cultures showing fewer cells when 
compared to captoprii or AcSD{/KP treated cultures. As shown in table 5.2, the 
number of cells per ml in the saline control in the adherent layers was (23,8 ± 2.7) x 
107 CeHs per flask. This number was increased to (33.0 ± 2,1) x 10® cells per flask in 
flasks treated with captoprii (p<0.05). The flasks treated with AcSD\|/KP had (31.8 ± 
3.4) x 10® cells per flask. While there was no statistical difference in flask celluiarity 
between flasks treated with captoprii and those treated with AcSDvplKP (p>0.05), 
there was a difference between saline controls and AcSD\|/KP treated flasks (p<0.05). 
There was also no difference in celluiarity between saline control flasks and flasks 
treated with captoprii and AcSDKP together which had (25.0 ±1.5) x 10® cells per 
flask (p>0.05).
5,03 The effect of Captoprii, AcSDy/KP and captopril plus AcSDKP on
GM-CFC
The numbers of GM-CFC were also determined during the whole period of 
long term cultures. As shown in Fig.5.1, the numbers of GM-CFC were not 
statistically different in each group at the times sampled. At week 2, the numbers 
ranged from 1011.9 ± 528 GM-CFC per flask in the saline controls to 1296.9 ± 706 
GM-CFC per flask in flasks treated with captoprii (p = 0.98). The values at week 3 
ranged from 605.7 ± 197 in flasks treated by a combination of captoprii and AcSDKP 
to 809.8 ± 356 in the flasks treated with saline (p = 0.29). At week 5, the numbers of 
GM-CFC ranged from 1240.0 ± 119 in captoprii treated flasks to 1698.9 ± 943 in the
AcSDyKP treated group (p = 0.55). There was no difference in the numbers of
Chapter 5 - Effect of Captopril & AcSDKP on LTBMCs 162
FIG. 5.1 Absolute GM-CFC numbers of LTBMCs
LTBMCs Absolute nos of GM-CFC (per flask)
Week 2 Week 3 Week 5 Week 6
(Adherent layer)
Saline 1011.8 ± 258 809.8 ±356 1240.0 ± 119 2888.4 ±558
Captopril 1296.8 ±706 618.6 ±279 1146.9 ±373 4316.0± 1180
AcSDyKP 1192.9 ± 1027 730.7 ±348 1698.9 ±943 3238.9 ± 1087
AcSDKP+ 1136.3 ±767 605.7 ± 197 1148.9 ± 215 2404.0 ± 248
Captopril
P = 0.98, n = 4 P = 0.29, n = 4 P = 0.55, n = 4 P = 0.14
GM-CFC in the adherent layers of long-term bone culture established in the presence 
of any of the treatment groups. As shown in Fig 5.1, the values ranged from 2888.4 ±
558 in the saline controls to 2404.0 ± 248 in flasks treated with captopril and 
AcSDKP together for GM-CFC per flask (p = 0.14).
There was a statistically significant difference in the proportion of GM-CFC in 
S-phase within treatment groups at weeks 2 (p = 0.02) and 3 (p = 0.003). As shown in
Fig 5.2, less GM-CFC were in S-phase in the treatment groups compared to the saline 
controls at week 2. However no significant difference was observed between
individual treatment groups. (57.5 ± 9.0)% GM-CFC were in S-phase in the saline
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control flasks at week 2. The values in other flasks ranged from (24.1 ± 4.6)% in
flasks treated with captoprii to (30.1 ± 7.9)% in flasks treated with AcSDKP together
FIG. 5.2 The proportion of GM-CFC in S-phase in LTBMCS
LTBMCs % GM-CFC in S-phase
Week 2 Week 3 Week 5 Week 6
(Adherent layer)
Saline (57.5 ± 9.0)% (53.6 ± 4.6)% (47.6 ±5.8)% (36.4 ± 4.5)%
Captoprii (24.1 ±4.6)% (17.4 ± 11.0)% (28.1 ±7.8)% (22.1 ± 11.6)%
AcSDij/KP (26.0 ± 6.7)% (23.0 ±4.6)% (26.9 ± 4.6)% (10.2 ±5.2)%
AcSDKP + (30.1 ±7.9)% (9.3 ± 4.5)% (27.5 ± 2.3)% (14.6 ±5.6)%
Captoprii
P = 0.02, n = 4 P = 0.003, n = 4 P = 0.05, n = 4 P = 0.12
S with Cap P < 0.05 P < 0.05 P < 0.05
S with Res. P < 0.05 P < 0.05 P < 0.05
AcSDKP
S with P< 0.05 P <0.05 P < 0.05
AcSDKP+Cap
NB: S = saline Cap = Captoprii, Res. AcSDKP = AcSDyKP,
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with captoprii (p<0.05). At week 3, there were also differences in the proportions of 
GM-CFC in S-phase between saline controls relative to other treatments (p<0.05).
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The proportion of GM-CFC in S-phase in the saline control was (53.6 ± 4.6)%. This 
was reduced to only (17.4 ± 11.0)% in the presence of captopril. AcSDvpKP reduced 
tlie proportion of GM-CFC in S-phase to (23.0 ± 4.6)%. Captopril and AcSDipKP 
separately reduced the proportion of GM-CFC in S-phase by the same margin hence 
showed the same inhibitory effect on GM-CFC proliferation (p>0.05). However the 
proportion of GM-CFC in S-phase in cultures treated with AcSDKP and captopril 
together was reduced further to (9.3 ± 4.5)%. Therefore cultures treated with 
AcSDKP and captopril together showed the least proportion of GM-CFC in S-phase 
(p<0.05). At week 5, there was a significant difference between individual sets of 
investigations (p = 0.05). While (47.6 ± 5.8)% GM-CFC were in S-phase in saline 
control, the values between treatment flask groups were (26.9 ± 4.6)% with 
AcSDyKP treatment and (28.1 ± 7.8)% with captopril. AcSDKP in combination with 
captopril had (27.5 ± 2.3)% of GM-CFC in S-phase. As shown in Fig.5.2, there was 
no difference in the proportion of GM-CFC in S-phase between all the treatment 
groups (p = 0.12) in adherent layer. (36.4 ± 4.5)% of GM-CFC were in S-phase in 
saline control flasks. The proportion GM-CFC in S-phase in the presence of captopril 
were (22.1 ± 11.6)% (p>0.05), (10.2 ± 5.2)% were in S-phase in the presence of 
AcSDyj/KP (p > 0.05) and (14.6 ± 5.6)% were in S-phase in the presence captopril 
plus AcSDKP (p > 0.05).
5.0.4 The effect of Captopril, AcSDy/KP and AcSDKP plus Captopril on 
HPP-CFC
There was a lower number of HPP-CFC per treatment flask compared to GM- 
CFC. The highest and lowest numbers of HPP-CFC were both in week 2 (see Fig 5.3). 
These were 1051.0 ± 794 HPP-CFC in flasks treated with AcSDyKP and 637.5 ± 272
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HPP-CFC in the control flasks in the non-adherent layers (p>0.05). In the adherent 
layer, the values for HPP-CFC per flasks ranged from 2212.3 ± 467 in saline controls 
to 1534.5 ± 258 HPP-CFC (p = 0.86) in flasks that were treated with captoprii 
combined with AcSDKP (see Fig 5.3). In general there was an increase the numbers 
of both HPP-CFC and GM-CFC in the adherent layer compared to the non-adherent 
layer.
There was no difference between all four-treatment groups in the proportion of 
HPP-CFC in S-phase at week 2 (p = 0.06) (see Fig 5.4). There was however a 
statistical significant difference between treatment groups at weeks 3 (p = 0.01) and 5 
(p = 0.03). At week 3, (24.1 ± 3.4)% of HPP-CFC were in S-phase in saline control 
flasks. This proportion was reduced to only (6.6 ± 3.8)% of HPP-CFC in S-phase with 
captoprii and to (6.5 ± 2.1)% of HPP-CFC in S-phase with AcSDi)/KP. Captoprii or
AcSDyKP had the lowest proportion of HPP-CFC in S-phase relative to both saline 
controls and the combination of AcSDKP and captoprii together (p > 0.05). No 
statistical significant difference in the proportion of HPP-CFC in S-phase between 
captoprii and AcSDyKP (p > 0.05) was observed. On the other hand (15.6 ± 7.6)% 
of HPP-CFC were in S-phase in flasks treated with captoprii and AcSDKP together. 
Therefore, there was no significant difference between the proportion of HPP-CFC in 
S-phase in flasks treated with captoprii and AcSDKP together when they were 
compared to control saline treated flasks (p>0.05). At week 5, saline controls had 
(47.0 ± 9.8)% of HPP-CFC in S-phase. Captoprii slightly reduced this proportion to 
(25.2 ± 10.1)% (p<0.05). AcSD\|/KP had the same influence. It reduced the proportion 
of HPP-CFC in S-phase to (17.9 ± 7.3)% (p<0.05). While both captoprii and
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FIG. 5.3 Absolute HPP-CFC numbers in LTBMCs
LTBMCs Absolute nos of HPP-CFC (per flask)
Week 2 Week 3 Week 5 Adherent layer
Saline 637.5 ±272 694.7 ± 342 856.7 ± 129 2212.3 ±467
Captopril 907.0 ±388 512.5 ±330 887.1 ±264 2190.3 ±968
AcSDv|/KP 1051.3 ±794 553.6 ±296 905.0 ±341 2229.2 ±580
AcSDKP + 916.9 ±688 584.0 ±278 724.8 ± 160 1534.5 ±258
Captopril
P = 0.86, n = 4 P = 0.54, n = 4 P = 0.14, n = 4 P = 0.86, n = 4
AcSDvj/KP reduced the proportion of HPP-CFC in S-phase relative to saline controls,
there was no observed statistically significant difference between them (p > 0.05). In 
contrast AcSDKP combined with captopril reduced the proportion of HPP-CFC in S- 
phase to (9.8 ± 1.3)% (p<0.05). Therefore a statistically significant difference was 
observed by combining AcSDKP and captopril when it was compared to saline
controls and to both captopril and AcSD\|/KP (p < 0.05). There was also no significant
difference in the proportion of HPP-CFC in S-phase between all the treatment groups
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FIG. 5.4 The proportion of HPP-CFC in S-phase in LTBMCs
LTBMCs % HPP-CFC in S-phase
Week 2 Week 3 Week 5 Week 6
(Adherent layer)
Saline (40.8 ± 6.6)% (24.1 ±3.5)% (47.0 ± 9.8)% (31.5 ±2.6)%
Captoprii (24.1 ±6.8)% (6.6 ± 3.8)% (25.2 ± 10.1)% (23.3 ± 4.7)%
AcSD\|/KP (16.0 ±8.8)% (6.5 ±2.1)% (17.9 ±7.3)% (26.6 ± 4.6)%
AcSDKP + (10.7 ±6.9)% (15.6 ±7.6)% (9.8 ± 1.3)% (22.3 ± 3.5)%
Captoprii
P = 0.06, n = 4 P = 0.01, n = 4 P = 0.03, n = 4 P = 0.38
S with Cap P > 0.05 P < 0.05 P < 0.05
S with Res. P > 0.05 P < 0.05 P < 0.05
AcSDKP
S with P> 0.05 P > 0.05 P < 0.05
AcSDKP+Cap
in the adherent layer (p = 0.38). The proportion of HPP-CFC in S-phase in saline 
control flasks was (31.5 ± 2.6)%, in captoprii flasks was (23.3 ± 4.6)%, in AcSDi/KP
flasks was (26.6 ± 4.6)% and in captoprii with AcSDKP flasks was (22.3 ± 3.5)% 
showing no statistical significant difference between the treatment groups.
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5.1 Discussion
The requirement of accessory cells for haematopoiesis to be accomplished in 
LTBMCs, makes this model ideal for studying haematopoiesis in vitro. Inhibition of 
stem cells and committed progenitors growth in LTBMCs treated with AcSDKP is 
well documented (Hong et al., 1995; Bonnet et al., 1992; Jackson et al., 1996). The 
observation that AcSDKP catabolism is under the control of ACE (Rousseau et al., 
1995) means that LTBMC is an ideal model for studying the role of ACE on 
haematopoiesis. Moreover, one of the adverse effects of chronic treatment with ACE 
inhibitors is haematological toxicity (Gravras et al. 1981), this means that LTBMC 
can resolve some of the underlying mechanism of ACE inhibitor induced 
myelotoxicity. These hypotheses prompted the evaluation of the effects of captoprii 
on the growth of hematopoietic cells in LTBMCs. The similar tendency for AcSDKP 
accumulation in the supernatants of bone marrow cells treated with captoprii for 24 
hours has been shown in these investigations (see Fig. 3.7). This raises the possibility 
that the effect of captoprii on the proliferation of stem cells is mediated via inhibition 
of AcSDKP degradation. These investigations have shown that captoprii with 
AcSDKP can inhibit in vitro the proliferation of HPP-CFC-1 triggered into S-phase 
by irradiation. On the other hand captoprii on its own inhibits HPP-CFC-1 
proliferation in vivo following all insults tested and in vitro following cytotoxic drug 
treatment. This suggests that captoprii and AcSDKP separately or combined may 
affect the proliferation of stem cells.
In the LTBMCs shown by these investigations Captoprii or AcSDj/KP
had no effect on the celluiarity of the non-adherent layers in LTBMCs. However, 
captoprii combined with AcSDKP slightly reduced cell numbers in the non­
adherent layers after 5 weeks in culture (see Table 5.1). On the other hand,
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captopril or AcSDyKP significantly increased the cellularity of the adherent 
layers of LTBMCs after 6 weeks in culture. In contrast, Jackson et al., 1996 did 
not find an increase in the adherent layer cell numbers. Their method of 
establishing LTBMCs was different from the present experiments. They used a 
single cell suspension and they had to re-feed their cultures with new bone 
marrow cells before assaying for AcSDKP. This increase in celluiarity of adherent 
layers of LTBMCs may be attributable to the ability of captoprii to reduce 
intracellular Ca2+ levels thereby inhibiting cell proliferation (Tepei et al., 1997). 
This would stop cell differentiation and death. Moreover, AcSDyKP also inhibits 
GM-CFC cell proliferation (see Fig. 3.2). The increase in adherent layer 
celluiarity might also be explained by an imbalance between the production of 
stimulatory factors and inhibitoiy factors following captoprii or AcSDipKP 
treatment. For example, stromal cells may be resistant to the influence of these 
drugs. Stromal cells may keep on producing stimulatory factors in their presence.
Assuming tliat serum used for tissue culture has angiotension-1 as well as 
ACE, the presence of ACE inhibitors in culture will inhibit ACE activity. Tliis 
will result in reduced levels of angiotensin-II. Since angiotensin-II is known to
increase production of TGF-p (Sadoshima & Izumo, 1993; Brooks et al., 1997; 
Guh et al., 1996), the presence of captoprii in LTBMCs may lead to a reduction in 
TGF-p levels. TGF-p has been shown to be continuously produced in the adherent 
layers of LTBMCs and is responsible for the quiescent nature of HPP-CFC in 
LTBMCs (Eaves et al., 1991). Therefore, the presence of captoprii will enhance 
cell division by reducing the levels of TGF-p. The reduction in TGF-p may also
result in an enhanced endogenous production and activity of MIP la, since in the
presence of TGF-p, MIP-la is at best a weak contributor to the overall
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physiological inhibition of stem cell proliferation (Maltman et at, 1993). MIP 
la synergises with M-CSF or GM-CSF to stimulate development of colonies 
from enriched murine GM-CFC (Lord et al., 1993). Adherent layer cells produce 
GM-CSF, this means that progenitor cell production can be enhanced in the 
presence of MIP la and in the absence of TGF-p (Lord et al., 1993; Eaves et al., 
1991). The involvement of AcSDKP on increased cell production may be 
mediated by an increase in MIP la production as suggested by Cashman et al.,
(1994). Interestingly MIP la has been shown to increase intracellular cAMP 
levels (Mantel et al., 1995). Therefore, there is a strong possibility that AcSDKP 
may mediate the effects of captoprii on cell proliferation. The possible 
involvement of MIP la in the cellular response by both captoprii and AcSDj/KP 
strengthens this hypothesis.
AcSDKP is known to enhance the adherence of haematopoietic cells to 
stromal cells (Lenfant et al., 1989a; Aizawa et al., 1992; Suzuki et al., 1998), 
therefore, the observed increase in celluiarity can be due in part to redistribution of 
cells from the non-adherent layers to the adherent layers. However, this is unlikely 
because there is no difference in non-adherent layer celluiarity numbers between 
saline, AcSDj/KP and captoprii, In addition, the combination of AcSDKP with 
captoprii show reduced non-adherent layer cell numbers despite having the same 
celluiarity with saline treated cultures in the adherent layers. The increase in cell 
numbers of the adherent layers with captoprii or AcSD\|/KP may be exploited in the 
expansion of adherent layer cell numbers for establishment of LTBMCs. The 
increase in cell numbers includes stromal cells as well as haematopoietic cells. 
Therefore, the levels of ground substances like fibronectin may also be regulated 
resulting in enhanced haematopoiesis. It has to be underlined that both captoprii and
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AcSDj/KP are not toxic to haematopoietic cells as shown by the increase in 
celluiarity in the adherent layers of LTBMCs and similar numbers of GM-CFC and 
HPP-CFC in each set of investigations.
There was a marked inhibition of HPP-CFC proliferation in LTBMCs treated 
for 3 weeks with either AcSDyKP or captoprii. Captoprii and AcSDyKP had 
identical suppressive effects on the proliferation of GM-CFC. However, captoprii 
combined with AcSDKP showed a more pronounced inhibitory effect on GM-CFC 
proliferation measured at week 3 and on HPP-CFC proliferation measured at week 5. 
In addition, the effect of captoprii combined with AcSDKP compared to the inhibitory 
effect of each drug alone was shown to be different in respect to time and responding 
cell population. The explanation for these differences is imclear. However, it may be 
attributed to the varying concentrations of the active molecule employed by these 
drugs in their modulatory role in LTBMCs haematopoiesis. It is thus likely that 
captoprii protects AcSDKP from degradation. Since there is a steady state production 
of AcSDKP in vivo and in long-term bone marrow cultures (Wdzieczak-Bakala et al., 
1990), a possibility exists that captoprii may increase the levels of AcSDKP. This is 
plausible because AcSDKP is endogenously produced by macrophages in long-term 
bone marrow cultures (Li et ah, 1997). It may also arise from the degradation of 
thymosin p4 and other macromolecules in vivo under steady state conditions (Grillon 
et al., 1990). These results show that captoprii modulates haematopoiesis in LTBMCs 
with the same potency as AcSDKP, thus demonstrating a common pathway in their
action.
AcSDKP inhibits haematopoietic progenitor cells only at optimal 
concentrations, high or low concentrations of AcSDKP have no effect on the 
proliferation of haematopoietic stem or progenitor cells in long-term cultures (Jackson
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et ai., 1996; Bonnet et al., 1992). This may be the reason for the varying effects on 
HPP-CFC proliferation observed when the combination of captoprii and AcSDKP 
was used. It could also explain the observed difference of inhibitory effect imposed by 
the two substances together on HPP-CFC and GM-CFC proliferation. The increase in 
the number of macrophages as a result of the increase in adherent cell numbers may 
lead to higher production of both ACE and AcSDKP (Costerousse et al., 1993; Li et 
al., 1997). The net result is unstable levels of active AcSDKP causing variable effects 
on cell proliferation. This is a plausible explanation because AcSDKP is only active at 
the G|/S boimdary with no effect on cells beyond the S-phase of the cell cycle 
(Monpezat & Frindel, 1989). Therefore, sufficient peak levels of AcSDKP are 
required at this critical period of the cell cycle to allow an inhibitory effect of this 
peptide. There was no effect on the proliferation of both HPP-CFC and GM-CFC in 
the adherent layers. These findings are in agreement with the findings of other people 
who have shown no inhibitory effect of AcSDKP on the proliferation of HPP-CFC in 
the adherent layers of murine long term bone marrow cultures (Jackson et al., 1996).
The mechanism underlying captopril-induced inhibition of hematopoietic cell 
proliferation remains unknown. However, the general discussion chapter will point 
out a few possible mechanisms that may need further investigations to be confirmed. 
It is well documented that AcSDKP prevents primitive hematopoietic cell entry into 
S-phase. Taking into consideration a steady state production of AcSDKP in vivo and 
LTBMCs (Wdzieczak-Bakala et al., 1990; Li et al., 1997), a possibility exists that 
captoprii indirectly controls the proliferation of hematopoietic stem cells via the 
regulation of endogenous AcSDKP levels as already pointed out. The close 
correlation between the enhanced plasma AcSDKP levels and the inhibition of HPP- 
CFC proliferation reported for irradiated mice given one dose of lisinopril (Rousseau
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et al., 1998) stays in agreement with such hypothesis. Therefore captopril and 
AcSDKP can be exploited in the study of haematopoiesis both in vivo and in vitro. 
Moreover, their use in myeloprotection is strongly strengthened by their shown ability
on LTBMCs.
Chapter 6 - General Discussion 174
CHAPTER 6
General Discussion
6.1 Captopril and cell proliferation
Captoprii suppresses interstitial fibrin deposition in coxsackievirus B3 
myocarditis by inhibiting inflammatory fibrin deposition, postmyocarditic myocyte 
hypertrophy and ventricular remodelling during inflammatory phase but not during 
fibrotic phase (Takada et al., 1997). This drug also inhibits the proliferation of 
cardiomyocytes and inhibits c-myc, c-fos mRNA expression in these cells (Lei & 
Guo, 1998). Captoprii decreases granuloma size in the liver, colon, and ileum in mice 
infected with schistosoma mansoni eggs (Weinstock et al., 1981). It has shown 
beneficial effects in alleviating symptoms of rheumatoid arthritis (Martin et al., 1984). 
This ACE inhibitor inhibits proliferation of aortic smooth muscle cells caused by 
hyperlipidemie serum (Xiong & Zhao, 1996). This effect is mediated by an increase 
in 6-keto-PGFlea and cAMP with a decrease in malondialdehyde and plasminogen 
activator inhibitor. High concentrations of captoprii produce a dose dependent 
inhibition of platelet-derived growth factor (PDGF)-stimulated mitogenesis and can 
potentiate the inhibitory effects mediated by kinins (Dixon & Dennis, 1997). 
Captoprii inhibits mitosis in human lung fibroblasts, bovine aorta and pulmonary 
artery endothelial cells, and of hamster pancreatic duct carcinoma cells (Nguyen et al., 
1992). Fibroblasts stimulated to proliferate by basic fibroblast growth factor are more 
sensitive to the antimitotic effect of captoprii than unstimulated cells (Nguyen et al, 
1994). Moreover, the ability of captoprii to inhibit human lung fibroblast proliferation 
is neither affected by exogenous angiotensin-II nor mimicked by lisinopril (Nguyen et 
al, 1994). Captoprii and enalapril both reduce neuroblastoma cell growth rate but
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they have differential effects on the proliferation of these cells, Captopril at doses 
higher than 0.1 mg in vitro suppresses neuroblastoma cell proliferation while enalapril 
showing effect only at doses of 5.0 mg (Chen et al., 1991). Captoprii modulates 
hormone receptor concentrations and at high doses inhibits proliferation of human 
mammary ductal carcinoma cells in culture. Both lisinopril and penicillamine, a thiol 
compoimd, have no such effect on these carcinoma cells (Small Jr. et al., 1997). When 
captoprii is incubated with hamster pancreatic duct cancer cells, it inhibits cell 
proliferation by increasing K-ras expression and lowering proliferation associated cell 
nuclear antigen (Reddy et al., 1995). In addition, captoprii has been shown to inhibit 
Tenon's fibroblast proliferation (Singh et al., 1997), a property it shares with Ca2+ 
channel blockers and other substances known to inhibit protein synthesis.
In general the proliferation of tumour cells is not affected by captoprii at low 
doses (Chen et al., 1991; Hii et al., 1998; Volpert et al., 1996; Nakagawa et al., 1995). 
Most of the cell proliferation inhibitory effects of captoprii show that captoprii has an 
indirect mode of action. Moreover, as shown in this investigation and by others, 
captopril has a universal inhibitory effect on normal cell proliferation while it has a 
little or no effect on inhibiting neoplastic cell proliferation at doses that inhibit normal 
cell proliferation (see Fig. 3.8). The capacity of captoprii to inhibit normal cell 
proliferation is unique to this drug and is not mimicked by other ACE inhibitors. The 
effect of captoprii on neoplastic cell proliferation is complicated and it requires 
further investigations.
The possibility that captoprii may have a direct effect on cell proliferation can 
not be excluded. However, it is difficult to envisage how captoprii can bring about all 
its cellular actions directly unless cells take it up into the intracellular space. It is 
tempting to suggest that captoprii influences cell proliferation by increasing AcSDKP
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concentrations in vivo and in the incubation medium in vitro. This speculation is 
strengthened by the observation that high levels of AcSDKP are found in the cell 
cytoplasm (Volkov et al., 1995). Indeed it is suggested that a co-ordinated decrease of 
intracellular and extracellular concentrations of AcSDKP could be necessary to allow 
the Go-Gi to S transition of quiescent cells (Volkov et al., 1997). Since AcSDKP is a 
natural peptide, AcSDKP may have receptors on cell surfaces and cells may take it up 
by endocytosis or other mechanisms.
6.2 Captopril and matrix metalloproteinase
Tlie most intriguing finding of captoprii is its ability to reduce tumour size 
without affecting cell proliferation (Hii et al., 1998; Volpert et al., 1996). This effect 
of captoprii may be mediated by inhibiting the activity of enzymes that are involved 
in tumour cell invasion. One group of such enzymes is the matrix metalloproteinases 
(MMPs). MMPs expression plays a critical role in cell invasion, migration and the 
process of angiogenesis. Indeed captoprii has shown a beneficial effect by inhibiting 
angiogenesis in Kaposi’s sarcoma (Vogt & Frey, 1997). There is ample evidence that 
ACE inhibitors in general can inhibit the activity of MMPs. For example, both 
captoprii and fosinoprilat inhibit leukotriene (LT) A4 hydrolyse, a metalloproteinase, 
resulting in the inhibition of LTB4 synthesis with captoprii having a greater potency 
than fosinopril (Shindo et al., 1994) on enzyme inhibition. Moreover, captoprii at low 
doses increases the levels of a 72-KDa type IV gelatinase in a human melanoma cell 
line while it decreases it at high doses (Prontera et al., 1997). Captoprii also hihibits 
capillary endothelial cell migration by inhibiting a zinc-dependent endothelial cell- 
derived 72 and 92-KDa MMPs known to be essential for angiogenesis (Volpert et al., 
1996). In addition captoprii inhibits gelatinolytic activities in the culture media of
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T98G glioma cell line (Nakagawa et at, 1995). The inability of ACE inhibitors to 
inhibit neuroblastoma cell growth may also be attributed to inhibition of MPPs since 
both captoprii and enalapril are weak inhibitors of neuroblastoma cell proliferation 
(Chen et al., 1991). The differential effects of captoprii, fosinopril and enalapril on 
MPPs inhibition may be the reasons for the observed differences in their potency on 
inhibiting neoplastic cell proliferation.
The processing of TNF a precursor to the active TNF a is dependent on a 
matrix metalloproteinase-like enzyme (Gearing et al., 1994). Despite the ability of 
captoprii to inhibit the production of other cytokines such as IL-lp, IL-2, or IL-6, the 
production of these cytokines is not mediated by metalloproteinases (McGeehan et al., 
1994). However, captoprii inhibits IL-lex and TNF a synthesis at a post­
transcriptional level, a factor that may be mediated by the inhibition of a 
metalloproteinase (Schindler et al, 1995). Therefore captoprii is utilising another 
mechanism in the negative regulation of IL-lp production. While the ability of 
captoprii to inhibit tumour cell invasion and an increase in tumour size may depend 
on its ability to inhibit MMPs, its inhibition of normal cell proliferation may depend 
on its ability to reduce levels of stimulatory cytokines during culture. The capacity of 
captoprii to reduce the levels of inflammatory cytokines may have no effect on 
tumour cell proliferation since it is known that tumour cells may produce their own 
cytokines in an autocrine loop. Therefore in addition to inhibiting ACE, captoprii may 
interact with other pathways involved in cell activation and proliferation in vivo. This 
shows the complexity of captoprii in its possible role in the regulation of cell 
proliferation. As discussed already lack of inhibitory effect on neoplastic cell 
proliferation makes captoprii a suitable drug to be used as adjuvant for neoplastic 
treatment. This then means that the inhibition of stem cell proliferation augmented
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with MMPs inhibition may stop tumour cell invasion and protect stem cells during 
therapy.
6.3 Captopril and irradiation
Captoprii reduces the incidence, growth and mitotic activity of radiation- 
induced fibrosarcomas in rats (Ward et al., 1994). It also ameliorates radiation- 
induced pulmonary endothelial dysfunction in rats sacrificed 2 months post irradiation 
(Ward et al., 1988). In addition, this drug reduces the severity of moist desquamation 
reaction after 30 Gy irradiation in addition to reducing the malignant skin reactions in 
the radiation treatment field (Ward et al., 1990). Animals receiving total body 
irradiation before bone marrow transplants develop bone marrow transplant 
nephropathy after 3 to 6 months (Moulder et al., 1993). However, at 6 months after 
total body irradiation, captopril-treated animals have a lower systolic blood pressure 
and a well-preserved renal function (Moulder et al., 1993), while captoprii has no 
effect on bone marrow ablation. Captoprii therapy started 25 days post bone marrow 
transplant is as effective as therapy started prior to bone marrow transplant in 
preventing nephropathy. However, bone mainow transplant nephropathy progresses 
very quickly when captoprii treatment is stopped (Moulder et al., 1997). Moreover, 
radiation nephropathy can be significantly attenuated by the use of captoprii from 3.5 
to 9.5 weeks after irradiation in young animals following total body irradiation 
(Cohen et al., 1997). Captoprii therefore has a complex mode of action when
administered to irradiated animals.
While captoprii has no effect on 2 Gy HPP-CFC-1 proliferation in vitro in the 
present investigations, it reduces the proportion of HPP-C'FC-1 in S-phase when 
administered in vivo. In addition, from this literature review, captoprii has various
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properties on cell proliferation when administered in vivo following irradiation. It can 
be concluded that captoprii has an indirect effect on the modification of irradiation 
induced cytotoxic effects. Captoprii may impose its action through its effect on the 
renin-angiotensin system, AcSDKP enhancing property or on its ability to scavenge 
free radicals. The observed effects of captoprii on irradiation are consistent with the 
ability of captoprii to inhibit cell proliferation in vivo. It is difficult to understand how 
captoprii may affect radiation induced cell proliferation in general partly due to the 
complexity of irradiation induced cell damage.
6.4 Captoprilas a scavenger of free radicals
There is a possibility that the effect of captoprii on cell proliferation may be
mediated by the ion scavenging properties of this drug. Captoprii is an extremely 
potent free radical scavenger with equivalent potency when compared to superoxide 
dismutase, catalase and allopurinol against polymorphonuclear-derived free radicals 
(Bagchi et al., 1989). Enalapril induces a progressive decline of red blood cell reduced 
glutathione, an important substrate for the reductive detoxification of free radicals, 
while captoprii has no such effect (Golik et al., 1995). This suggests that captoprii is 
able to scavenge free radicals without involving glutathione. However, captoprii may 
also act as a pro-oxidant in the presence of ferritin in vivo as shown by the fact that 
captoprii induces both oxidative stress and releases iron from ferritin (Lapenna et al., 
1995). The sulfhydryl group has been implicated in the free radical scavenging ability 
of captoprii by many authors quoted in this work. It has also been implicated in the 
inhibition of dopamine p-hydroxylase by captoprii (Palatin et al., 1989) and
prostacylin synthesis by the same drug (Guivemau et al., 1991). This free radical 
scavenging property of captoprii has been implicated in some of the cellular
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proliferation inhibitory effects of captoprii (Hammond et al., 1988). Therefore, it is 
possible that some of the observed inhibitory effects of captoprii may be mediated by 
its free radical scavanging properties.
AcSDKP may also have free radical scavenging properties. Coutton & 
Chermann, 1997 speculate that the effect of AcSDKP on HIV conditioned medium 
may involve free radical scavenging mechanism. Even though there is no concrete 
evidence to back up this hypothesis, the ability of AcSDKP to inhibit haematopoietic 
cell proliferation in vivo following irradiation (Watanabe et al., 1996) and cytotoxic 
drugs (Bogden et al., 1991), may involve the ability of AcSDKP to scavenge free
radicals.
6.5 ACE inhililors andgranulocytopenia
Captoprii is the most studied ACE inhibitor with regards to ACE inhibitor 
induced granulocytopenia. While most cases of granulocytopenia do not affect 
erythropoiesis or megakaryocytosis (Amann et al., 1980; DeSilva et al., 1995), in 
some cases of agranulocytosis, a bone marrow aspirate revealed hypocellularity of the 
erythropoietic and granulopoietic cells with a nonnal population of megakaryocytes 
(Staessen et al., 1981). In such cases a granulopoietic cell that is regenerating and 
consisting of myeloblasts, myelocytes with few other myeloid cells was observed.
More often than not in captoprii induced granulocytopenia, no maturation of 
granulocytes is observed beyond the promyelocytic stage (DeSilva et al., 1995). In 
cases of captoprii induced pancytopenia bone marrow biopsy shows empty fatty 
spaces and stromal elements without haematopoietic tissue (Kim et al., 1989). In the 
dog captoprii induced severe hypoplasia of erythrocytic, granulocytic, and 
megakaryocytic cells with a relative increase in early granulocytic cells in the bone
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manow (Holland et al., 1996). In some cases of reversible captopril-associated bone 
marrow aplasia, bone marrow aspirate shows lymphoid cells, plasma cells and 
histiocytes without haematopoietic elements (Strair et al., 1985).
Almost all cases of captoprii induced pancytopenia are reversible after drug 
discontinuation. Moreover, administration of G-CSF after captoprii withdrawal 
accelerates the recovery of haematopoietic cell numbers (DeSilva et al., 1995; 
Holland et al., 1996). Other ACE inhibitors have been reported to cause 
pancytopenias. Lisinopril causes pancytopenia in elderly patients (Schiatzlseer et al., 
1994). A case of fatal aplastic anaemia associated with lisinopril treatment has also 
been reported (Harrison et al., 1995), however in this case the patient was first treated 
with captoprii before lisinopril was started. Enalapril too is associated with anaemia in 
renal transplant recipients treated for hypertension (Ylahakos et al., 1991). Patients 
treated with either captoprii or enalapril combined with interferon, develop severe 
granulocytopenia a few days after starting treatment (Casato et al., 1995). Therefore, 
haematological toxicity caused by ACE inhibitors is not only drugs related but might 
also involve ACE inhibition. Lack of literature on the haematological toxicity of other 
ACE inhibitors apart from captoprii, lisinopril and enalapril, makes it difficult to 
generalise this property of ACE inhibitors. An individual drug effect on 
haematological toxicity cannot be mled out because captoprii has been the only drug 
that has been extensively studied in relation to haematological toxicity. This is due to 
historical reasons as well as the molecular design of captoprii. However the ability of 
captoprii to suppress haematopoietic cell proliferation may be beneficial as shown by 
the fact that captoprii ameliorates haematological toxicities induced by adriamycim 
(Al-Shabanah et al., 1998).
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The observation of a pancytopenia suggests an inhibition of the proliferation 
of cells with stem cell potential. Moreover, the histology of bone marrow aspirations 
following ACE inhibitor induced pancytopenia is consistent with what is expected 
following the inhibition of haematopoietic stem cell proliferation. The observation of 
lymphoid cells without megakaryocytic, granulocytic cell lines (Strair et al., 1985) 
adds weight to this hypothesis. Lymphoid cells in the bone mairow have been shown 
to represent cells with stem cell properties (Jones et al., 1990). In addition, the 
absence of cell maturation to promyelocytic stages in the presence of captoprii 
(DeSilva et al., 1995), also demonstrates the multipotential nature of cells being
inhibited.
Stem cell inhibition can result from either an increase in the concentration of
inhibitors of stem cell proliferation or a decrease in stimulators of stem cell 
proliferation. G-CSF can act as both a maturation growth factor as well as a 
synergistic growth factor involved in the recruitment of primitive haematopoietic cells 
into cell cycle (Ogawa, 1993). The fact that G-CSF can rescue ACE inhibitor induced 
pancytopenia, suggests that stem cells may mediate this effect. Therefore, it is 
reasonable to speculate that G-CSF not only helps with maturation of granulocytes 
following captoprii treatment but it also helps in the induction of haematopoietic stem 
cells into cell cycle. If G-CSF was acting only on committed progenitor cells, the 
recovery in other cell lines would not be observed and anaemia resulting from lack of 
red blood cells as well as platelets would be observed. Thus, inhibitors of stem cell 
proliferation may be involved in ACE inhibitor induced pancytopenia. Moreover, the 
complete recovery of haematopoietic cells after discontinuation of captoprii suggests 
the non-toxic nature of captoprii on haematopoietic cells. It also shows the ability of 
captoprii to preserve the stem cell pool. This later effect might be achieved by the
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inhibition of stem ceil proliferation. Therefore, captoprii is either a stem cell inhibitor 
or it induces the production of inhibitors of stem cell proliferation in vivo. The later 
mechanism is likely to be the case as shown by cited literature in the earlier part of 
this discussion. Moreover, the rarity of captoprii induced pancytopenia agrees with 
the second assumption.
6.6 Haematopoietic stem cell inhibitors may mediate ACE inhibitor 
induced pancytopenia.
The observation that ACE inhibitors cause severe granulocytopenia in 
combination with interferon (Casato et al., 1995), suggests that inhibitors of stem cell 
proliferation may be involved in this mechanism. Interferon is an inhibitor of 
haematopoietic stem cell proliferation (Coutinho et al., 1986; Snoeck et al., 1994). 
ACE inhibitors have been shown to increase plasma levels of AcSDKP (Azizi et al., 
1996; Azizi et al., 1997; Comte et al., 1997a). In addition both human burst forming 
units-erythroid (BFU-E) and CFU-GM are significantly reduced in vivo in the 
presence of increased levels of AcSDKP (Comte et al., 1997a). Since AcSDKP is an 
inhibitor of stem cell proliferation with inhibitory effect on progenitor cells, both 
pancytopenia and anaemia observed after ACE inhibitors can be explained by this
mechanism.
However, the effect of AcSDKP on haematopoietic cell proliferation may be 
mediated by accessory cells (Lauret et al., 1989). In addition to increasing AcSDKP 
levels, captoprii may be increasing the levels of active substances produced by these 
accessory cells involved in the AcSDKP inhibitory mechanism. In theory, there is a 
differential effect by ACE inhibitors in the magnitude by which they can increase 
AcSDKP levels due to their differential effects on the two domains of ACE (Wei et 
al., 1992). However, since the mode of action of both ACE inhibitors and AcSDKP is
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largely unknown, some of the underlying mechanisms that may be involved in 
inhibitory effect of AcSDKP and ACE inhibitors in cell proliferation, will be
speculated.
6.7 AngrotennimlHs a growth factor
There are two types of angiotensin-H receptors designated ATi and AT2
(Crabos et al., 1994). The ATi receptor mediates most of the known functions of 
angiotensin-II. It shows characteristic features of a G-protein coupled, seven 
transmembrane receptors with three cytosolic loops (Ohyama et ai., 1992). 
Angiotensin-II induces c-fos gene expression (Lei & Guo, 1998) via activation of 
phospholipases A, C and D, and protein kinase C with Ca2+ playing a permissive role 
(Sadoshima & Izumo, 1993). Therefore, angiotensin-II receptor activation causes an 
increase in cAMP, inositol triphosphate, diacylglycerol, phosphatidic acid and 
arachidonic acids. Moreover, angiotensin-II causes an induction of many immediate- 
early genes such as c-jiin, jun B, Erg-1, c-myc in addition to c-fos (Sadoshima & 
Izumo, 1993). In addition, angiotensin-II ATi receptor activation induces a rapid 
phosphorylation of tyrosine in the intracellular kinases Jak2 and Tyk2 which 
phosphorylate STAT1 and STAT2 (Marrero et ai., 1995) and activates the STAT91- 
nuclear signaling pathway (Bhat et al., 1994). Angiotensin-II ATi receptor is tyrosine 
and serine phosphorylated and can serve as a substrate for the Src family of tyrosine 
kinases, a factor that may be mediated by the SH2 domain of PLC-y (Paxton et al., 
1994; Liao et al., 1993). Indeed, angiotensin-II activates pp60c'src in vascular smooth 
muscle cells (Ishida et al., 1995). However angiotensin-II is a weak mitogen and it 
induces the expression of endogenous growth factors including TGF-pi and PDGF 
and this effect can be inhibited by the growth factor inliibitor drug suramin (Weber et
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ai., 1994). Angiotensin-II increases synthesis of a 230-KDa tenascin and fibronectin 
without stimulating laminin production or general increase in the synthesis of secreted 
proteins (Sharifi et ai., 1992). In addition, angiotensin-II induces collagen type 1, al 
chain transcript expression in cardiac fibroblasts as well as the synthesis and secretion 
of collagen by these cells (Crabos et al., 1994). ACE inhibitors antagonise some of the 
effects of angiotensin-II. For example, in cultured monocytic and vascular smooth 
muscle cells, angiotensin-II elicits an increase in nuclear factor-xB activation and 
monocyte chemo-attractant protein-1 while quinapril inhibits these effects of 
angiotensin-II (Hemandez-Presa et al., 1997), In addition, captopril decreases TGF-p 
receptor types 1 and type II protein expression without affecting TGF-p production 
(Guh et al., 1996).
Interestingly, captopril inhibits c-fos expression induced by angiotensin-II 
in neurones (Pastuskovas & Vivas, 1997) and modifies gene expression in 
hypertrophied and failing hearts of aged spontaneously hypertensive rats without 
affecting plasma levels of angiotensin-II (Brooks et al., 1997). Surprisingly, 
bradykinin also stimulates c-fos expression, AP-l-DNA binding activity and 
proliferation of mesangial cells (El-Dahr et al., 1996), while bradykinin B2 receptor 
antagonist icatibant blocks the ability of captopril to reduce c-fos and c-myc 
expression of cultured neonatal rat cardiomyocytes (Lei & Guo, 1998). This makes it 
difficult to understand the role bradykinin might have on gene expression. In vivo 
inhibition of ACE results in an increase in bradykinin levels and a reduction in 
angiotensin-II. Therefore the inhibition of c-fos expression by ACE inhibitors is 
difficult to interpret. Assuming that bradykinin increases c-fos expression, ACE 
inhibitors should not be expected to reduce c-fos expression. Since ACE inhibitors 
inhibit c-fos expression, it can be assumed that this mechanism is partly regulated by
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brady^n^. Therefore, in addition to affecting the renin-angiotensin system, the effect 
of ACE inhibitors on cell proliferation may be mediated by other mechanisms that 
may involve ACE independent of the renin-angiotensin system. This is also confirmed 
by the fact that captopril inhibits pp60 c'src tyrosine phosphorylation in cultured human 
mesangial cells with a greater effect than lisinopril (Ruiz-Gines et al., 1997).
6.8 ACE inhibitor induced pancytopenia may be mediated by
angiotensin-II reduction
High plasma renin activity is associated with high erythropoietin (Epo) levels 
in chronic haemodialysis patients. However, in the presence of captopril high renin 
activity is not associated with high Epo levels (Vlahakos et al., 1995) in these 
patients. Moreover, captopril reduces erythrocytosis in post renal transplant patients 
with normal renal function allografts (Suh et al., 1996). It has been shown that this 
effect may be mediated by reduction in Epo levels following ACE inhibitor therapy. 
This results in a significant reduction in haematocrit, haemoglobin and red blood cell 
count (Torregrosa et al., 1994). Therefore, ACE inhibitor related anaemia in renal 
transplant recipients seems to be due to the erythropoietin-lowering effect of this 
group of drugs (Gossmann et al., 1996). Indeed, there is need for increased 
recombinant human Epo maintenance doses in haemodialysis patients who are 
receiving angiotensin-converting enzyme inhibitors (Matsumura et al., 1997). The 
inability of captopril to reduce Epo levels in the presence of angiotensin-II in 
subsuppressor amounts has also been observed (Gould et al., 1980). Thus a direct 
involvement of angiotensin-II in Epo production has been confirmed. From these 
observations it is clear that ACE inhibitors may decrease angiotensin-II, which 
stimulates erythropoietin production (Nomura et al., 1996). Surprisingly losartan,
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angiotensin-II ATi receptor antagonist does not alter Epo levels (Shand et al., 1995). 
Since there are two potential receptors for angiotensin-II, it is possible that AT2 
angiotensin-II receptors or other unknown mechanisms may mediate the Epo 
increasing effect of angiotensin-II. While the above observations explain the cause of 
anaemia by ACE inhibitors in the post renal transplant patients and haemodialysis 
patients, they do not explain the imderlying mechanism in aplastic anaemia caused by 
ACE inhibitors in other patients. Epo is a growth factor which is committed to the 
mature erythroid progenitors (Ogawa, 1993) therefore, its absence should not cause a 
dramatic effect on cells of the granulocytic series. This observation also suggests that 
ACE inhibitors induce anaemia in haemodialysis patients by both the Epo mechanism
and indirect of it. It also shows that the mechanism involved in anaemia in
haemodialysis patients may be different from the ACE inhibitor induced 
granulocytopenia in individuals without renal transplants. There are pathways shared 
by angiotensin-II and haematopoietic cell growth factors that can be utilised by ACE 
inhibitors in bringing about myelosuppression. It is possible that one of these 
pathways may be significant in ACE inhibitor induced pancytopenia both in normal 
individuals and in individuals with underlying disease. However, there may also be 
independent pathways that may affect cell proliferation by ACE inhibitors. One of 
these pathways may involve interleukm-10 (IL-10).
6.9 Interieukin-lOmay mediate ACE inhibitor inducedpancytopenia
Interleukin-10 (IL-10) has important regulatoiy effects on immunological and
inflammatory responses because of its capacity to dowmegulate class II MHC 
expression and to inhibit the production of proinflammatory cytokines by monocytes. 
As reviewed by Moore et al., 1993, IL-10 also known as cytokine synthesis inhibitory
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factor (CSIF), was discovered by searching for a product of T helper 2 (Th2) that 
inhibited proliferation, effector function and development of T helper 1 (Thl) cells. In 
the presence of monocyte/macrophage activated peripheral blood cells, IL-10 inhibits 
T-cell proliferation by reducing IL-2 production. IL-10 also inhibits 
monocyte/macrophage-dependent synthesis of IFN and TNF by human natural killer 
cells stimulated by IL-2. In addition IL-10 inhibits both proliferation and cytokine 
production in a primary mixed lymphocyte reaction (MLR) with allogenic human 
monocyte. This characteristic of IL-10 is shared by AcSDKP (Lavignac et al., 1992). 
IL-10 inhibits LPS-induced PG-E2 production in monocytes and PG-E2 augments the 
production of IL-10 by LPS (Niho et al., 1998). This mechanism may involve the 
ability of IL-10 to reduce the expression of COX-2 (Niiro et al., 1995). In addition IL- 
10 also suppresses the ability of mouse peritoneal macrophages to release TNF-a and 
reactive oxygen intennediates (Bogdan et al., 1991). Moreover, IL-10 inhibits the 
expression of I antigens (MHC class II) on lymphocytes without influencing the 
capacity of tumour cells to induce cytotoxic T lymphocyte (CTL)-mediated lysis by 
cold target inhibition (Matsuda et al., 1994; de Waal Malefyt et al., 1991). As 
observed by de Waal Malefyt et al., (1991), IL-10 is produced following LPS- 
stimulation of monocyte in vitro after 7 hours and maximum production is only 
observed after 24-48 hours. However, high levels of IL-la, IL-lp, IL-6, IL-8 GM- 
CSF and G-CSF are produced between 4-8 hours after activation, de Waal Malefyt et 
al., 1991 also demonstrated that addition of IL-10 to monocytes activated by IFN-y, 
LPS, or a combination of LPS and IFN at the on set of cultures strongly inhibited the
production of IL-la, IL-lp, IL-6, IL-8, TNF-a, GM-CSF, G-CSF and IL-10 mRNA 
synthesis. Indeed, IL-10 may bring about the reduction in cytokine production by its 
ability to inhibit NFkB activation in monocytes without affecting NF-IL-6, AP-1, AP-
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2, GR, CREB, Oct-1 and Sp-1 (Wang et al., 1995), NFkB is involved in the 
expression of inflammatory cytokine genes.
It is possible that the inhibitory effect of captopril on cell proliferation may be 
mediated by IL-10. Captopril may bring about IL-10 production by its ability to 
induce PG-E2 production (Swartz et al., 1980; Johnsen et al., 1997). The increased in 
IL-10 levels may contribute to the ability of captopril to inhibit MHC class-II 
expression on macrophages indirectly by inhibiting IFN-y production (Snyder et al., 
1982; Figueiredo et al., 1990). Captopril also delays hypersensitivity reactions in 
rodents (Wang et al., 1996). This effect may involve the loop cascade that involves a 
number of cytokines with an ultimate involvement of IL-10. Interestingly captopril 
induces pancytopenia in patients with systemic lupus erythematosis (SLE) (Amann et 
al., 1980). In • SLE patients, a positive correlation is observed between IL-6 and TNF- 
a levels (Mongan et al., 1997). While IL-10 causes a concentration-dependent 
suppression of IL-6 production in normal B cells and monocytes, this suppression is 
deficient in B cells and monocytes from lupus patients (Mongan et al., 1997). 
Captopril also reduces the granuloma size following Schistosoma mansoni infestation 
(Weinstock et al., 1981). The proliferative response of peripheral blood monocytes 
(PBMC) following stimulation with Schistosoma mansoni soluble eggs and adult 
waim antigens is increased by blockage of IL-10 production with specific IL-10 
monoclonal antibodies (Malaquias et ai., 1997). Moreover, immune complexes 
isolated from sera of Schistosoma infected individuals reduce the granulomatous 
hypersensitivity by decreasing production of TNF-<a and increasing production of IL- 
10 by PBMC treated with immune complexes (Rezende et al., 1997). From the 
present investigations it can be suggested that administration of captopril in mice 
following cytotoxic treatment produced high levels of IL-10 that caused the inhibition
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of cytokine production with a net result of inhibiting HPP-CFC-1 proliferation. Indeed 
the ability of captopril to alleviate symptoms of autoimmune diseases such as 
rheumatoid arthritis, may also be mediated by the ability of captopril to alter the 
pattern of cytokines produced in these diseases (Martin et al., 1984).
AcSDKP inhibitory effect on HPP-CFC-1 may involve IL-10 as well. 
Captopril increases both AcSDKP in vivo and in vitro levels (Grillon et al., 1993; 
Azizi et al., 1996; Azizi et al., 1997; Rousseau et al., 1995), and it increases PG-E2 
levels which may induce IL-10 production. It follows that AcSDKP and IL-10 may 
augment each other in bringing about the inhibitory effects of captopril. Moreover, the 
inhibitory effect of AcSDKP on cell proliferation will be enhanced in the presence of 
captopril due to IL-10 production.
The ability of AcSDKP to inhibit the inhibitory factors involved in the 
suppression of GM-CFC proliferation following HIV infection (Coutton & Chermann, 
1997), may involve the ability of AcSDKP to oppose the effect of PG-Ez on GM-CFC 
proliferation. Increased concentrations of PG-Ez are found in ultrafiltrates from HIV- 
infected monocyte (Foley et al., 1992). Since the mode of AcSDKP action is 
unknown, it is possible that AcSDKP may have an individual effect on IL-10 
production which in turn may lead to inhibition of PG-Ez production.
6.10 CapPopril andAcSDKPmay z’^^^z’^z’l1 phosphodiesterase
The observation that TNF-a production may be under the control of a 
metalloproteinase while production of IL-13 is not (McGeehan et al., 1994), suggests 
that another mechanism is involved in the observed inhibitory action of captopril on 
the production of both TNF-a and IL-13 (Schindler et al., 1995). This other 
mechanism may involve inhibition of phosphodiesterases. Phosphodiesterases
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degrade cyclic AMP and cyclic GMP. Phosphodiesterase inhibitors cause a 
concentration dependent inhibition of TNF-a production by lipopolysaccharide (LPS)
stimulated human and rat blood (Foster et al., 1993). TNF~a suppression is mediated 
by an increase in cyclic AMP while IL-1 suppression is mediated by an increase in 
cyclic GMP following LPS stimulation of mouse macrophages (Endres et al., 1991). 
However, the expression of both TNF and IL-1 following LPS activation of murine 
peritoneal macrophages may be selectively suppressed by agents that only elevate 
intracellular cAMP (Tannenbaum & Hamilton, 1989). The specific types HI and IV 
phosphodiesterase inhibitors suppress the formation of TNF by macrophages. This 
effect is synergised with adenylate cyclase activator PG-E2 (Schade & Schudt, 1993). 
Moreover, type TV phosphodiesterase inhibitors inhibit LPS-induced TNF-a with 
500-fold greater potency than non-specific phosphodiesterase inhibitors (Angel et al.,
1995). From these observations it is possible to see that immunological effects of 
captopril may be mediated by inhibiting phosphodiesterases. While captopril, 
enalapril, cilazapril and delapril all inhibit cytokine production following LPS human 
mononuclear cell activation, ramipril, lisinopril, peridopril and spirapril do not have 
this effect (Fukuzawa et al., 1997; Schindler et al., 1995). This mechanism may or 
may not be mediated by angiotensin-II inhibition. The effects of angiotensin-II on 
phosphodiesterase activity are not well known, therefore, it is difficult to rule out the 
effects of angiotensin-II on the phosphodiesterase activity. The ability of captopril to 
inhibit granuloma formation following injections of schistosoma mansoni eggs 
(Weinstock et al., 1981), may also be mediated by phosphodiesterase inhibition by 
this drug. Granuloma formation following injections of schistosoma mansoni eggs in 
mice is mediated by early recruitment of IL-1 with TNF taking part in the later stages 
of hypersensitivity (Chensue et al., 1989). Captopril has also been shown to inhibit
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neutrophil synthesis of Leukotriene B4 (LTB4) in vitro and in vivo (Shindo et aL, 
1994), Phosphodiesterase inhibitors block the formation of LTC4 (Schade & Schudt,
1993).
If the hypothesis that captopril inhibits phosphodiesterases is correct, an 
increase in AcSDKP might be one of mechanisms of this effect. This may be 
mediated by the ability of captopril to differentially inhibit the N-domain ACE active 
site thereby increasing the levels of AcSDKP. Since the mode of action of AcSDKP is 
still unknown, it is reasonable to speculate that the peptide may be responsible for the 
inhibition of phosphodiesterases. This is plausible because AcSDKP levels are 
markedly elevated in vivo and in vitro in the presence of captopril in mice that have 
not received cytotoxic insults (see Figs. 3.7 & 4.8). This is also confirmed by the fact 
that AcSDKP inhibits phosphodiesterase (Voelter et al., 1995) and the observation 
that AcSDKP prevents CFU-GM inhibition induced by HIV-infected cell-derived 
conditioned medium (Coutton & Cliermann, 1997). As discussed by Coutton & 
Cheunaun, 1997, HIV infected cells produce a number of cytokines that may be 
involved in the inhibition of CFU-GM proliferation. Moreover, the exclusive
potentiation by TNFa of the metabolic events triggered by an increase in intracellular 
Ca2+ in human granulocytes is inhibited by cAMP agonists (Yuo et al., 1989). There 
is enough evidence therefore, to suggest that the phosphodiesterase inhibitory effect 
of captopril is crucial in the cellular proliferation effects of this drag. Captopril does 
not seem to be a selective inhibitor of phosphodiesterase isoforms. This is confirmed 
by the fact that captopril is a potent inhibitor of LTB4 synthesis in intact neutrophils 
rather than in cytosol (Shindo et al., 1994). Therefore the captopril inhibitory effect on 
cell proliferation requires cytoplasmic molecules for the effect of captopril to be 
shown. In addition type IV phosphodiesterase inhibitors are weak inhibitors of LTC4
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and there is no additive effect between adenylate cyclase activators and type HI or 
type rV phosphodiesterase inhibitors on the inhibition of LTC4 synthesis (Schade & 
Schudt, 1993).
However, as stated already LTC4 inhibition is mainly mediated by the ability 
of captopril to inhibit a matrix metalloproteinase in addition to this observed 
phosphodiesterase mechanism. Moreover, both LTB4 and LTC4 induce a two to three 
fold increase in GM-CSF-stimulated myeloid progenitor cells (GM-CFC) 
proliferation and GM-CSF enhances in vitro synthesis of LTB4 and LTC4 by 
neutrophils and eosinophils (Stenke et al., 1994). Thus, the ability of captopril to 
inhibit the production of these leukotrienes may have a direct effect on cell 
proliferation by reducing the levels of stimulatory factors. This mechanism may 
require accessory cells to be accomplished. The involvement of phosphodiesterases in 
the ability of captopril to influence cell proliferation may be responsible for its 
immune regulation. Indeed this effect may link to IL-10 production. For example, PG- 
Ez any increase cAMP, which in turn may play a role on the production of IL-10,
TNFa, IL-1 and other cytokines, as already described. The involvement of 
phosphodiesterases, may also explain the differential effect of captopril on HPP-CFC- 
1 proliferation following 2 Gy irradiation and cytotoxic drugs. Captopril suppresses 
the primary antibody response of B-lymphocytes only in the presence of both 
adherent cells and radiosensitive Tg suppressor effector lymphocytes (Delfraissy et al., 
1984).
6.11 Captopril and intraenllclar ion concentrations
Signal transduction pathways can only be achieved in the presence of 
appropriate intracellular pH and ionic balance. ACE inhibiting drugs in general
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increase the Na+-K+ pump current of isolated cardiac myocytes when intracellular Na+ 
is at near-physiological levels, an effect that is opposed by angiotensin-II (Hool et al.,
1996) . The study of captopril on potassium influx in a kidney epithelial cell line 
showed that the frusemide sensitive Na+/K+/2Cf co-transport was significantly 
decreased and the Na+/K+-ATPase activity was only lowered when high amounts of 
captopril were used. Moreover, low doses of captopril strongly inhibited cell 
proliferation and higher amounts did not further suppress cell proliferation (Bauer et 
al., 1990). This suggests an indirect mechanism in the action of captopril. Captopril 
decreases the concentrations of zinc in blood, of copper and calcium in the epididymis 
and of magnesium in the testes (Kohler-Samouilidis et al., 1997). The decrease in 
blood zinc ion concentration affects the activity of both zinc dependent 
metalloproteinases and ACE. In addition captopril has been shown to reduce human 
sperm binding to the plasma membrane of zona-free hamster oocytes (Kohn et al.,
1997) . In contrast, AcSDKP has been shown to enhance binding of sperm to 
interstitial cells of the testes (Wdzieczak-Bakala personal communication). It can 
therefore be speculated that changes in ionic concentrations imposed by AcSDKP and 
captopril (dependent or independent of AcSDKP) may increase the affinity of sperm 
to testicular tissue while reducing its affinity to eggs. Captopril reduces the aiginine 
vasopressin and PDGF-induced increase of cytosolic free calcium concentration in 
vascular smooth muscle cells and cultured glomerular mesangial cells. In the presence 
but not absence of extracellular Ca/+, captopril reduces the angiotensin-II induced 
intracellular Ca/+ increase (Tepel et al., 1997). This mechanism may lead to an 
inhibition of the molecular mechanism involved in one or more key steps in signal 
transduction pathways. The involvement of extracellular Ca/+ ions in captopril’s 
effect on angiotensin-II ionic exchange may involve the integrity of gap junction or
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Ca2+ channels. The integrity of gap junctions is regulated by connexins. Couuexin 43 
is phosphorylated by phosphorylated C-src (Swenson et al., 1990; Crow et al., 1990). 
C-src is phosphorylated by angiotensin-II (Ishida et al., 1995). Therefore by this 
mechanism captopril may affect the integrity of gap junctions. The ability of captopril 
to affect Ca22 channels is suggested by the fact that an increase in intracellular 
calcium by angiotensin-II has been shown to be blocked or reversed by addition of 
verapamil, a Ca2+ channel blocker (Baker et al., 1989).
It is possible that the inhibition of Ca2+ intracellular influx may be responsible 
for captopril induced inhibition of cell proliferation. If this hypothesis is true then the 
intracellular Ca2+ concentration following both captopril and AcSDKP should be 
regulated by Ca2+ concentrations from the extracellular space as shown by the effect 
of captopril on angiotensin-II mediated intracellular Ca22 Crease. Captopril inhibits 
an increase of the intracellular free Ca in thymocytes in spontaneously hypertensive 
rats (Xie et al., 1996), In addition to being a co-factor to many enzymes involved in 
signal transduction, Ca22 is involved in cell cycle progression into S-phase. This is 
shown by the fact that elevation of calmodulin at the Gi-S is independent of the Gi, 
and the increase in calmodulin appears to be related to progression into S-phase 
(Chafouleas, et al., 1982). Therefore, the absence of Ca2+ at the Gi/S boundary may 
be responsible for AcSDKP Gj/S block during cell proliferation. This points strongly 
to the involvement of pp60 c'src and gap junctions. Certainly in the absence of 
calmodulin, AcSDKP reduces the basal activity of phosphodiesterase 2- to 3-fold. 
However, AcSDKP causes an incomplete competitive inhibition of hypothalamic 
calmodulin dependent phosphodiesterase in the presence of calmodulin (Voelter et al., 
1995). Therefore the absence of Ca2+ enhances the inhibitory activity of AcSDKP on 
cell proliferation. The ability of captopril to reduce intracellular free Ca2+ and to
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increase AcSDKP levels in vivo and in vitro may synergise to bring about the effects 
of AcSDKP on cell proliferation.
6.12 Rocs sarcoma virus proto-oneognnn (pp6f~src) as a mediator of 
AeSDKP and Captopril indcend enllclar proliferation inhibition
As reviewed by Bolen in 1993, the C-src kinase family belongs to a group of
the non-receptor tyrosine protein kinases. The function of C-src kinases appears to be
to phosphorylate members of the src family of tyrosine protein kinases at a common
tyrosine residue corresponding to the C-src tyrosine 527. There are nine members of
src gene family group. The src-family protein tyrosine kinases are widely expressed in
cells of haematopoietic origin (Liao et al., 1993). Other transmembrane proteins
including cytokine receptors, integrins, glycophosphatidylinositol-linked proteins, and
multichain lmmuno-recogmtior receptors have been found associated with one or
more C-src family kinases (Cooper & Howell, 1993). The viral oncogene of pp60src is
not an integral membrane protein, but rather associates peripherally with the
cytoplasmic face of several cytoplasmic membranes including plasma membrane and
perinuclear membranes (Hunter & Cooper, 1985). Phosphorylated C-src can activate
STAT3 in the Jak/STAT signaling pathways (Yu et al., 1995). Keeping src inactive
requires phosphorylation of tyrosine residue 527 and dephosphorylation of tyrosine
residue 416 (Cooper & Howell, 1993). Activation of C-src requires phosphorylation
of SHP-1 tyrosine phosphatase that dephosphorylates C-src by dephosphorylating the
COOH-tenninal regulatory tyrosine (Somani et al., 1997).
Captopril has been shown to inhibit pp60c'src tyrosine phosphorylation 
(Ruiz-Gines et al., 1997). The net result of this may be an indirect inhibition of PLC 
(Liao et al., 1993). Since activated pp60v'src phosphorylates connexin 43, a protein 
involved in the formation of gap junctions, with a net result of loss of gap junctional
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communication (Swenson et ai., 1990; Crow et al., 1990), inhibition of pp60c'src 
tyrosine phosphorylation will restore gap junction function with inhibition of cell 
proliferation. Moreover, inhibition of C-src tyrosine phosphorylation will reduce the 
levels of diacylgycerol through inhibition of PLC phosphorylation. Diacylgycerol 
inhibits gap junction communication in cultured epidermal cells (Gainer & Murry, 
1985). Therefore, inhibition of C-src by captopril may directly or indirectly influence 
cell proliferation. The fact that captopril is shown to inhibit haematopoietic cell 
proliferation in these investigations and tyrosine phosphorylated C-src is involved in 
the cytokine mediated signal transduction strongly supports the involvement of 
pp60c'sre in the inhibitory effect imposed by captopril in the inhibition of HPP-CFC-1 
proliferation. Moreover, a slight inhibition of pp60c'src tyrosine phosphorylation was 
also observed in the presence of lisinopril but not tocopheral, a pure antioxidant 
(Ruiz-Guines et al., 1997), suggesting that the inhibition of pp60c'src is slightly 
mediated by angiotensin-II with no involvement of antioxidant mechanism of 
captopril. Interferon-y and TNF-a enhance pp60c’src expression in human 
macrophages and myelomonocytic cell lines (Soiio et al., 1993). Therefore, in the 
presence of captopril which inhibits TNF-a production, pp60c'src expression will be 
inhibited with a loss of some signal transduction amplifications.
Captopril has been shown to alleviate the symptoms of polycythaemia rubra 
vera (PV) (Nomura et al., 1996). Polycythaemia rubra vera is a clonal 
myeloproliferative disorder that leads to trilineage (erythroid, myeloid, and 
megakaryocytic) hyperplasia in the bone marrow with a principal clinical 
manifestation of erythrocytosis and plethora. People with this condition have high 
levels of normal CD34+ cells in peripheral blood (Andreasson et al., 1997). The levels 
of AcSDKP in serum of people with PV are significantly increased (Liozon et al..
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1993), An increase in membrane or membrane associated protein tyrosine 
phosphatase activity is shown to be responsible for this disease (Sui et al., 1997). In 
addition, increased PKC activity is also thought to be responsible for the increased 
cell proliferation in PV patients (Kawada et al., 1995). The involvement of membrane 
associated protein tyrosine phosphatase activity may suggest the involvement of C-src 
in the pathogenesis of PV. Moreover, high levels of AcSDKP in serum of people with 
PV may suggest a feed loop mechanism that increases the levels of stem cell 
inhibitory factors. This disease may set the levels of AcSDKP at a higher threshold 
than normal. It can be speculated that addition of captopril inhibits C-src activity 
directly or indirectly to levels that will stop the transduction pathway involved in the 
proliferation of progenitors responsible for red blood cell production. The net effect is 
inhibiting CD34+ proliferation directly or by gap junctional mechanisms. Apart from a 
direct effect of captopril on cell proliferation and indirect effect mediated by 
angiotensin-II, the only other mechanism known by which captopril can influence cell 
proliferation is the AcSDKP inhibitory mechanism.
As already discussed, either inhibition of phosphodiesterases or an increase 
in cAMP activity may be a common pathway between captopril and AcSDKP 
proliferation inhibitory. mechanisms. Moreover, both lisinopril and captopril can 
increase levels of AcSDKP (Rousseau et al., 1995; Azizi et al., 1997). Therefore, 
captopril may be acting to increase AcSDKP levels that counteract the C-src 
dependent phosphatase activity or the PLC activity mediated by C-src which in turn 
affects the PKC activity. This is confirmed by the fact that in normal cells the 
retinoblastoma gene protein and C-src gene proteins are both associated with 
phosphatases (Coats & Roberts, 1996; Somani et al., 1997). Moreover, a 60 KDa 
fragment of hypophosphorylated retinoblastoma gene has been found in the nucleolus
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(Rogalsky et al., 1993). It is speculated by Rogalsky et al, (1993) that this fragment 
of the retinoblastoma gene protein may have some effect on the ribosomal RNA 
production in the nucleolus. While low levels of AcSDKP have no effect on tumour 
cell cycling, high levels inhibit the proliferation of human leukaemic cells (Defard et 
al., 1997). This characteristic is also shown by capt<^jpri. Therefore, derangement of 
cell proliferation in PV patients can be explained simply by an increase in C-src 
activity and by up regulating levels of AcSDKP. However, it is difficult to mle out a 
direct involvement of captopril on this effect since a direct correlation between 
captopril and AcSDKP levels has not been shown in vivo in PV patients.
The wide distribution of C-src on cells of the haematopoietic system suggests 
that the observed inhibition of HPP-CFC-1 proliferation in vivo and in vitro in this 
investigation by captopril may be mediated by the phosphorylation status of C-src. 
The involvement of angiotensin-II on C-src phosphorylation (Ishida et al., 1995) as 
already stated suggests that angiotensin-II inhibition, while not the main mode of 
action of ACE inhibitors on cell proliferation, may play a small part in the ACE 
inhibitor inhibitory effect on cell proliferation. Since AcSDKP is haematopoietic stem 
cell specific inhibitor, C-src phosphorylation may also play a major part.
6.13 CONCLUSION.
These investigations have demonstrated unique properties of ACE inhibitors 
on haematopoiesis. Not only have they shown the differential effects of captopril and 
lisinopril on reducing the proportion of HPP-CFC-1 in S-phase both in vitro and in 
vivo, they have also shown that captopril has a unique property as an inhibitor of 
haematopoietic cell proliferation. Captopril has been shown to inhibit haematopoietic 
cell proliferation by mechanisms specific to captopril and ones common to all ACE
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inhibitors. In addition, the signal transduction pathways employed by captopril and its 
cellular inhibitory effects have also been discussed even though mostly by 
speculation. The ability of captopril to inhibit cell proliferation may depend on the 
endogenous production of cytokines. The involvement of PG-Ez and IL-10 has been 
discussed in relation to the ability of captopril to induce an inhibition of cell 
proliferation. The ability of captopril to inhibit cell proliferation strongly points to the 
involvement of C-src pp 60. It seems that cells expressing this gene are likely to be 
inhibited by captopril. Moreover, the effect of captopril on cell proliferation may also 
involve phosphodiesterases. The uniqueness of captopril to increase endogenous 
levels of AcSDKP seems to be a strong mechanism in captopril’s ability to inhibit cell 
proliferation. Apart from hepatocyte proliferation in vivo (Lombard et al., 1990), the 
effect of AcSDKP on non-haematopoietic cell proliferation has not been extensively 
studied. It is possible that AcSDKP may also inhibit cells that are inhibited by 
captopril. The similarities between the captopril and the AcSDKP effect on neoplastic 
cell proliferation strongly suggests a common mode of action between AcSDKP and 
captopril in their proliferation inhibitory effects. Moreover, both substances inhibit 
cell proliferation better in the presence of accessory cells. In addition, involvement of 
cytokines in the cellular inhibitory effects of both substances has been shown. Both 
captopril and AcSDKP seem to inhibit Gi/S transition in the proliferating cells and 
have no effect on quiescent cells. In the long-teim bone marrow presented in this 
investigation, captopril and AcSDKP had the same effect on the integrity of 
LTBMCs. While it is not possible to rule out the inherent effect of captopril on cell 
proliferation, these results and the literature reviewed strongly suggest that AcSDKP 
mediate the effects of captopril.
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The use of AcSDKP instead of captopril may prove beneficial in the immune 
regulatory mechanisms due to the blood lowering effects of captopril. The treatment 
of shock, Asthma, HIV and other hypersensitivity reactions may be envisaged with 
AcSDKP. Moreover, captopril may be employed for the treatment of neoplastic 
diseases as an adjuvant to chemotherapy. Not only will captopril presort 
haematopoietic stem cell damage, but it will also stop tumour ceU invasaonby 
inhibiting matrix metalloproteinases. Therefore, the net result may bee reductionin 
the severity of pancytopenia following chemotherapy and cure of the disease. 
Captopril may also be employed in the purging of neoplastic cells from bone maiTow 
transplants. All in all, this thesis has analysed the underlying mechanism of ACE 
inhibitor induced pancytopenia. It has also suggested the possible use of this 
mechanism in the protection of haematopoietic cells during therapy. The use of ACE 
inhibitors in haematoprotection would help to enhance the therapy of neoplastic 
disease by reducing the severity of bone marrow suppression.
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APPENDIX
ACE activity means used to calculate the final means presented in the text (U/L)
Experiment Plasma
Control
Serum
Control
Plasma with 
Lisinopril
Plasma
with
Captopril
Serum
with
Lisinopril
Serum with 
Captopril
1 520 420 52 62 30 169
2 353.3 355 34.25 202 35.7 229
3 483.8 417 102.6 51 29 185
4 214.3 621.2 64 28.8 20.4 211.9
The Proportion (%) of Normal Bone Marrow GM-CFC in S-phase after incubation 
with AcSDKP + Captopril
Experiment % S-phase
Control
% S-phase AcSDKP + 
Captopril
1 33.0 ± 3.4 17.9 ±2.1
2 26.3 ± 2.2 14.3 ±2.8
3 29.5 ± 2.4 13.7 ±3.2
4 27.0 ± 2.3 20.1 ± 4.3
The proportion (%) of Normal Bone Marrow GM-CFC in S-phase after incubation 
with AcSDj/KP
Experiment % S-phase
Control
% S-phase AcSDKP + 
Captopril
1 26.6 ± 2.4 9.3 ± 2.7
2 34.9 ± 2.2 13.3 ±31
3 26.2 ±3.7 16.8 ± 1.8
4 30.6 ±2.1 20.9 ± 1.7
Proportion (%) of Normal Bone Marrow HPP-CFC-1 in S-phase Following in vitro 
incubation
Experiment % S-phase (T = 0) % S-phase ( T = 24)
1 12.2 ± 2.1 16.8 ± 2.5
2 4.2 ± 2.3 15.6 ±2.8
3 7.1 ±32 2.7 ±3.8
4 9.0 ±3.7 13.7 ±4.3
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The proportion (%) of Normal Bone Marrow HPP-CFC-l in S-phase following in 
vitro incubation with Lisinopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 16.9 ±2.1 17.9 ±5.2
2 19.4 ±10.2 16.3 ±3.8
3 13.5 ±4.4 2.7 ± 3.2
4 5.8 ±3.6 3.5 ±4.3
The proportion (%) of Normal Bone Marrow HPP-CFC-1 in S-phase following in 
vitro incubation with Captopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 17.0 ±7.9 18.5 ± 10.2
2 10.6 ±3.6 17.9 ±3.8
3 11.2±5.5 13.3 ±3.2
4 14.8 ±21.3 9.1 ±6.3
The proportion (%) of HPP-CFC-1 in S-phase from 2 Gy inadiated mice following in 
vitro incubation with Medium
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 37.4 ±2.2 29.2 ±3.1
2 34.6 ± 3.2 43.1 ±3.9
3 29.0 ± 2.7 29.0 ± 3.0
4 35.4 ± 1.2 24.7 ±2.2
The proportion (%) of HPP-CFC-1 in S-phase from 2 Gy in*adiated mice following in 
vitro incubation with Captopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 40.2 ±5.8 35.2 ± 14.7
2 62.3 ± 5.4 42.6 ± 5.7
3 43.8 ±4.0 59.0 ±6.7
4 32.9 ±4.0 54.2 ± 10.6
The proportion (%)of HPP-CFC-1 in S-phase from 2 Gy irradiated mice following in 
vitro incubation with Lisinopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 41.9 ±2.9 41.5 ±3.2
2 38.9 ±2.4 51.8±2.3
3 34.0 ±21.8 43.6 ±3.5
4 39.7 ± 1.3 35.4 ±5.9
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The proportion (%) of HPP-CFC-1 in S-phase from 2 Gy irradiated mice following in 
vitro incubation with AcSDKP
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 46.6 ± 5.6 35.9 ±8.7
2 34.6 ± 3.3 24.5 ± 6.4
3 41.6 ±4.5 37.2 ± 5.4
4 38.0 ± 6.8 29.7 ± 8.0
The proportion (%) of EPP-CFC-1 in S-phase from 2 Gy inadiated mice following in
vitro incubation with AcSDKP & Lisinopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 33.5 ±2.8 34.6 ± 3.2
2 35.3 ±2.2 21.0 ±5.9
3 34.0 ±2.5 21.5 ±3.6
4 30.8 ±0.8 25.7 ±3.1
The proportion (%) of HPP-CFC-1 in S-phase from 2 Gy irradiated mice following in
vitro incubation with AcSDKP & Captopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 33.2 ± 5.0 9.7 ±3.7
2 42.6 ±3.4 8.1 ± 5.6
3 32.8 ±3.0 11.9 ±5.7
4 59.8 ±2.6 11.5 ±30
The proportion (%) of HPP-CFC-1 in S-phase from Ara-C mice following in vitro 
incubation with Medium
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 51.4± 1.8 29.0 ± 2.7
2 43.2 ±2.1 25.8 ± 5.6
3 35.7 ±2.3 19.9 ±3.1
4 45.7 ±3.4 31.3 ±1.5
The proportion (%) of HPP-CFC-1 in S-phase from Ara-C treated mice following in 
vitro incubation with Lisinopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 53.7 ±5.4 24.5 ± 2.8
2 48.7 ±3.9 33.7 ±2.2
3 56.6 ± 2.5 29.5 ± 2.8
4 50.2 ±2.5 26.3 ± 2.6
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The proportion (%) of HPP-CFC-1 in S-phase from Ara-C treated mice following in 
vitro incubation with Captopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 52.6 ±3.2 6.7 ± 2.2
2 40.6 ±5.2 3.0 ±21.8
3 37.8 ±33 4.6 ± 4.2
4 41.9±3.2 5.3 ±2.9
The proportion (%) of HPP-CFC-1 in S-phase from 5 FU treated mice following in 
vitro incubation with Medium
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 40.0 ± 1.7 26.1 ±33
2 46.5 ± 2.0 20.8 ±4.1
3 40.7 ± 1.9 25.5 ±4.8
4 57.4 ±2.5 29.8 ± 7.2
The proportion (%) of HPP-CFC-1 in S-phase from 5 FU treated mice following in 
vitro incubation with Lisinopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 44.3 ± 3.2 43.7 ±7.0
2 45.4 ± 1.9 24.0 ± 2.9
3 44.5 ± 3.3 31.1 ±2.4
4 29.6 ± 1.8 33.8 ± 4.6
The proportion (%) of HPP-CFC-1 in S-phase from 5 FU treated mice following in 
vitro incubation with Captopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 34.9 ± 2.3 7.5 ± 3.2
2 47.8 ± 2.9 5.6 ± 3.3
3 49.8 ± 2.5 9.4 ± 4.4
4 49.2 ± 6.7 13.0 ± 12.0
The proportion (%) of SA2 cells in S-phase following in vitro incubation with Saline
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 44.7 ±23 67.9 ± 4.7
2 51.3 ±5.0 55.7 ±4.8
3 60.9 ± 2.0 46.3 ± 4.0
4 81.0± 1.2 66.5 ± 2.6
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In Vitro AcSDKP concentration following incubation
AcSDKP (nM)
Supernatant Captopril Medium (Placebo)
Normal Bone 
Marrow T = 0 T = 24 T = 0 T = 24
Experiment 1 0.5 1.14 0.65 0.71
Experiment 1 0.62 1.19 0.71 1.41
Experiment 2 0.52 1.01 0.75 0.66
Experiment 2 0.58 1.33 0.75 0.75
Experiment 3 0.68 1.12 0.66 0.68
Experiment 3 0.75 0.92 0.88 0.68
Ara-C Bone 
Marrow
Experiment 1 0.55 0.93 0.46 0.44
Experiment 1 0.55 0.94 0.57 0.41
Experiment 2 0.59 0.79 0.52 0.45
Experiment 2 0.52 0.66 0.48 0.44
Experiment 3 0.54 0.9 0.72 0.39
Experiment 3 0.6 0.62 0.67 0.4
5 FU Bone 
Marrow
Experiment 1 0.68 0.79 0.49 0.51
Experiment 1 0.5 0.77 0.45 1.05
Experiment 2 1.08 0.6 0.62 0.58
Experiment 2 0.43 0.53 0.77 0.67
Experiment 3 0.59 0.56 0.78 0.53
Experiment 3 0.6 0.6 0.81 0.61
2 Gy Bone 
Marrow
Experiment 1 0.79 0.82 0.58 0.54
Experiment 1 1.75 0.93 0.83 0.52
Experiment 2 1.1 1.61 2.68 0.74
Experiment 2 1.16 1.88 1.82 0.74
Experiment 3 0.74 0.83 0.5 0.36
Experiment 3 0.62 0.87 0.67 0.49
The proportion (%) of SA2 cells in S-phase following in vitro incubation with 
Captopril
Experiment % S-phase (T = 0) % S-phase (T = 24)
1 37.8 ±6.5 62.1 ±2.9
2 75.9 ±21.2 55.6 ±5.8
3 37.2 ±3.3 63.3 ±2.3
4 82.0 ±0.7 63.4 ±3.1
Appendix-Raw Data 257
The proportion (%) of HPP-CFC-1 in S-phase following a 4 hr m vitro incubation 
with Captopril & AcSDKP after depleting all cells that were in S-phase in vivo.
2 Gy Bone Marrow
Experiment % S-phase (Control) % S-phase (Captopril & 
AcSDKP)
1 23.3 ± 2.9 5.0 ±4.7
2“ 25.6 ±4.5 7.4 ±3.1
3 34.5 ±2.5 7.6 ±2.1
4 30.4 ±3.0 1.7 ±3.8
The proportion (%) of HPP-CFC-1 in S-phase following a 4 hr m vitro incubation 
with Captopril & AcSDKP after depleting all cells that were in S-phase in vivo. 
Ara-C Bone Marrow
Experiment % S-phase (Control) % S-phase (Captopril & 
AcSDKP)
1 45.2 ±2.1 19.8 ±4.4
2 29.0 ±3.8 1.5 ± 4.9
3 32.5 ± 7.4 9.8 ± 7.7
4 35.7 ±5.0 22.0 ±3.1
The proportion (%) of HPP-CFC-1 in S-phase following a 4 hr in vitro incubation 
with Captopril & AcSDKP after depleting all cells that were in S-phase in vivo. 
5FU
Experiment % S-phase (Control) % S-phase (Captopril & 
AcSDKP)
1 40.9 ± 5.3 22.8 ±5.9
2 45.8 ± 7.9 18.9 ±7.9
3 31.0± 11.2 5.6 ± 7.2
4 37.5 ± 13.8 17.2 ± 10.4
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo 
administration of 10 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 10.2 ±3.7 18.9 ±3.7
2 20.1 ± 11.8 12.8 ±3.6
3 17.2 ±3.2 7.4 ± 4.5
4 12.9 ±4.7 6.5 ± 2.7
Appendix-Raw Data 258
The proportion (%) of HPP-CFC-1 in S-phase following 2 Gy irradiation in vivo with 
10 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 54.1 ±4.0 26.1 ±5.2
2 42.4 ± 9.4 38.2 ± 5.2
3 43,0 ±4.2 16.4 ±4.2
4 31.3 ± 10.7 28.1 ±4.7
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo
administration of 10 mg/kg captopril
Experiment % S-phase (Saline control) % S-phase (Captopril)
1 4.2 ± 3.5 15.1 ±3.2
2 4.4 ± 6.4 8.2 ± 4.2
3 7.0 ± 2.2 4.4 ±4.8
4 8.8 ±3.7 2.3 ± 4.3
The proportion (%) of HPP-CFC-1 in S-phase following 2 Gy irradiation in vivo with 
10 mg/kg captopril
Experiment % S-phase (Saline control) % S-phase (Captopril)
1 50.8 ±5.8 47.1 ±2.7
2 43.3 ±3.1 50.0 ±7.2
3 43.8 ± 4.5 16.5 ±9.4
4 40.7 ± 10.0 34.9 ± 4.0
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo 
administration of 10 mg/kg lisin opril
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 16.4 ±6.3 -4.4 ± 10.7
2 1.4 ±9.6 14.7 ±4.6
3 -2.4 ± 6.2 5.4 ±3.7
4 0.0 ±4.8 1.2 ±5.9
The proportion (%) of HPP-CFC-1 in S-phase following Ara-C (100 mg/kg) in vivo 
with 10 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 31.8± 17.6 19.4 ±3.8
2 45.7 ±5.1 32.3 ± 6.6
3 43.7 ±2.9 19.1 ±41.5
4 47.4 ±3.8 11.2 ± 6.6
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Tlie proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo 
administration of 10 mg/kg captoprii
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 7.5 ± 2.3 8.6 ± 2.1
2 13.8 ±3.8 17.8 ±4.3
3 13.6 ±2.7 14.3 ±2.5
4 9.1 ±3.9 10.1 ± 2.3
The proportion (%) of HPP-CFC-1 in S-phase following Ara-C (100 rag/kg) in vivo 
with 10 mg/kg captoprii
Experiment % S-phase (Saline control) % S-phase (Captoprii)
1 37.7 ±3.8 27.0 ± 5.6
2 33.1 ±4.4 30.0 ±4.1
3 43.4 ±4.8 47.7 ±2.1
4 39.5 ±3.1 36.2 ±4.1
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo
administration of 100 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 -1.5 ±8.9 12.5 ± 1.8
2 19.4 ± 6.8 14.3 ±3.5
3 0.8 ±5.6 5.6 ±4.8
4 -1.3 ±7.7 5.2 ±3.1
The proportion (%) of HPP-CFC-1 in S-phase following 2 Gy in-adiation in vivo with 
100 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 32.9 ±2.0 29.8 ± 3.5
2 19.4 ±5.1 25.2 ±3.3
3 22.2 ±5.4 35.3 ± 7.7
4 32.9 ±4.3 26.5 ± 5.3
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo
administration of 100 mg/kg captoprii
Experiment % S-phase (Saline control) % S-phase (Captoprii)
1 13.4 ±2.9 14.9 ± 1.9
2 19.8 ±3.5 9.9 ± 2.3
3 6.6 ± 4.4 2.6 ±4.8
4 10.5 ±2.8 7.1 ±5.2
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The proportion (%) of HPP-CFC-1 in S-phase following 2 Gy irradiation in vivo with 
100 mg/kg captoprii
Experiment % S-phase (Saline control) % S-phase (Captoprii)
1 29.7 ±5.4 14.3 ±2.7
2 41.5 ±3.8 10.2 ±4.8
3 31.5 ±2.7 10.0 ±32
4 40.9 ±4.9 20.4 ±8.1
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo 
administration of 100 mg/kg lisinopril
Experiment % S-phase (Lisinopril)
1 10.8 ±4.5
2 9.1 ±3.9
3 12.5 ±3.5
4 14.4 ±5.2
The proportion (%) of HPP-CFC-1 in S-phase following Ara-C (100 mg/kg) in vivo 
with 100 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (LismoprU)
1 34.0 ± 4.4 36.2 ± 4.4
2 33.8 ±3.8 26.5 ± 4.0
3 17.3 ±32 32.7 ±3.0
4 38.0 ±2.3 33.0 ± 4.6
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo
administration with 100 mg/kg captoprii
Experiment % S-phase (Saline control) % S-phase (Captoprii)
1 17.1 ±5.9 15.4 ±32
2 -0.9 ±52 3.4 ±41.1
3 14.9 ±7.7 17.3 ±5.1
4 23.1 ±5.7 10.8 ±52
The proportion (%) of HPP-CFC-1 in S-phase following Ara-C (100 mg/kg) in vivo 
with 100 mg/kg captoprii
Experiment % S-phase (Saline control) % S-phase (Captoprii)
1 33.3 ±3.5 5.0 ± <5.3
2 27.2 ± 4.5 2.4 ± 4.8
3 27.9 ± 5.6 10.2 ±412
4 30.7 ±3.4 13.3 ±2.6
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The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo
administration of 100 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (Lisinopril)
1 17.2 ± 6.8 19.9 ±7.7
2 -1.3 ±9.4 7.4 ± 8.9
3 2.4 ±5.9 6.4±11.2
4 -1.8 ±4.8 3.3 ±7.4
The proportion (%) of HPP-CFC-1 in S-phase following 5 FU (150 mg/kg) in vivo 
with 100 mg/kg lisinopril
Experiment % S-phase (Saline control) % S-phase (Lisrdopril)
1 70,6 ±2.5 60.2 ± 2,5
2 64.1 ±3.1 71.0 ±3.3
3 39.1 ±4.2 63.1 ±2.2
4 68.1 ±3.1 62.5 ±2.7
The proportion (%) of HPP-CFC-1 in S-phase in mice following in vivo
administration of 100 mg/kg captoprii
Experiment % S-phase (Captoprii)
1 3.2 ±5.5
2 14.1 ±3.6
3 7.2 ±4.9
4 5.6±4.1
The proportion (%) of HPP-CFC-1 in S-phase following 5 FU (150 mg/kg) in vivo 
with 100 mg/kg captoprii
Experiment % S-phase (Saline control) % S-phase (Captoprii)
1 53.3 ±5.2 36.4 ± 8.6
2 60.4 ± 7.0 21.9± 12.1
3 60.3 ± 4.4 22.9 ±9.1
4 53.8 ±6.1 7.9 ±18.8
Is Vivo AcSDKP concentration in plasma following Captoprii (100 mg/kg)
AcSDKP (nM)
Plasma Captoprii Saline
2 hrs 6 hrs 24 hrs 0 hrs 2 hrs 6 hrs 24 hrs
Saline Experiment 1 7.06 7.38 2,66 2.3 2.08 L22
Experiment 2 3.85 1.9 1.05 0.94 1.41 1.02 0.9
Experiment 2 4.85 1.28 1.12 1.54 1.21 1.05
Experiment 3 3.58 3.55 1.62 0.69 1.3 0.46 0.64
Experiment 3 3.78 3.95 1.64 0.52 1.12 0.56 0.56
Ara-C Experiment 1 10.94 5.36 2.48 2.72 2.52 1.74
Experiment 2 7.1 4.4 1.55 0.47 0.93 0.51
Experiment 2 10.15 5.2 1.65 0.58 0.86 0.67
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Experiment 3 5.25 2.75 175 1.0 0.7 1.05
Experiment 3 5.8 3.0 1.1 070 0.60 1.10
2 Gy Experiment 1 11.42 4.54 3.58 1.72 2.28 2.66
Experiment 2 12.30 4.85 1.85 0.94 1.13 0.61
Experiment 2 9.60 4.75 1.60 0.72 173 0.49
Experiment 3 8.0 3.8 175 0.69 0.57 0.65
Experiment 3 7.65 3.25 1.45 0.55 0.53 0.63
RECOVERY EXPERIMENTS 
Femur cellularities & Spleen weights in untreated mice
Mouse Femur Cellularities (x 10 7) Spleen Weights (gms)
1 1.1 138.7
2 1.35 128.9
3 1.56 166.1
4 1.35 144.3
GM-CFC & HPP-CFC-1 numbers in untreated mice
Experiment GM-CFC Nos (xlO) HPP-CFC-1 Nos (10J)
1 2.7 12.1
2 2.4 16.1
3 2.8 13.7
4 2.7 20.7
The Proportion (%) of GM-CFC & HPP-CFC-1 in S-phase in untreated mice
Experiment GM-CFC HPP-CFC-1
1 26.4 ±3.7 5.9 ±4.1
2 32.7 ± 1.9 9.1 ± 5.2
3 32.9 ± 4.2 14.3 ±27
4 21.7 ±3.3 4.1 ±37
Femur cellularities (106) in mice given 2 doses of Ara-C (200 mg/kg) fractionated by 
captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 9.6 14.5 18.9 7.6 13.7 23.1
2 10.8 20.9 24.5 9.2 24.5 227
3 9.0 18.6 18.0 11.4 14.4 18.6
4 8.1 20.0 20.3 4.6 17.4 17.9
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Spleen weights (gms) in mice given 2 doses of Ara-C (200 mg/kg) fractionated by 
  captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 100 143.5 119.5 92.8 124.7 145.3
2 108.3 103.4 116.9 85.2 117.9 116.6
3 89.6 127.5 143.3 159.6 99.0 106.7
4 94 123.5 115.2 93T 152.4 146.8
GM-CFC numbers (xlO4) in mice given 2 doses of Ara-C (200 mg/kg) fractionated by
captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 1.8 1.6 1.8 2.0 1.4 2.6
2 1.7 2.4 3.0 1.6 3.1 2.6
3 2.1 2.6 1.8 2.0 1.5 1.7
4 1.3 2.8 2.3 1.1 2.2 2.3
HPP-CFC-1 numbers (xl 0 4) in mice given 2 doses of Ara-C (200 mg/kg) fractionated 
by captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 21.9 19.4 21.5 16.7 15.4 257
2 15.6 287 27.2 13.5 37.5 21.0
3 16.0 26.4 17.9 16.5 21.1 17.7
4 14.5 22.2 21.4 7.7 19.4 20.7
The Proportion (%) of GM-CFC in S-phase in mice given 2 doses of Ara-C (200 
mg/kg) fractionated by captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 27.1 ± 3.9 23.6 ±37 33.1 ±3.5 12.6 ±27 12.8 ±3.3 25.7 ±2.9
2 31.6 ±2.3 35.0 ±2.9 33.0 ±2.9 14.6 ± 1.8 2.2 ± 3.2 32.0 ± 1.6
3 34.1 ±3.3 33.9 ±3.6 26.4 ± 2.6 5.0 ±4.4 1.5 ±4.4 27.1 ±3.2
4 22.8 ±20 31.6 ±2.4 28.9 ±3.8 10.0 ±4.6 4.2 ±2.9 33.9 ±31
The Proportion (%) of HPP-CFC-1 in S-phase in mice given 2 doses of Ara-C (200 
mg/kg) fractionated by captoprii (10 0 mg/kg)
Saline Captoprii
Experiment No. Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 17.0 ±4.9 26.1 ±4.0 32.0 ±2.7 5.0 ±3.6 6.6 ± 2.9 5.3 ±3.6
2 241 ±27 27.8 ± 2.4 17.6 ±2.2 4.0 ± 6.4 5.0 ±4.0 3.7 ±4.0
3 16.1 ±4.5 25.1 ±51 28.5 ± 5.3 11.7 ±3.2 0.34 ±7.3 5.2 ± 6.2
4 20.6 ± 6.6 22.4 ± 2.6 26.1 ±5.6 12.2 ±27 -2.3 ± 6.9 14.2 ±3.8
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Femur cellularities (10 6) in mice given 2 doses of Ara-C (400 mg/kg) fractionated by 
captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 4.0 14.5 19.3 4.0 14.8 17.7
2 3.7 18.2 18.3 5.2 18.4 19.2
3 4.4 19.8 19.2 4.5 16.4 16.8
4 5.1 17.3 19.1 5.3 15.7 19.9
Spleen weights (gms) in mice given 2 doses of Ara-C (400 mg/kg) fractionated by 
captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 75.2 122.2 110.7 66.4 89.2 122.5
2 73.7 101.4 1384 83.6 141.9 154.3
3 91.6 176.6 169.7 105.7 175.6 151.1
4 93.5 174.6 187.7 107.7 150.6 168.6
GM-CFC numbers (xlO 6) in mice given 2 doses of Ara-C (400 mg/kg) fractionated by 
captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 6.8 15.1 24.7 8.1 324 25.7
2 7.6 19.0 15.8 13.8 19.3 20.7
3 6.5 24.0 247 7.5 21.3 17.4
4 7.1 20.6 21.5 8.8 15.6 19.1
HPP-CFC-1 numbers (xlO 6) in mice given 2 doses of Ara-C (200 mg/kg) fractionated 
by captoprii (100 mg/kg)
Saline Captoprii
Experiment
No.
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 5.4 16.1 24.0 4.5 24.2 2 L 2
2 6.8 207 13.8 11.5 17.4 27.7
3 6.3 16.8 19.3 6.7 10.4 10.9
4 6.1 17.3 17.8 6.2 10.6 12.0
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The Proportion (%) of GM-CFC in S-phase in mice given 2 doses of Ara-C (400 
mg/kg) fractionated by captoprii (100 mg/kg)
Saline Captopril
Experiment
No,
Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 56.7 ± 1.9 40.5 ± 5.0 48.2 ±2.5 16.8 ±3.1 21.6±4.l 43.0 ± 2.7
2 53.6 ±2,5 38.1 ±29 50.8 ±2.0 15.0 ±3.0 15.6 ±2.8 29.0 ±3.5
3 50.0 ± 2.2 30.4 ± 2.4 36.5 ±2.3 15.5 ±2.3 0.8 ± 29 25.0 ±3.0
4 47.2 ±2.1 25.7 ± 3.4 35.9 ±2.1 14.1 ±21 4.8 ±4.8 27.9 ± 4.0
The Proportion (%) of HPP-CFC-1 in S-phase in mice given 2 doses of Ara-C (400 
mg/kg) fractionated by captoprii (100 mg/kg)
Saline Captoprii
Experiment No. Day 3 Day 7 Day 10 Day 3 Day 7 Day 10
1 57.2 ±3.6 30.0 ±3.7 33.3 ±3.6 25.0 ±3.3 1.5 ±3.6 7.1 ±5.0
2 52.7 ± 2,4 37.2 ± 5.4 38.4 ±2.7 15.7 ±29 6.4 ± 5.8 1.4 ±3.3
3 42.3 ± 3.4 25.9 ±5.3 37.8 ±2.7 6.3 ± 6.4 2.4 ±3.4 1.5 ±4.9
4 50.2 ±2.1 26.0 ± 4.0 26.1 ±3.8 10.8 ±6.4 3.7 ±4.2 2.4 ± 7.2
Femur Cellularities in LTBMC (xlO5 Cells/ml)
Week/
Experiment No.
Saline Captoprii (10"°6M) AcSDyKP
(10-9M)
AcSDKP (lO‘6M)
+ Captoprii (lO^M)
Week 2
1 3.2 3.5 2.9 2.1
2 7.6 10.0 8.8 10.0
3 6.8 9.6 13.1 11.4
4 3.0 6.4 4.8 5.4
Week 3
1 5.2 7.4 7.3 6.6
2 15.8 12.0 8.9 8.0
3 10.8 8.2 6.1 8.3
4 77 9.1 12.8 9.8
Week 5
1 15.9 16.3 17.0 12.8
2 12.1 10.0 10.3 8.4
3 11.9 8.7 8.3 12.6
4 9.5 5.8 16.3 10.6
Week 6
(Adherent layer) 
(xlO6 Cells/ml)
1 22.8 35.7 22.5 22.2
2 31.6 2 7. 0 383 22.5
3 21.7 36.1 31.5 27.7
4 18.8 43.7 39.9 27.2
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Absolute GM-CFC numbers in LTBMC
i f in-&jur\ ........a -on...Week /
Experiment No.
Saline Captopril (10^M) AcSDij/KP
(10-9M)
AcSDKP (10%D 
+ Captoprii (lO^M)
Week 2
1 422.9 521.0 305.4 180.3
2 690.6 701.2 614.2 324.5
3 1600 2057.8 1713.5 1960.0
4 1334.0 1908.4 2138.7 2080.5
Week 3
1 327.6 356.5 678.9 433.6
2 202.1 262.7 423.4 272.5
3 951.8 540.0 708.8 008.2
4 1757.6 1315.0 1111.7 1263.6
Week .5
1 1450.8 1540.3 2588.1 1235.2
2 1085.0 1524.0 2639.8 1344.0
3 I255.2 730.0 996.4 1297.8
4 1169.1 791.3 57L9 7184
Week 6
(Adherent layer)
1 2587.8 4506.7 2756.3 2475.2
2 2485.2 3168.4 2829.4 2278.4
3 3333.8 2835.4 4298.8 2390.4
4 3146.5 6750.0 3071.3 2472.0
Absolute HPP-CFC numbers in LTBMC (xlO5 Cells/mi)
Week /
Experiment No.
Saline Captoprii (10‘°M) AcSDyKP
(10-9M)
AcSDKP (lO^M)
+ Captoprii (lO^M)
Week 2
1 410.2 564.1 305.4 242.2
2 322.4 473.5 207.4 210.7
3 1088.6 1535.2 1546.2 1291.4
4 729.3 1054.9 2145.0 1918.2
Week 3
1 616.2 428.4 513.9 336.6
2 793.8 213.7 224.1 520.7
3 062.0 235.4 330.2 339.4
4 901.3 1172.3 1146.1 1139.4
Week 5
1 1240.2 884.1 977.5 841.5
2 772:2 1304.0 1113.5 614.4
3 768.4 777.0 782.8 872.4
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4 645.9 582.4 7461 57L0
Week 6
(Adherent layer)
1 1540.7 2284.2 2240.5 1136.3
2 2670.2 230L5 2031.8 1385.0
3 1491.7 2420.0 3188.0 1884.0
4 3146.4 4034.0 1456.7 1732.8
The Proportion (%) of GM-CFC in S-phase in LTBMC
Week /
Experiment No.
Saline Captoprii (10‘°M) AcSDyKP
(10-9M)
AcSDKP (lO^M)
± Captoprii (lO"6M)
Week 2
1 73.0 ± 1.4 33.8 ± 4.6 40.6 ± 4.4 53.7 ±4.6
2 50.8 ± 1.9 25.6 ±2.6 26.6 ± 2.8 23.9 ±42
3 34.4 ± 4.7 11.6 ±3.7 8.0 ± 2.6 19.5 ±2.1
4 70.9 ±2.3 25.5 ±34 28.7 ± 4.6 23.6 ±5.4
Week 3
1 63.1 ±2.9 30.8 ±2.9 32.7 ±3.7 8.6 ±3.1
2 51.9 ±2.7 -1.7 ± 5.6 23.1 ±3.8 20.9 ±3.7
3 41.5 ± 3.2 -0.8 ± 13.7 11.0 ±9.3 10.2 ±7.8
4 57.8 ±2.7 41.2 ±4.5 25.0 ±4.7 -2.3 ± 6.8
Week 5
1 30.8 ±5.8 28.6 ±3.9 24.0 ± 4.5 28.3 ± 4.4
2 55.8 ±3.5 30.1 ±32 16.7 ± 6.1 27.9 ± 5.0
3 50.0 ±2.6 7.8 ±77.1 27.9 ± 4.6 21.2 ± 2.6
4 54.0 ±4.0 45.6 ±4.7 38.9 ±2.7 32.4 ± 7.2
Week 6
(Adherent layer)
1 37.8 ± 1.9 31.3 ± 3.1 9.1 ±3.7 0.0 ± 6.4
2 42.4 ±2.5 2.7 ±3.4 0.3 ±32 22.4 ±3.3
3 41.9 ±2.3 9.3 ±3.7 8.9 ±3.3 12.0 ±39
4 23.3 ±4.2 54.4 ±39 25.4 ± 5.3 24.0 ±551
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The Proportion (%) of HPP-CFC.in S-phase in LTBMC
Week/
Experiment No.
Saline Captoprii (lO^M) AcSDyKP
(10-9M)
AcSDKP (10"M)
± Captoprii (lO^M)
Week 2
1 55.6 ± 2.6 43.2 ±2.7 16.9 ±4.2 9.1 ±6.0
2 27.5 ± 3.3 17.6 ±2.7 6.4 ±3.7 5.5 ±3.1
3 32.0 ±6.6 12.1 ±4.3 0.5 ± 4.0 0.0 ± 4.6
4 48.1 ±5.8 23.6 ±3.6 40.3 ± 4.5 30.3 ±4.1
Week 3
1 24.4 ±2.8 17.6 ±2.5 9.0 ±4.6 0.0 ±3.7
2 25.0 ±4.1 2.7 ± 8.3 7.2 ± 7.7 36.0 ±4.7
3 31.9 ±3.7 0.8 ± 12.1 9.4 ± 6.3 9.5 ± 5.4
4 15.0 ±47 5.2 ±5.1 0.3 ± 4.7 17.1 ±3.0
Week 5
1 19.0 ±8.0 12.6 ± 6.3 17.0 ±4.7 11.7 ±4.5
2 48.2 ± 2.6 23.9 ±5.1 5.1 ±5.8 8.8 ±7.1
3 61.9 ±1.2 10.2 ±2.3 10.9 ±4.7 5.7 ± 4.9
4 59.1 ±4.1 54.0 ± 9.8 38.5 ±8.3 10.4 ±5.6
Week 6
(Adherent layer)
1 34.8 ± 3.9 9.5 ±4.7 19.8 ±4.1 14.2 ±4.9
2 28.4 ± 4.5 27.2 ±3.5 29.3 ± 4.2 31.4 ±6.2
3 25.7 ±5.1 29.6 ±2.5 19.0 ±4.0 20.0 ± 6.1
4 37.0 ±4.6 27.0 ± 6.6 38.4 ±8.2 22.9 ±5.6
Inhibitory Action of the Peptide AcSDKP on the Proliferative State of 
Hematopoietic Stem Cells in the Presence of Captoprii but not LIsiroprii
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Abstract
The effect of Angiotensin I-converting enzyme (ACE) 
inhibitors on their own and in combination with the pep­
tide AcSDKP on tlie proliferation of hematopoietic stem 
cells has been investigated. Hematopoietic stem cells from 
murine bone marrow induced into cell cycle following 
exposure to 2 Gy Y-irradiation were incubated in vitro for 
up to 24 h in the presence of medium, captopriVHsinopril, 
AcSDKP, and AcSDKP with either ACE inhibitor. 
Hematopoietic stem cells were monitored using the high 
proliferative potential-colony forming cell-1 (HPP-CFC-1) 
population cloned in the presence of human EL-lp, mnrine 
IL-3, and murine M-CSF. No significiant irhIbItpry effect 
was observed in the presence of AcSDKP on its own and
AcSDKP in combination with iIsmopril/ However, there 
was a significant inhibition of stem cell cycling when 
AcSDKP and captoprii were combined. This suggests that 
captoprii inhibits AcSDKP breakdown better than lisino­
pril. The combination of AcSDKP and captoprii also had 
an inhibitory effect on cell recruitment into S phase. The 
fact that a combination of AcSDKP and captoprii switches 
cycling hematopoietic stem cells out of cycle indicates the 
importance of the N-active catalytic site of ACE in 
AcSDKP hydrolysis in vitro. Thus, AcSDKP in combina­
tion with appropriate ACE inhibitors may be of use in reg­
ulating the proliferation of hematopoietic stem cells in 
vitro. Stem Cells 1997;15:455-460
Introduction
Hematopoietic stem cell proliferation is controUed by a 
series of positive find negative regulatory factors. Stimulatory 
factors are produced following insult to the hematopoietic 
system [1]. This damage induces stem cells to enter into cell 
cycle. If the insult persists when stem cells are cycling, there 
is a possibility of stem cell depletion and therefore bone mar­
row failure [2]. To prevent this depletion, it is suggested that 
a balance between inhibitory and stimulatory factors be main­
tained during cytotoxic insults to the hematopoietic system by 
increasing the concentrations of inhibitors [3]. A number of 
inhibitory factors have been identified, but some lack speci­
ficity while others can be toxic. Some of these inhibitors also 
suppress tumor cells from cycling [4, 5].
A tetrapeptide, Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP), 
was first identified in extracts from fetal calf bone marrow 
[6]. It has been shown to exhibit no effect on the cycling 
status of tumor cells at a concentration which inhibits
normal hematopoietic progenitor cell cycling [7]. It is syn­
thesized in mice under steady-state conditions and is secreted 
by the bone marrow in long-term culture [8]. AcSDKP 
opposes the action of stimulators which recruit cells from 
Go or early G, to enter into S phase [9, 10]. Since AcSDKP 
enhances the adherence of hematopoietic cells to stromal 
cells [11], it has been suggested that the peptide may influ­
ence inhibitory factor production by the stroma. AcSDKP 
protects normal hematopoietic cells from cytotoxic effects 
of drugs [12], hyperthermia [13], and phototherapy [14]. This 
is of clinical significance because these agents are used to 
purge neoplastic cells from autologous bone marrow trans­
plants. AcSDKP with granulocyte colony-stimulating factor 
rescues stem cells from the cytotoxic effects of inadiation in 
vivo [15]. Cells responsible for AcSDKP production in vivo 
have not yet been identified. However, it has been recently 
reported that macrophages could be responsible for AcSDKP 
synthesis [16]. Certain endogenous macromolecuies contain
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the SDKP sequence [17]. There have been suggestions that 
thymosin (34, one of these macromolecuies, may be the source 
of AcSDKP. It has also been shown that thymosin (34 inhibits 
hematopoietic stem cell proliferation [18].
AcSDKP is degraded by Angiotensin I-converting enzyme 
(ACE), a ubiquitous ^pepl^yl carboTypeptlUase. This enzyme 
is involved in the first rate-limiting step of AcSDKP degrada­
tion in human plasma [19]. Human ACE has NH2 and CO2H 
active catalytic domains which act independently with ACE 
inhibitors [20]. ACE hydrolyses AcSDKP by the N-active site 
[21]. Inhibition of ACE activity by captopiil in vivo in humans 
has been shown to increase the plasma concentration of 
AcSDKP [22].
We have studied the effects of two ACE inhibitors: capto­
prii, which is more potent at the N-active site, and ^nopal, 
which is more active at the C-active site in combination with 
AcSDKP on the kinetics of hematopoietic stem cell. The stem 
cells were studied using the in vitro high proliferative potential 
colony-forming ceIls-1 (HPP-CFC-1) assay [23].
Materials and Methods
Mice
All experiments were canied out using female 8- to 12- 
week-old CD l mice. Animals were bred and housed at the 
University of St. Andrews, Scotland, UK. Animals in groups 
of threes were given 2 Gy whole body yli^•aUiatlod (CIS 
Bioidterdatiodal IBL 437C l37Cs Y-irradiation source. Dose 
rate 4.66 Gy/minute).
AcSDKP and Ace Inhibitors
AcSDKP (Mr = 487) ( IPSEN-Biotech; Paris, France) was 
supplied as a lyophilized sample and stored at -20°C. The peptide 
was dissolved in sterile distilled water, and aliquoted in 
polypropylene cryotubes (Nunc; Denmark), and stored at -20°C. 
For use, each sample was diluted in Dulbecco’s medium (GIBCO 
BRL; Paisley, Scotland, UK) supplemented with 2% fetal calf 
serum (FCS) (dobephar^m; Esher, Suney, UK). A final concen­
tration of 10" M was added to a pair of petri dishes or universal 
tubes containing iiradiated bone marrow cell suspensions with 1 
niM captoprii (Sigma; UK) or ImM lisinopril (Sigma) [24].
Stem Cell Assay: HPP-CFC-1
A feeder layer containing two ml of Dulbecco’s medium, 
20% horse serum (Globepharm) penicillin 50 Ul/ml 
(Sigma)/streptomycin 50 |ig/ml (Sigma) and 2 mM L-gluta- 
mine (D20% HS PS/G) with 0.5% (v/v) melted agar (Bacto 
Agar; Difco Labs; Detroit, MI) and recombinant murine inter­
leukin-3 (IL-3) at 100 ng/ml (R&D; Abingdon, Oxon, UK), 
recombinant human interleuki^^^l (3 (IL-Ip) at 100 U/ml and 
recombinant murine macrophage colony-stimulating factor
(M-CSF) at 200 ng/ml (R&D) were plated in a 60 mm 
dod-tlssue-cuiture petri dish (Nunc).
Cells were sampled 24 h post-irradiation. Cytosine arabi­
noside (Aia-C) suicide assay was carried out before plating to 
analyze the percentage of cells in S-phase [25]. Cells were 
washed twice after incubation, suspended in D20% HS PS/G 
with 0.3% melted agar (Bacto Agar; Difco Labs) and plated on 
the feeder layer at a final dose of 5 x 10“ cells per petri dish in 
four separate petri dishes. Petri dishes were incubated for 14 
days at 37°C in 10% CO2 in a fully humidified atmosphere. A 
day before assaying, 2-(9-lodophedyl)l3l(9-nrtrophedyl)-5- 
phedyitetrazollum chloride (INT) (BDH Chemicals, Ltd.; 
Poole, UK) was added to all culture dishes [26] and colonies 
were scored macroscopically. For comparison, normal bone 
marrow cells were incubated and treated in the same way as 
inadiated cells. Statistical comparison of the proportion of 
HPP-CFC-1 population in S phase among the cell populations 
was determined by using the unpaired Student’s f-test.
Effect of Ace Inhibitors and AcSDKP on Stem 
Cell Cycling
The proportion of HPP-CFC-1 in S phase was measured 
in the presence or absence of ACE inhibitors. It was also mea­
sured in the presence of ACE inhibitors with or without 
AcSDKP and in the presence of AcSDKP on its own. All 
these protocols were measured using a one-h incubation 
with Ara-C. The bone maiTow cell suspension (2 ml) was 
transferred to two pairs of 20 ml universal tubes (Sterilin, 
Stone; Staffordshire, UK). Captoprii or llsidoprii was added 
to one pair. 25 flg/ml Ara-C (Sigma) in Dulbecco’s 
medium, 30% FCS, penicillin 50 lU/ml/streptomycin 50 
jtg/ml and 2 mM L-glutamine (D30% FCS PS/G) was added 
to one tube of each pair and plain medium (D30% FCS PS/G) 
to the other. All tubes were incubated for one h at 370C. To 
test the effect of AcSDKP, ACE inhibitors plus AcSDKP 
(10" M) or AcSDKP (10" M) only were incubated in the 
same way as above. At the end of the incubation period, cells 
were washed twice with D20% HS PS/G. Cellularity was 
adjusted to 2.5 x 10* cells/ml and plated for HPP-CFC-1 
assay. The proportion of HPP-CFC-1 in S phase was assessed 
24 h after in vitro incubation to test the response of cells to 
ACE inhibitors and AcSDKP. Bone marrow cell suspension 
(2 ml) was transferred to each of four 30 mm triple-vent don- 
tissue-culture grade petri dishes (Sterilin). To one pair, capto­
prii or lisinopril was added. The other pair of dishes had no 
ACE inhibitors added. For the AcSDKP assay, ACE 
inhibitors plus AcSDKP (10" M) or AcSDKP (1C"9 M) alone 
were added to petri dishes. Dishes were incubated at 37°C in 
a 10% CO2 fully humidified atmosphere. After 23 h of incu­
bation, an Ara-C suicide assay was performed. Cells were 
transferred to labeled 20 ml universal tubes, washed, the
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cellularity adjusted, and plated for HPP-CFC-1 assay. Eight 
independent experiments were performed in the assay where 
captoprii was incubated in the presence of AcSDKP. Four 
independent experiments were performed in the rest.
The Effect of AcSDKP and Captopril on the 
Cell Cycle
Irradiated bone marrow cells were flushed from femurs 
and tibias and incubated in the presence of D10% HS PS/G 
and 25 gg/ml Ara-C for one h. Cells were immediately washed 
twice with D20% HS PS/G. They were suspended in D10% 
HS PS/G then transferred to two pairs of universal tubes each 
containing 2 ml cell suspension. They were incubated with or 
without 1 mM captoprii and AcSDKP (10"6 M) per pair for 
three h, after which another S phase suicide assay was per­
formed. At the end of the incubation period, cells were washed 
twice and the cellularity adjusted for HPP-CFC-1 assay.
Results
In Vitro Incubation with Captoprii Has No Effect on Normal 
Hematopoietic Stem Cell Cycling
As shown in Figure I, in the absence of captoprii, 
8.13% ± 2.57% of HPP-CFC-1 were in S phase at time 0. 
The proportion in S phase did not significantly change after 
24 h of incubation and was found to be 12.28% ± 4.72% 
(j) > 0.05). Incubation of normal bone maiTow cells with cap­
toprii in vitro did not significantly change the proportion of
Duration of In vitro Incubation (hours)
Figure L Normal bone mairow cells were incubated for 24 h in 
vitro with and without captoprii (1 niM), The percentage of HPP- 
CFC-1 in S phase Mm not significantly reduced after 24 h incubation 
in the absence of captoprii (T=0 and T = 24; p > 0.05). Captoprii 
had no effect on the proportion of HPP-CFC-1 in S phase after 24 h 
incubation (T=0 and T =24; p > 0.05) (n = 4, error bars = + SE).
stem cells in S phase. While 13.58% ± 2.58% were in S phase 
at time 0, the proportion in S phase after 24 h of incubation in 
the presence of captoprii was 14.67% ± 3.54% (p > 0.05).
Effects of Ace Inhibitors and AcSDKP on the 
Proliferation of Hematopoietic Stem Cells
As shown in Figures 2 and 3, when inadiated bone mar­
row cells were incubated for up to 24 h in the absence of ACE 
inhibitors, they remained in cell cycle. With lisinopril, the 
proportion in S phase was 38.61% ± 1.68% at time 0 and 
43.08% ± 3.39% ip > 0.05) after 24 h of incubation (Fig. 2A). 
There was no significant reduction in the proportion of stem 
cells in S phase after the addition of AcSDKP (IO^M) in the 
presence of lisinopril. The initial proportion in S phase was 
33.19% ± 0.83%, and it was 25.69% ± 4.44% after 24 h of 
incubation j > 0.05) (Fig. 2B). In the presence of captoprii, 
45.18% ± 6.17% of cells were in S phase at time 0, and the 
proportion did not significantly change after 24 h of incuba­
tion at 47.74% ± 5.41% {p > 0.05) (Fig. 3A). In the presence 
of AcSDKP, 40.19% ± 2.56% of HPP-CFC-1 were in S phase 
and 31.82% ± 2.95% (p > 0.05) were still cycling after 24 h 
of in vitro incubation (Fig. 3B). However, after the addition 
of AcSDKP (10‘6 M) in the presence of captoprii, there 
was a significantly reduced proportion of HPP-CFC-1 in 
S phase at the end of the 24-h incubation period. While at 
time 0,42.12% ± 3.70% of cells were in S phase, only 10.27% 
± 1.86% (p < 0.001) (Fig. 3B) were in S phase after 24 h.
AcSDKP Directly Blocks Cell Entry Into 
S Phase
Treating cells for one h with Ara-C kills cell in S phase 
[25]. Therefore, addition of captoprii and AcSDKP soon 
after Ara-C treatment gives an insight to the mode of action 
of the peptide. After an initial one-h incubation with Ara-C, 
there are no cells in S phase at the beginning of the subse­
quent incubation period. Consequently, the percentage of 
cells in S phase following this second incubation in the 
presence or absence of captoprii and AcSDKP is the result 
of cell entry during the second incubation period. Cells 
were incubated for four h after the initial S phase suicide 
with Ara-C to allow a large proportion to enter S phase. As 
shown in Figure 4, the proportion of cells in S phase in the 
absence of captoprii and AcSDKP was 28.44% ± 2.50%. 
However, there was a significant reduction in cell entry into 
S phase in the presence of captoprii and AcSDKP; only 
5.44% ± 1.38% Q) < 0.001) had entered S phase after four h 
of incubation.
Discussion
In vitro incubation with or without ACE inhibitors had no 
effect on the cycling status of HPP-CFC-1 from both nonnal
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Figure 2. Bone marrow cells 
removed one day after 2 Gy irradia­
tion were incubated in the presence 
and absence of lisinopril. The pro­
portion of HPP-CFC-1 in S phase in 
irradiated hone marrow cells 
remained high after in vitro incuba­
tion in the presence or absence of 
lisinopril, where n is the number of 
individual experiments. A) ± lisino­
pril fn = 4), (error bars = ± SE). 
Following addition of AcSDKP the 
proportion of HPP-CFC-1 in S 
phase in the presence of lisinopril 
was not sii^iujfiwutl^' reduced (p > 
0.05). B) ±AcSDKP + lisinopril fn = 
4), (error bars = ±SE).
Figure 3. Bone marrow cells 
removed one day after 2 Gy 
irradiation were incubated in 
the presence and absence of 
captopril. The proportion of 
HPP-CFC-1 in S phase in irra­
diated bone marrow cells 
remained high after in vitro 
incubation in the presence or 
absence of captopril, where n is 
the number of individual exper­
iments. A) ± captoprii fn = 4) , 
(error bars = ± SE). Following 
addition of AcSDKP the propor­
tion of HPP-CFC-1 in S phase 
in the presence of captopril was
significantly reduced f p > 0.001 J. B) ± AcSDKP + captoprii (n = 8) AcSDKP had no effect on stem cell cycling both with short and 
long term incubation, fn = 4). (error bars = ±SE).
Figure 4. Bone marrow cells removed one day after 2 Gy irradia­
tion were incubated with Ara-C for one h, washed then incubated 
for a further four h with AcSDKP plus captoprii or with medium. 
The proportion of HPP-CFC-1 that had entered S phase in the 
absence of AcSDKP plus captoprii was high. However, a combina­
tion of AcSDKP and captoprii blinked cell entry into S phase aid the 
proportion in S phase was low 1p < 0.001) fn = 4, error bars = ±SE).
or irradiated bone marrow cell suspensions. Incubating cells in 
the presence of AcSDKP alone did not reduce the proportion 
of cells in S phase, either after a short or a long incubation 
period. It has been shown previously that AcSDKP on its own 
has no inhibitory effect on the proportion of HPP-CFC in S 
phase in regenerating bone marrow following short incuba­
tion periods in serum-free supplemented Dulbecco's medium 
[9]. AcSDKP has a half life of approximately 3.5 h in FCS 
[24]. This presumably explains the lack of a noticeable 
inhibitory effect with the peptide alone. These results indicate 
that stem cells once induced into cycle remain in cycle until a 
high enough concentration of inhibitors can switch them out of 
cycle. The fact that stem cells incubated in the presence of 
AcSDKP and captoprii are switched out of cycle while more 
remain in cycle when incubated in the presence of AcSDKP 
and lisinopril suggests the importance of AcSDKP in the 
regulation of cell cycle if its degradation is prevented. The 
inhibitory effect of captoprii and AcSDKP on regenerating 
bone marrow also suggests that the peptide may have a direct
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inhibitory effect on cycling hematopoietic stem cells, 
However, an indirect effect cannot be excluded as whole bone 
marrow preparation was used. It is possible that this action is 
mediated by opposing the effect of stimulators of stem cells 
as previously shown by Robinson et al. [9]. AcSDKP and cap­
toprii blocks the cycling of CFU-S-12 in vitro from regener­
ating bone marrow [13], and now we have shown that cycling 
HPP-CFC-1 are also inhibited.
The difference in the ability of the two ACE inhibitors to 
prevent AcSDKP degradation can be attributed to their varying 
influence on the two catalytic domains of ACE. Captoprii binds 
preferentially to the NHr terminal domain of ACE in vitro [20], 
and it aiso has the lowest IC50 (10'9 M) for inhibition of 
AcSDKP hydrolysis by ACE. At 10'8 M captoprii inhibits 88% 
of ACE activity as measured by tlie hydrolysis of AcSDKP, 
while lismopril inliibits only 80%. Enalaprilat, another ACE 
inhibitor, inliibits 85% of ACE activity on AcSDKP hydrolysis 
at the same concentration [19]. Thus, it is initially surprising 
that a differential effect of the two ACE inliibitors was observed 
in vitro. However, some in vitro work has shown lisinopril to 
have greater inliibitory potency than captoprii on tlie activity of 
N-active site when AcSDKP is a substrate [27], but tliis is 
highly dependent on Cl' concentration and pH [20]. Thus, 
lisinopril will not be active in culture medium at the N-active 
site and AcSDKP action will be compromised.
Captoprii is the ACE inhibitor which is most frequently 
associated with development of neutropenia [28,29]. More­
over, people at risk of neutropenia are those with renal, col­
lagen, vascular, or autoimmune diseases suggesting high 
levels of ACE. Since captoprii inhibits the N-active catalytic 
site strongly, it is possible that there is an increase in 
AcSDKP levels during captoprii therapy. Azizi et al. [22] 
have demonstrated an increase in AcSDKP concentration 
following in vitro administration of captoprii. This could 
lead to the switching of cycling stem cells out of cycle 
and/or blocking of stem cell recruitment into cycle and thus 
contributing to the neutropenia. Captoprii, but not llsidoprii in 
vitro, suppresses IL-lp-induced synthesis of tumor necrosis 
factor, and IL-lP-induced synthesis of IL-la by human 
peripheral blood mononuclear cells [30]. Since IL-la is 
involved in the recruitment of primitive stem cells [31], it
implies that captoprii on its own may influence cytokine- 
mediated stem cell proliferation. Captoprii and the ability of 
AcSDKP to inhibit stem cell proliferation in vitro, if realized, 
could have tremendous implications for purging neoplastic 
cells from autologous bone marrow transplants.
AUmidlstratlod of the partially purified fractions of fetal 
calf bone marrow probably containing AcSDKP has been 
shown to protect mice from the cytotoxic effects of Ara-C 
[32]. AcSDKP given at an appropriate time after Ara-C admin­
istration in vivo prevents colony-forming units-spleen entry 
into S phase [10]. Therefore, it has rightly been suggested that 
AcSDKP may be acting at G(/Gi S boundary from the fact tliat 
tlie peptide protects murine hematopoietic cells from the cyto­
toxic effects of Ara-C. It has now been shown for the first time 
tliat AcSDKP in vitro blocks cycling HPP-CFC-1 entry into S 
phase. In addition, this investigation shows that AcSDKP not 
only blocks recruitment of stem cells into S phase but also 
switches them out of cycle. Thus, AcSDKP is active at the 
G]/S boundary. The possibility that AcSDKP may be active in 
other phases of the cell cycle cannot be excluded in these stud­
ies, which are only investigating the proportion of cells in S 
phase. It has been suggested that inhibition cell entry into S 
phase may be mediated by counteracting one or a few key 
steps of the mitogen signal transduction pathways [33], 
AcSDKP has been shown to inhibit the GOG] to S phase tran­
sition using continuous cell lines.
This study has shown that ACE inhibitors (captoprii), 
presumably by prevention of AcSDKP degradation, act in 
concert with the peptide to switch cycling hematopoietic 
stem cells out of cycle. This could be one of the reasons for 
bone marrow suppression observed after captoprii therapy. 
As captoprii is active on tlie N-domain of ACE, and ACE 
activity on angiotensin-I is mainly restricted to the 
C-domain, it should be possible to minimize hematotoxicity 
by using C-domain-specific ACE inhibitors for treatment of 
hypertension.
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